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Human immunodeficiency syndrome (HIV-1) has infected over 75 million people and over 35 
million have succumbed to virus related illnesses. Despite access to a variety of antiretroviral 
therapy (ART) options, ART programs have been disproportionally spread in the world with low-
and middle-income countries (LMICs) facing challenges to access the most potent ART options. 
With less potent ART remaining in use in LMICs, HIV-1 drug resistance (HIVDR) presents a 
growing challenge in LMICs. Since approval of the first-generation integrase strand transfer 
inhibitor (INSTIs), Raltegravir (RAL) in 2007, INSTIs remain the best choice as a backbone of 
ART. Access to second generation INSTIs, Dolutegravir (DTG) and bictegravir (BIC) in LMICs 
is based on need and not on a full evaluation of the effectiveness of these treatments in patients 
infected with non-B HIV-1 subtypes. To address this challenge of limited INSTIs associated 
HIVDR data in non-B HIV subtypes, we first screened for the presence of INSTIs associated drug 
resistance mutations (DRMs) in ART naïve and experienced patients in Uganda using Sanger and 
Illumina sequencing. In Uganda, 47% of patients failing on RAL carry resistance to RAL-and 
elvitegravir (EVG), and only 4% harbor resistant virus to DTG. A panel of recombinant viruses 
from patient-derived HIV-1 integrases carrying resistant mutations was created and tested for 
susceptibility to a panel of INSTIs: EVG, RAL, DTG, BIC, and CAB. The virus carrying N155H 
or Y143R/S was susceptible to DTG, BIC, and CAB but highly resistant to RAL and EVG (>50-
fold change). Two patients, one with E138A/G140A/Q148R/G163R and one with 
E138K/G140A/S147G/Q148K, displayed the highest reported resistance to RAL, EVG (FC, 
>1000) and even DTG (FC, >100), BIC (FC, 60->100), and CAB (FC, 429->1000). All viruses 
had impaired replication fitness and <50% reduction in integration capacity. We further 
determined potential novel polymorphisms associated with INSTI resistance in HIV-1 subtype A 
and D using simple vector machine analysis. The identified I208L and I203M, did not show 
reduced susceptibility to RAL or DTG with 1.3-1.8-fold and 1-1.4-fold observed, respectively. 
Further investigation is required to determine how these novel mutations influence susceptibility 
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Summary for Lay Audience 
Human immunodeficiency syndrome virus type 1 (HIV-1) is the causative agent for Acquired 
immunodeficiency syndrome (AIDS) which is characterized by rapid depletion of CD4+ T cells 
which eventually results in emergence of opportunistic infections. HIV-1 like other retroviruses, 
hijack host DNA machinery to be able to replicate and cause havoc in the infected individual. 
Because of high replication rate and numerous errors during replication, there are diverse strains 
of HIV-1 circulating in world population which are commonly referred to as subtypes, circulating 
recombinant forms, and unique recombinant forms. The non-B HIV-1 subtypes are predominantly 
in low- and middle-income countries (LMICs) and account for up to ~ 90% of HIV-1 infections. 
The antiretroviral therapy (ART) has tremendously improved the lives of individuals infected with 
HIV-1 and discovery of an even more potent class of ART, the integrase strand transfer inhibitors 
(INSTIs) has further improved HIV-1 treatment outcomes. Despite these advances, research of 
HIV-1 drug resistance associated with INSTIs has historically been done in HIV-1 subtype B virus 
which is predominant in high-income countries. With improved access to INSTIs by HIV-1 
patients in LMICs, there is urgent need to assess susceptibility of HIV-1 non-B strains to INSTIs 
and also discover novel potential pathways to resistance in these strains. From a cohort of HIV-1 
infected patients in Uganda, we show that prolonged virological failure on INSTI, raltegravir, leads 
to accumulation of drug resistance mutations which confer resistance to all currently available 
INSTIs. Novel mutations in the HIV-1 integrase gene which show no impact on INSTIs 
susceptibility by themselves, may act as secondary mutations to other drug resistance mutations 
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Chapter 1  
1 Introduction 
1.1 HIV-1   
The human immunodeficiency virus type 1 (HIV-1) belongs to a subgroup of retroviruses which 
infects humans and was first recognized in 1981 among a group of homosexual mean in the US 
(1,2).   In 1982, a resident doctor in the East African country of Uganda started seeing patients 
with major clinical manifestations of severe weight loss and diarrhea among heterosexual 
individuals (3). This was a kick start for global awareness campaigns of a strange new disease 
called GRID (gay-related immunodeficiency disease) in the US and SLIM disease in East Africa 
(Slim being related to emaciation of immunodeficient patients). HIV-1 was later discovered (1983) 
as the causative agent for Acquired Immunodeficiency syndrome (AIDS) (formerly GRID and 
SLIM) (4–6) which is characterized by severe depletion of CD4+ T cells leading to susceptibility 
to numerous opportunistic infections and cancers (7–9). If left untreated, the average time of 
survival is about 9-10 years depending on the virulence of infecting HIV-1 strain. The current 
literature indicates that HIV-1 was introduced into humans between 1920-1940 (10). Based on 
phylogenetic analysis, HIV-1 is classified as HIV-1 based on the zoonotic transmission to humans 
from simian immunodeficiency virus (SIV) from chimpanzee (SIVcpz) and gorilla (SIVgor) in 
West Central Africa, and HIV-2, based on the transmission from West Africa sooty mangabeys 
(Cercocebus atys, SIVsmm) (11,12). HIV-1 was first isolated in 1983 and HIV-2 in 1986, and both 
spread and diversified exponentially to create numerous subtypes that are circulating today.  
 
1.2 HIV-1 particle and genome 
HIV-1 is roughly spherical with a diameter of ~100nm-150nm and two identical single strands of 
RNA enclosed in the viral core (Fig. 1). HIV-1 has a total of 15 proteins from three major open 
reading frames, gag, pol, and envelope. The outer membrane proteins are translated from env open 
reading frame and they include highly glycosylated surface protein (SU, gp120) and 
transmembrane (TM, gp41) glycoproteins for attachment and fusing to host cell. From outside to 




nucleocapsid (p7, NC) protein that is tightly bound to genomic RNA strands (Fig. 1). Functional 
viral enzymes are coded by the pol open reading frame and they include, protease (p12, PR), 
reverse transcriptase (p66, RT), RNase H (the C-terminal p15 of RT p66) and integrase (p32, IN). 
Rev (RNA splicing regulator), and Tat (transactivator protein), act as regulatory proteins 
controlling RNA transcription and metabolism. Accessory genes, Vpu (viral protein unique), Vif 
(viral infectivity factor), Vpr (viral protein r), and Nef (negative regulatory factor), play critical 
roles in viral pathogenesis, replication and budding of the virus among a host of other regulatory 
functions during HIV-1 lifecycle or to avoid host restriction factors (13,14). The genomic RNA is 
flanked on both ends by identical long terminal repeats (LTRs) sequences with 5' LTR acting as 
promoter site and 3′ LTR having polyadenylation signal. HIV-1 and HIV-2 have similar genome 
structure except that Vpx is encoded in HIV-2 in place of Vpu found in HIV-1 (15).  
 
 
Figure 1. HIV-1 particle. At the center of HIV-1 mature virion, there are two copies of viral RNA 
tightly associated with nucleocapsid protein and copies of reverse transcriptase and integrase viral 
enzymes. These are encapsulated in cone-shaped capsid protein which is also surrounded by 
protease enzyme and matrix protein. The outer membrane consists of host-derived cell membrane 





1.2.1 Structural proteins 
Gag is expressed in the form of a 55-kDa precursor, Pr55Gag and is the major structural component 
of HIV-1. The Pr55Gag polyprotein is cleaved by HIV-1 protease to structural proteins p17 matrix 
(MA), p24 capsid (CA), p7 nucleocapsid (NC), spacer protein1, spacer protein 2, and p6 proteins 
(16,17) (Fig. 2).  
CA (p24) is a cone-shaped protein which surrounds the two strands of viral genome and viral 
proteins. It is mainly involved in maturation of virions and virus assembly processes. CA is made 
of two domains, N-terminal core domain (NTD, 1-145) and C-terminal dimerization domain 
(CTD, 151-231). The NTD is highly helical due to secondary structure of 7 alpha helices and 2 β-
hairpin, in addition to exposed loop which acts as binding site for cyclophilin A (18).  Whereas, 
NTD is implicated in maturation of virions and incorporation of cyclophilin A into the virion, CTD 
has been shown to be involved in recruitment of Gag-pol (Pr160gag-pol) precursor which eventually 
facilitate incorporation of viral proteins IN, RT and PR (19). The CTD is also involved in Gag 
oligomerization (20,21). Despite NTD being a core domain for CA, induced mutations in this 
domain generally have no effect on HIV-1 virion production, whereas mutations in CTD cause 
significant loss of virion particle assembly and release by proviral DNAs (22).  
NC (p7) is typically bound to genomic RNA in the HIV-1 particle core. It contains two zinc finger-
like motifs (Cysteine-Histidine boxes) which are highly conserved in retroviruses and each box 
coordinates a zinc ion. p7 is involved in packaging of genomic RNA and segments of the protein 
may facilitate assembly and release of viral capsid particles (23).  
MA (p17) is a protein of 128 amino acids made up of 5-α helices and mixed β-sheet. It forms the 
N-terminal end of Pr55Gag precursor protein. MA forms a core domain of mainly α -helices and 
three-stranded β-sheet while the C-terminus of the protein comprises an α-helix that connects MA 
and CA. The protein plays a critical role in intracellular targeting of polyproteins (24) including 
targeting Gag precursor to the site of viral assembly on the plasma membrane, and incorporation 
of Env glycoprotein into the virions. MA also targets the preintegration complex (PIC) to the 




HIV-1 p1 also known as spacer peptide 2 (sp2) is a protein derived from cleavage of Pr55Gag and 
is located at C-terminus of Gag between NC and p6 (Fig. 2). It is made up of 16 amino acids with 
two highly conserved proline residues, Pro-439 and Pro-445 and substitution to leucine decreases 
infectivity and reduces stability of RNA (25). It is crucial for Gag and Pol incorporation into virus 
particles (26).  
HIV-1 p2, also known as spacer peptide 1 (sp1), is a 14 amino acid peptide that is found between 
the CTD of CA and NTD of NC proteins (Fig. 2). p2 plays a significant role in CA assembly and 
HIV-1 infectivity (27–29). Deletion of p2 results in decreased ordered assembly and infectivity 
which results in “bent” core structures in virus particles produced. (27–29). Gag constructs lacking 
p2 are only able to form tubular and conical shapes but not spherical viral particles (30).  
Ribonucleoprotein formation of genomic RNA and condensation of CA core has been shown to 
be influenced by proteolytic processing of p2 from NC. CA-p2 cleavage during late viral 
processing enables CA shape by modulating CA-CA interactions. 
HIV-1 p6 is a 52 amino acid protein that is important in formation of infectious viruses and could 
be categorized as regulatory versus structural protein. P6 aids the process of HIV-1 particle 
maturation by incorporation of Vpr into virus particles (31) and supports budding off of HIV-1 
virion from host cell membrane (32). It has been shown to interact with Vpr and cyclophilin A 
(33). HIV-1 p6 is also involved in regulation of CA processing and virus core (34), and MHC-







Figure 2. HIV-1 genome structural organization. HIV-1 is made up of 9719 base pairs in total 
with three major open reading frames of gag, pol, and env. HIV-1 genome is franked with similar 
sequences in 5′ long terminal repeat and 3′ long terminal repeat regions which are important for 
regulatory functions such as transcription and polyadenylation.  
Pol: The proteolytic processing of Pr160gag-pol polyprotein by HIV-1 protease yields structural 
proteins, MA, CA and Pol and catalytic enzymes RT, PR, RNase H, and IN (36,37) (Fig. 2 and 3). 
Gag-Pol precursor is a product of fusion of Gag and Pol polyproteins from -1 translational 
frameshift which happens at UUA leucine codon near 5′ end of overlap region between Gag and 
Pol. The ribosomal frameshift signal consists of “slippery” sequence U UUU UUA and upstream 
ACAA tetraloop and this ensures 5% of -1 Pol open reading frame and 95% Gag alone products 
(38,39). 
Reverse transcriptase: The mature form of HIV-1-RT is an asymmetric heterodimer enzyme 
containing a 66 and 51 kDa protein produced and possibly self assembled following the cleavage 
of gag-pol polyprotein by HIV-1 protease during virion maturation. In each HIV-1 particle, there 
are about 50 p66/p51 RT molecules (40). Only one (p66) of two subunits contains a functional 
polymerase and RNase H domains (41). Despite sequence homology between the p66 and p51 
subunits, polymerase has a different structure between the two subdomains with p66 forming a 
large active-site cleft and p51 exhibiting an inactive closed morphology. The p66 polymerase 
active site has a catalytic amino acid triad (Asp 110, Asp 185 and Asp 186) in the “palm” 
subdomain, which is similar and conserved in many reverse transcriptase enzymes and other RNA 
polymerases (41–43).  When RT binds to a primer-template nucleic acid duplex the catalytic triad 
in palm is positioned “over” the 3′-OH of the primer terminus and catalyzes the nucleophilic attack 




primer terminus and this new nucleoside monophosphate. As such p66 is involved in catalytic 
activities and p51 in structural roles of HIV-1-RT (41,43). HIV-1 RT catalyses reverse 
transcription of genomic RNA. The C-terminus of the p66 subunit of RT forms RNase H domain 
(441-560) which degrades the RNA genome except for the PPTs (44).  The full process of HIV-1 
reverse transcription is described in section 1.3.3. 
Protease is a 99 amino acid aspartyl protease which cleaves the Gag and Gag-Pol precursors 
during viral assembly to form structural and functional enzymes (45) (Fig. 3). The initial 
processing is initiated by activated protease releasing itself from Gag-Pol precursor (46). It then 
cleaves Gag-pol and Gag polyproteins into functional enzymes, RT, PR, IN and structural proteins, 
matrix (MA), capsid (CA), nucleocapsid (NC), and proteins p1, p2 and p6 (45). It is only functional 








Figure 3. HIV-1 Pr55Gag and Pr160gag-pol polyprotein cleavage by HIV-1 PR. The polyproteins 
Pr55Gag and Pr160gag-pol from transcription of provirus are cleaved by HIV-1 PR enzyme late during 
assembly and maturation of new virions. Pr55Gag is proteolytically cleaved by HIV-1 PR in orderly 
manner with first cleavage happening between p2 and NC followed by MA and CA then p1 and 
p6, NC and p1, and finally CA gets cleaved from p2. Pr160gag-pol polyprotein from ribosomal 
frameshift contains region with transframe locus which encodes p6 and a transframe protein 
covalently linked to N-terminus of HIV-1 PR. Pr160gag-pol gets cleaved into gag structural proteins 
of MA, CA, P2, NC, P6 and pol proteins, PR, RTp51, RTp15 and IN. 
Integrase: HIV-1 integrase (HIV-1 IN) is a 32 kDa protein produced from gag-pol polyprotein 
cleavage by HIV-1 protease gene and about 40-100 integrase molecules are packaged in each HIV-
1 virion. HIV-1 IN is involved in a number of viral steps of reverse transcription (47), nuclear 
import of PIC (48,49), and integration of cDNA into host chromosome (50). The process of HIV-
1 integration into host chromatin is a two-step process of 3' processing and subsequent strand 
transfer process both mediated by HIV-1 IN. In 3' processing, HIV-1 IN dimer binds to each end 
of the newly synthesized linear viral DNA (vDNA) and cleaves the two nucleotides (GT) from 
each 3′ end which leaves conserved CA dinucleotide at terminus and exposes hydroxyl group 
(CAOH) (51,52). The cleaved vDNA is a component of the PIC that translocates into the nucleus 
for subsequent strand transfer process. Details of this HIV-1 integrations process are described in 




HIV-1 IN is composed of 288 amino acids and 3 domains, NTD (NH2-) (1-49), catalytic core 
domain (50-212)-CCD, and CTD (213-288) (COOH-) (53) (Fig. 4). HIV-1 IN is relatively 
conserved compared to RT and PR HIV-1 enzymes, with well-defined cytotoxic T lymphocyte 
epitopes of n=11, compared to PR, n=7 and RT, n=41 (54). All the three domains of HIV-1 IN are 
required for 3′ processing and strand transfer processes (55,56). However, disintegration can solely 
be carried out by CCD (56,57).  When strand transfer product is added to a protein mixture of 
mutated NTD and mutated CTD both with active site, it was shown that 3′ processing and strand 
transfer only occur after complementation with a protein with active site mutants which shows that 
HIV-1 IN functions as a multimer (58). In solution, HIV-1 IN forms dimers (59–62) and tetramers 
(61,62), and each domain taken separately can also form dimers:  the same CCD+CTD and 
CCD+NTD. The active form of HIV-1 IN during integration is shown to be  a tetramer upon 
interaction with the 3′ and 5′ ends of vDNA (63,64) (Fig. 4). 
 
 
Figure 4. The intasome complex of HIV-1 IN, vDNA and target DNA. The active form of HIV-
1 IN when bound to 5′ and 3′ ends of vDNA is a tetramer as shown by four HIV-1 IN monomers 
colored (sky blue, limon, cyan, and pink). The vDNA is depicted in orange and target DNA, hot 





The NTD structure has been solved for both HIV-1 and HIV-2 using nuclear magnetic resonance 
spectroscopy and it shows a domain with a bundle of 3 α-helices that are stabilised by Zn2+  (66,67). 
The isolated NTD is folded and only becomes a dimer when zinc ions are present (66,67). The 
NTD of HIV-1 like all other retroviruses has a pair of highly conserved His and Cys residues (HH-
CC) that forms a zinc finger (68). Despite having a different structure than the canonical zinc 
fingers, the HH-CC motif of HIV-1 IN binds zinc (69,70) which allows NTD folding, 
multimerization, and enhancement of enzymatic catalytic activity (70). There is less effect on 
disintegration and impairment of 3′ processing and DNA joining by mutations induced in HH-CC 
motif of NTD (60,71–74). Mutations in HH-CC motif reduce ability of HIV-1 IN to bind zinc (57). 
However, integrase lacking HH-CC motif are still able to recognise the CA/GT at the end of viral 
DNA but cannot catalyze the 3′ processing activity (60). 
The crystal structure of CCD shows a α/β structure consisting of a 5-stranded β-sheet and 6-α 
helices numbered 1-6 (Fig. 5). The α4 contains residues Y143 and Q148 which directly bind 
terminal ends of vDNA (75).  Between α5 and α6, there is a flexible finger-like loop of glycine 
rich sequence of about 12 residues (F185-A196) in HIV-1 (Fig. 5). The loop is stabilised by 
connections for example a salt bridge between R187 and E198 in HIV-1 has been shown to support 
enzymatic activity, conformational structure rearrangement of IN on binding DNA, nuclear 
localisation, stabilising tetramerization, and viral infectivity. The CCD domain is relatively 
resistant to proteolysis (71) and binds ends of vDNA via residue Q148. The Q148 lies within a 
flexible loop of residues 140GIPYNPQSQG149 that is disordered in most integrase crystal structures 
but suggested to become ordered upon DNA binding and is involved in stabilising the 5′-end of 
vDNA (75,76). The interaction between Q148 residue and 5′-C at the end of vDNA enables 
efficient strand-transfer process by HIV-1 IN (77). The domain has a highly conserved motif of 
acidic residues, D64, D116, and E152 (D,D-35-E) motif present in all retroviral integrases and 
transposases. This motif embedded in a RNase H fold protein is used to bind metallic cationic 
cofactors in all retroviruses, retrotransposon integrase proteins, and some prokaryotic transposases 
(71,74,78,79), and they are in a similar position in ribonuclease H (76). The D,D-35-E enables 
enzymatic activity by binding to at least one divalent metal cofactor Mg2+ or Mn2+ (80–83) and is 
also implicated in nuclear import (48,84). Within the CCD, the active site is contained within 
amino acids 50-212, as evident from recombinant peptide encoding this segment being sufficient 




D116, and E152 residues results in abrogation of catalytic activity (71,73,74). Despite CCD 
containing the catalytic site for the enzyme, NTD and CTD are indispensable for 3′ processing and 
strand transfer processes (85). In CCD, a 13-amino acid sequence 161IIGQVRDQAEHLK173 
located outside the catalytic triad motif but around a surface exposed loop connecting α4 and α5 
helices has been shown to have karyophilic property (86).  
 
 
Figure 5. The structural organization of HIV-1 integrase. A) The N-terminal domain consists 
of 3α-helices with a zinc finger-like motif of 2-His and 2-Cys amino acids for coordinating zinc 
ions. The catalytic core domain is made up of 6 α-helices and 5-stranded β-sheet with highly 
conserved residues D16, D116 and E152 for coordinating magnesium ions required for catalytic 
activity of the enzyme. The C-terminal domain is least conserved with an SH3-fold structure. B) 
The crystal structure of HIV-1 IN for antiretroviral therapy naïve patient sample ‘GS221’ was 
predicted using template d1wfa (99.9% confidence) for NTD, d1c6vx (100% confidence) for CTD 
and d1hyva (100% confidence) for CCD in PHYR2 (87). The α-helices are shown in green, β 
strands in magenta, the finger-like loop between α5 and α6 of CCD is shown in orange and divalent 
metal coordinating residues of NTD and CCD shown in blue. The structures were visualized and 
analyzed in UCSF Chimera (88). 
The CTD is least conserved among all retroviral integrases and binds DNA non-specifically. Based 




which make two antiparallel β sheets (68,89). The overall folding topology of CTD is closely 
similar to that of Src-homology 3 (SH3-fold) (68,89,90); though there have been variations in CTD 
interfaces in IN crystal structures containing CTD domain (91). When CTD is joined to CCD, it 
forms a monomeric structure (91). The structure of full-length HIV-1 IN with all three domains 
has been elusive due to the natural tendency to form large aggregates under test conditions. But 
the structure of double domains of CTD/CCD for HIV-1, SIV and RSV (91–93), and NTD/CCD 
has been solved. Sequence fragment of minimal region of CTD (220-270) is adequate for DNA 
binding (94) and residues between 245-270 make interactions with bases A (4) and T (5) of vDNA 
end (75,95). Mutation of CTD basic residue K264 in HIV-1 results in a significant decrease in 
DNA binding and catalytic activity (94). Mutating residues Leu 241 and Leu 242 to alanine impairs 
dimerization which significantly decrease catalysis activity (96). CTD may be critical in stabilising 
interaction of HIV-1 IN and vDNA by aligning DNA to fit in position that allows proper binding 
of viral terminal ends. In support of this observation, CTD is involved in 3’ processing but not in 
disintegration process (97). CTD also provides a karyophilic property of IN by having a bipartite 
NLS of amino acids 211 KELQKQITK219 and 261PRRKAK266 which are recognised by karyopherin-
α (48). To function properly, HIV-1 IN associates with a number of cellular proteins which act as 
catalytic cofactors for integration processes. High mobility group protein A1 (HMGA1) and barrier 
to autointegration factor (BAF) appear to directly interact with DNA substrate whereas, lens 
epithelium-derived growth factor/transcription coactivator p75 (LEDGF/p75), EED and HSP have 
been shown to directly interact with HIV-1 IN.  
Env: HIV-1 env gene is about 2.5 kb and is translated into 850 amino acids. HIV-1 env is first 
produced as precursor glycoprotein gp160 that undergoes a number of stages during its maturation 
including, formation of disulfide bonds, extensive glycosylation, cleavage by furin-like proteases, 
transport to cell membrane, and package into HIV-1 particle (98). Gp160 undergoes glycosylation 
in the endoplasmic reticulum and subsequently gets cleaved by cellular furin-protease in golgi 
apparatus, producing surface glycoprotein gp120 (~ 480 amino acids) and transmembrane 
glycoprotein gp41 (~ 345 amino acids). Gp120 has five conserved domains (C1, C2, C3, C4 and 
C5) and five variable domains (V1, V2, V3, V4, and V5). HIV-1 gp41 consists of seven domains, 
N-terminal fusion peptide, heptad repeat 1 (HR1), disulfide loop, HR2, membrane proximal 
ectodomain region, transmembrane and cytoplasmic tail (99). A trimer of heterodimers from three 




spike protein that is ~ 50% carbohydrate, recognises and binds to primary receptor CD4 (101) 
which induces conformational changes in gp120 and allows recognition of C-C chemokine 
receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) (102). This triggers 
conformational change of gp41 which triggers heptad repeats HR1 and HR2 to form a 6-helical 
bundle which creates a pore to allow fusion with host cell plasma membrane and delivery of viral 
genome into the cytoplasm of host cell (103). 
 
1.2.2 Accessory proteins 
HIV-1 Nef: It is a multifunctional 27-kd myristoylated protein that is encoded by a single exon 
that extends into the 3’ LTR of primate retroviruses. After packaging in virions, Nef is cleaved by 
HIV-1 protease during maturation (104,105). It is the first protein to be produced to sufficient 
levels inside an infected cell (106). Although Nef is predominantly localised in the cytoplasm and 
associated with the plasma membrane via the myristoyl residue, it has also been found in the 
nucleus in some studies. It is implicated in increasing the infectivity of the virus. In early phases 
of HIV-1 infection, Nef downregulates CD4 from the cell surface by endocytic pathways involving 
clathrin and AP2 (107–109) and eventually degraded in lysosomes (110,111). Downregulation of 
CD4 is crucial because accumulation of CD4 on cell surface prevents Env incorporation and 
budding (112,113). Nef is also implicated in downregulation of MHC-1 molecules from cell 
surface by rapid internalisation and degradation in endosomal vesicles (114), which inhibits lysis 
by cytotoxic CD8+ T cells and for viral spread and disease progression in vivo. Defective Nef has 
been observed in HIV-1-infected long term progressors, (115) indicating its role in maintaining 
high viral loads in infected individuals. Nef increases viral infectivity in both lymphocytes and 
macrophages (116) and relative infectivity of virus particles in Nef (+) compared to Nef depleted 
virus has been shown to be 3-to10-fold higher (117).  
HIV-1 Vpu: viral protein U, is a 16-kDa of 81-amino acid that is expressed late in HIV-1 life 
cycle and is coded by an open reading frame between the first exon of tat and env genes (118,119). 
Vpu is a product of Rev-dependent bicistronic mRNA which also encodes env showing their 
coordination in HIV-1 infection (120). Vpu is unique to HIV-1, and its closest homologs are in 




SIVmon), SIV from greater spot-nosed monkey (Cercopithecus nictitans; SIVgsn), SIV from 
mustached monkey (Cercopithecus cephus; SIVmus), SIV from Dent’s mona 
monkey(Cercopithecus mona denti; SIVden) and SIV from gorilla (Cercopithecus Gorilla gorilla; 
SIVgor) (121–126). There is no similar protein in either HIV-2 nor other related SIVs, SIV from 
sooty mangabey (SIVsmm) and SIV from rhesus macaques (SIVmac) (118,119). It is implicated 
in degradation of CD4 molecules by mediating the proteasomal degradation of newly synthesized 
CD4 molecules in endoplasmic reticulum (127). It also enhances virion release from plasma 
membrane of HIV-1 infected cells  (119,128) by antagonizing interferon-regulated host restriction 
factor-tetherin which directly cross links virions on host cell surface (129–131) .  
HIV-1 Vpr: the viral protein R (Vpr) is a 14-kDa protein of 96-amino acid that is incorporated 
into the virion with around 100 copies of Vpr copies present in each virion (132). The incorporation 
of Vpr in virions is mediated by specific interaction with carboxyl-terminal region of Pr55Gag (133). 
Vpr is involved in binding of PIC to importins and nucleoporins to promote nuclear import of 
HIV-1 into non-diving cells (134,135), and activation of HIV-1 LTR through binding to sp1 (136) 
or primarily through sequences of -278 to -176 of HIV-1 LTR (137). Vpr is also involved in 
preventing infected cells from passing through mitosis by arresting them in G2 phase (G2 cell 
arrest) through interactions with a DDB1 and Cullin4A-containing ubiquitin ligase complex (138–
142) and direct and indirect promotion of T-cell dysfunction. Vpr induces T-cell apoptosis through 
inhibition of NF-kB activity (143), but it is also involved in inducing the NF-kB activity by 
phosphorylation and degradation of IkB (144).  In HIV-2, G2 cell arrest is still carried out by Vpr 
and protein Vpx (close sequence homology to Vpr) is involved in PIC nuclear import (145,146). 
Interaction of Vpr with cellular Uracil-DNA glycosylase, a protein implicated in DNA repair 
process (removes uracil from synthesized DNA) influences in vivo mutation rate (147). 
HIV-1 Vif: Viral infectivity factor is a 23 kDa protein that is incorporated in virions (148) and 
exists in both membrane-associated and soluble cytosolic forms. Vif is required during late stage 
of infection and promotes viral infectivity by 10-1000 fold (149–152). Vif protein also antagonizes 
the activity of Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3G (APOBEC3G) 
enzyme which redirects it by ubiquitination to degradation in the proteasome (153–155) through 
recruitment of Cullin CUL5, elongins B and C, and Rbx1 to form ubiquitin ligase complex which 




1.2.3 Regulatory proteins 
HIV-1 Rev: is a 19 kDa protein made up of 116 amino acids that is critical for regulation of HIV-
1 protein expression. It is a product of completely spliced mRNA transcript. It functions as a 
tetramer and a nuclear localisation signal encoded by the protein allows its localisation in the 
nucleus. Rev sequence has an arginine-rich sequence on amino-terminal domain which acts as a 
nuclear localisation signal (157–160) and RNA-binding domain (157,161–165). The flanking 
sequences on both sides are required for multimerization (163–165). The leucine-rich carboxyl 
terminal domain of Rev (158,164,166) exhibits nuclear export signals (167–169). It is involved in 
nuclear export of intron-containing ∼ 9 kb-unspliced (Gag and pol) and ∼ 4-kb incompletely 
spliced (Env) transcripts into the cytoplasm for translation or packaging into new virions (170–
172). HIV-1 Rev response element (RRE) found in Env region of unspliced and partially spliced 
mRNAs is required for Rev function. Rev in the presence of RRE increases levels of both unspliced 
(Gag) and partially spliced (Env) mRNAs (173) and decreases the amount of mRNAs targeted for 
splicing. In early (Rev independent) stage, ∼ 2-kb mRNA transcripts which encode Tat, Nef, and 
Rev proteins accumulate in the cytoplasm, and importation of Rev into the nucleus allows binding 
to RRE of ∼ 9 kb and ∼ 4-kb transcripts which enables their nuclear export out of nucleus in late 
Rev-dependent stage. In absence of Rev, late genes, Gag, Pol, Env, Vpr, Vpu and Vif are localised 
in the nucleus and cannot be translated.  
HIV-1 Tat: Reverse transcription of provirus DNA is regulated by HIV-1 trans activator protein, 
Tat, which enhances the process of reverse transcription by binding to the cis-acting stem loop 
element in the 5’ end of HIV-1 LTR encompassing nucleotides +1 and +59 known as TAR (174). 
TAR is made up of the first ~60 nucleotides of nascent RNA transcript 5’ end LTR promoter and 
acts as a binding site for Tat and assembly site for a large number of transcriptional elongation 
factors. TAR sequence has a region of highly conserved 3-nucleotide pyrimidine bulge that binds 
Tat and 6-nucleotide loop for binding positive transcriptional elongation factor P-TEFb (175). The 
binding of Tat to TAR region, recruits P-TEFb (cyclin T1/ cyclin dependent kinase 9) to TAR 
region. With Tat bound to TAR, pTEFb recruits TATA box binding protein to the promoter region 
and CDK9 phosphorylates the C-terminal domain of RNA polymerase II which increases 




within TAR (between positions +55 and +59) are produced due to early termination by RNA 
polymerase II enzyme (176). 
 
1.3 Overview of HIV-1 life cycle 
HIV-1 undergoes several steps in a life cycle that only lasts 24-48 hours. Each step is crucial for 
effective viral replication and this has allowed the discovery of different antiviral compounds 
which target different stages to halt HIV-1 viral replication (Fig. 6). HIV-1 uses a number of viral 
and cellular proteins during its replication to produce nine open reading frames which code for 15 
proteins. Please note that this review will focus on HIV-1 reverse transcription, protease 
processing, and integration which are the primary targets for the current and most effective 
antiretrovirals.  Other steps in the lifecycle of HIV-1 are not described in detail. 
 
 
Figure 6. HIV-1 replication life cycle. 1) HIV-1 surface glycoprotein gp120 binds to host cell 
through mainly CD4+ receptor. 2) Fusion with host cell membrane occurs after a change in 
conformation of gp120 to expose gp41 transmembrane glycoprotein. 3) HIV-1 core uncoats inside 




4) HIV-1 genomic RNA is reverse transcribed by reverse transcriptase enzyme into double 
stranded DNA. 5) Dinucleotide ‘GT’ of synthesized viral DNA is cleaved at conserved CA site on 
U3 and U5 of 3′ end within the preintegration complex (PIC) by HIV-1 IN. 6) The nuclear 
localization signal of PIC components Vpr and matrix allows its importation through nuclear pore 
into the cell nucleus. 7) The exposed hydroxyl group on cleaved 3′ ends cut through host DNA 
and viral DNA integrates into host chromatin. 8) When infected cell is activated, the provirus acts 
as a template for transcription of viral RNAs. 9) Spliced and unspliced viral RNAs are exported 
out of nucleus to cytoplasm for translation. 10) Viral proteins and genomic RNA assemble on 
plasma membrane. 11) The immature virion buds off cell membrane. 12) HIV-1 virion undergoes 
maturation under HIV-1 protease accompanied by structural changes of virion proteins to form a 
mature infectious HIV-1 virion. 
 
1.3.1 HIV-1 binding and fusion  
The first stage of HIV-1 infection is binding or attachment coordinated by surface envelope 
glycoprotein. HIV-1 env is around 400 kDa in size and trimeric in structure (trimers of gp120/gp41 
complexes). Through coordinated events, the viral envelope glycoprotein attaches to its primary 
cellular CD4+ receptor and subsequently to CXCR4 or CCR5 chemokine co-receptors. HIV-1 
receptor CD4+ marker is a member of the immunoglobulin superfamily that is expressed on cells 
including helper and regulatory T cells, CD4 T cells, macrophages, monocytes, and dendritic cells 
(177). The Van der waal forces and hydrogen bonds stabilise the complex of gp120-CD4 through 
interaction between the negatively charged gp120 pocket and positively charged CD4 receptor. 
The amino acid Phe 43 on CD4 receptor has been implicated in increasing the binding affinity of 
gp120 to CD4 receptor by 23%. The binding of gp120 to CD4 receptor triggers a change in 
conformation of gp120 which enables interaction with coreceptors, CCR5 (178) or CXCR4 (179). 
HIV-1 tropism is defined by the type of coreceptor usage during infection; CCR5 binding viruses 
(M-tropic) (178) CXCR4 (T-tropic) (179) and CCR5-CXCR4 (dual-tropic) (180). It has been 
shown that CCR5 mainly expressed on surface of macrophages is preferred during early infection 
and CXCR4 is largely preferred during late phase of HIV-1 infection. On binding of gp120 to its 
coreceptor CCR5 or CXCR4, triggers conformational change of transmembrane protein gp41. 
gp41 consists of fusion protein and N-terminal heptad repeat (HR) 1 and C-terminal HR2 regions. 
The fusion protein has hydrophobic glycine-rich residues which facilitate penetration of HIV-1 
virion into target cell membrane (181). After binding of gp120 to its coreceptor, fusion protein is 




form 6-helix structure which leads to formation of a fusion pore through which HIV-1 capsid enters 
into cytoplasm of CD4+ cell (181). 
 
1.3.2 Uncoating 
After successful viral attachment and fusion, the cone-shaped viral capsid (CA) dissembles in the 
cytoplasm during the process of uncoating (182). The CA encompasses genomic RNA, viral and 
cellular proteins (50) and around 1500 CA molecules that oligomerize through interactions 
between their N-and C-terminals. Despite the timing of uncoating being not properly explained, 
the limited presence of CA molecules in the reverse transcription complex indicates early 
occurrence of uncoating (182). In support of this view, defects in viral core leads to impaired steps 
like reverse transcription (183–185). The viral core stability is critical for the uncoating as it affects 
the ability of HIV-1 to infect non-dividing cells (186) and nuclear import of PIC to the nucleus 
(187). The IN is among viral proteins facilitating CA uncoating (188). Host factors are also 
involved in uncoating of the viral core; TRIM5α impairs the process through increased output of 
uncoating (189,190) and recognition of CA lattice by TRIM5α activates innate immune signaling 
pathways (191). Cyclophilin A promotes uncoating of viral core (192,193) and interaction between 
cyclophilin A and CA leads to specific increase in infectivity in some cell lines (194–196). Host 
factors are also known to facilitate the shedding of the CA protein to release the two single-
stranded viral RNA copies and accessory proteins inside the cell cytoplasm. Inside the cytoplasm, 
the viral single-stranded RNA must undergo reverse transcription to complementary DNA (cDNA) 
to facilitate viral replication. The viral reverse transcriptase enzyme and cellular factors are 
required for the process of reverse transcription to occur.   
 
1.3.3 Reverse transcription 
After viral entry into the host cell cytoplasm, the HIV-1 core slowly disassociates to reduce spatial 
constraints and allow for infusion of dNTPs into a PIC in which reverse transcription of the 
genomic RNA occurs. The host tRNALys,3 primer already packaged and bound to genomic viral 




nucleotide from 5′ end of vRNA. The stability of vRNA and tRNALys3 complex is mediated by 
complex, extended base pairing interactions that are likely facilitated and then stabilized by the 
nucleocapsid protein (197,198). The minus-strand cDNA is initiated from tRNALys3 and becomes 
the first product of reverse transcription (minus strand strong stop DNA). RNaseH degrades the 
RNA portion of the newly formed RNA/DNA hybrid and releases the minus strand strong stop 
DNA. The complementarity repeat (R) of sequences at 5′ end of minus-strand strong stop DNA 
and 3′ of vRNA allows minus strand DNA to hybridize 3′ end of one of two vRNAs in HIV-1 
particle and continue the synthesis of full-length minus-strand DNA, a process known as first 
template switch. During the minus strand DNA synthesis, the RNAse H activity of RT degrades 
the genomic RNA in RNA-DNA hybrid but retains a RNase H-resistant, highly conserved purine 
rich-polypurine tract (PPT) at the 3′ of genomic RNA and PPT acts as a primer for synthesis of the 
plus-strand DNA synthesis.  The synthesis of positive-strand DNA is initiated at PPT and proceeds 
to the end of HIV-1 genome and it also copies the first 18 nucleotides of tRNALys3 primer which 
becomes a substrate for RNaseH once it has been copied to DNA. HIV-1 cleaves tRNA from 3′ 
end leaving a single A ribonucleotide at 5′ end of minus-strand. The 18 nucleotides copied from 
tRNALys3 are complementary to the 18 nucleotides at the 3′ end of minus-strand DNA copied from 
the pbs. The two complementary sequences anneal which allows synthesis of both positive and 
minus-strands to ends of templates completing proviral double-stranded DNA. This process is 
summarized in Figure 7. 
The synthesized proviral vDNA becomes the specific substrate for the PIC. The PIC consists of 
viral proteins, RT, IN, matrix and Vpr (199–201) and ever increasing number of host proteins 





Figure 7. HIV-1 reverse transcription. HIV-1 is a retrovirus with two copies of viral RNA which 
are reverse transcribed into double-stranded DNA for integration into human genome. A) In the 
first step of reverse transcription, human tRNAlys3 binds to the complementary sequence on pbs 
region of 5′ of viral RNA. The binding of tRNAlys3 at pbs initiates synthesis of minus -strand DNA. 
B)  The complementarity repeat (R) of sequences at 5′ end of minus-strand strong stop DNA and 
3′ of vRNA allows minus strand DNA to hybridize 3′ end of one of two vRNAs. C) The binding 
at the R allows synthesis of full-length minus-strand DNA. In the process, the original viral RNA 
template is degraded by RNaseH except for the RNaseH-resistant highly conserved purine rich-
polypurine tract (PPT) at the 3′ of genomic RNA which subsequently acts as a primer for synthesis 
of the plus-strand DNA synthesis. D) The synthesis of positive-strand by RT is initiated at PPT 
and proceeds to the 5′ end of viral genome including 18 nucleotide sequence of tRNAlys3. E) The 
complementarity of tRNAlys3 sequence allows annealing of positive strand on pbs. F) The 
annealing of two complementary sequences allows synthesis of both positive and minus-strands 
to generate proviral double-stranded DNA. 
 
1.3.4 3′ processing of terminal vDNA sequences 
The HIV-1 IN recognizes and binds to short specific sequences (12-20 bp) on both 3′ ends of viral 
LTRs. This high-order nucleoprotein complex of linear vDNA and HIV-1 IN known as intasome 
mediates integration of HIV-1 into target DNA. Reverse transcription of genomic RNA by reverse 
transcriptase results a blunt-ended vDNA duplex with terminal sequences 5′-ACTGCAGT-3′. The 




transposable elements. During 3′ processing which occurs in the cytoplasm (203), and in PIC 
(204), HIV-1 IN catalyzes the cleavage of dinucleotide (GT) from both 3′ ends of vDNA at 
conserved CA and exposed CAOH-3′ acts as nucleophiles for cleavage of target DNA later during 
strand transfer process in the nucleus (51,52) (Fig. 8).  
 
 
Figure 8. HIV-1 3′ processing and strand transfer processes. HIV-1 integrates into the host 
chromatin in a two-step process involving cleavage of dinucleotide ‘GT’ at conserved CA site of 
3′ LTR of HIV-1. The HIV-1 integrase remains bound to cleaved viral DNA which is translocated 
into the nucleus in pre integration complex. During strand transfer, the exposed hydroxyl act as 
nucleophiles and cut through phosphodiester bond of the phosphate at 5′ end of host DNA in 
staggered fashion creating 5-base pair insertion. The lone CA is removed and cut DNA ligated by 
cellular proteins which completes integration process. 
 
1.3.5 Import of PIC into nucleus 
The HIV-1 PIC is formed after viral core uncoating and formation of cDNA from reverse 
transcription of viral RNA. The HIV-1 PIC has karyophilic properties which it inherits from three 




associated cellular proteins, barrier-to-autointegration factor (BAF), HRP-2, and LEDGF/p75 
contain the nuclear localization signals (NLS) which allow active transport of PIC via nuclear pore 
(less than 40 kDa) into the cell nucleus. The karyophilic property of the HIV-1 PIC accounts in 
part for the ability of HIV-1 to infect both terminally differentiated macrophages and G2-and S-
phase arrested cells (206,208). The MA has a stretch of highly conserved amino acids, Gly-Lys-
Lys-Lys-Tyr-Lys (209), which is recognized by importin/karyopherin proteins (205,210). Indeed, 
a synthetic peptide containing putative NLSs of MA acted as nuclear import signal when combined 
with bovine serum albumin contrary to abolished nuclear import when the peptide was conjugated 
to wheat-germ agglutinin, an inhibitor of nuclear pore-mediated import heterologous protein in-
vitro (205). The phosphorylation of carboxyl-terminal tyrosine residue of matrix protein may be 
required for direct nuclear export of PIC (211). Nuclear import of PIC is further facilitated by 
several importins which transport proteins with NLS through nuclear pore. Importins, Imp7 (212), 
Impα1 (48,213), Impα3 (49,214), and Transportin 3(TNP03) directly bind to HIV-1 IN in cells in 
interphase to promote nuclear import of PIC (215,216). Nucleoporins, Nup153 interacts and 
facilitate import of HIV-1 Vpr (217) and HIV-1 IN (218), whereas Nup358 specifically binds to 
HIV-1 Rev and enables cDNA nuclear import (219). The role of HIV-1 Vpr for nuclear import of 
PIC may be stimulated by heat shock protein 70 (Hsp70) (220). In dividing cells, the HIV-1 PIC 
targets disassociation of cell nuclear membrane during mitosis to enter nucleus during interphase 
stage by signal mediated and energy dependent import through nuclear pore (208,221,222).  
 
1.3.6 Strand transfer-integration 
Once inside the nucleus, the PIC is tethered to host DNA by several cellular proteins including 
LEDGF/p75, BAF, Integrase interactor 1 (INI-1), and high mobility group protein A1 (HMGA1). 
The most well characterized of these is LEDGF/p75 (223–226). LEDGF/p75 is a 530 amino acid 
protein that acts as a transcriptional factor and a survival factor encouraging cell growth by 
preventing stress-induced cell death. LEDGF/p75 is localized to the nucleus where it is found in 
tight association with chromosomes (227), and its nuclear abundance perfectly matches that of 
HIV-1 IN (228). The close contact of LEDGF/p75 with chromosomes helps to tether PIC to highly 
transcribing regions of cellular DNA (229,230). The role of LEDGF/p75 in HIV-1 integration is 




transfer activity exhibited by recombinant HIV-1 IN in the presence of recombinant LEDGF/p75 
in vitro (228). In addition to tethering PIC to chromatin, LEDGF/p75 increases the HIV-1 IN half-
life by preventing its ubiquitination and degradation by proteasomes (232).  
BAF is an 89 amino acid protein that bridges DNA molecules in a nucleoprotein complex by 
binding double stranded DNA. BAF is recruited in PIC (233) and has been implicated in 
orientating the PIC to chromatin (234–237). BAF also prevents autointegration of cDNA before 
integration (238). Lamina-associated polypeptide 2 alpha (LAP2alpha) is also involved in 
positioning PIC to chromatin by interacting with BAF (236). PIC associated HMGA1 protein has 
been implicated in facilitating DNA unwinding, supercoiling and bending. HMGA1 shows no 
interaction with HIV-1 IN but may facilitate HIV-1 integration by bringing vDNA ends together 
and into close contact with HIV-1 IN. INI-1 is a 385 amino acid protein that interacts with HIV-1 
IN and activates HIV-1 LTR by synergizing with tat and p300/CBP at 5′ HIV-1 LTR.  
In the nucleus and following dinucleotide cleavage/processing of the 3′ of vDNA, integratable 
vDNA associated with the PIC will mediate proviral DNA integration into the host genome. The 
IN bound to exposed 3′-OH ends of vDNA now cuts the host DNA by breaking down a pair of the 
phosphodiester bonds via nucleophilic attack by the reactive 3′-OH of vDNA (Fig.7). The host 
DNA cuts occurs simultaneously at both strands in a staggered fashion typically at position 
separated by 5 base pairs between the two opposite ends of insertion, exposing the 5′ phosphate 
end of host DNA that is ligated to the 3′-OH of the vRNA (239). After strand transfer, the vDNA 
and host DNA junctions have a 5 base pair sequence gap on the leading and lagging DNA strand 
in addition to 2 base pairs on 5′ of vDNA that remain unpaired.  In the subsequent step of HIV-1 
integration, the host cellular enzymes remove 5′ dinucleotide (CA) ‘flaps’ on vDNA and catalyze 
the filling of the gaps to complete integration process (240,241). The PIC is dissembled within 
minutes following joining of vDNA 3′ ends to the target DNA which results in an irreversible 
process of proviral integration. The cleavage of host DNA mediated by HIV-1 IN and ligation of 
vDNA and host DNA doesn’t require exogenous energy source. In addition to 3′ processing and 
strand transfer activities, HIV-1 IN can cleave integrated vDNA from host DNA in vitro in process 
termed disintegration and this can be accomplished in absence of either NTD or CTD (242–245). 
As described above and possibly related to LEDGF/p75 binding, HIV-1 proviral DNA is 




to facilitate virus infection and transmission (231). The provirus serves as a template for 
transcription into mRNAs in a process catalyzed by host RNA polymerase II or goes into 
transcriptionally inactive phase called latency. The latency phase is characterized by 
transcriptionally silent cells which don’t produce virions (246). 
Not all proviral DNA circularizes and associates with PIC/IN as a substrate for proviral DNA 
integration.  Unintegrated extrachromosomal vDNA can also be found as linear (3′ processed 
cDNA) and circularized DNA unintegrated forms inside the cell nucleus (Fig. 9). The circularized 
DNAs have covalently closed DNA circles with either single LTR sequence or two LTR sequences 
commonly referred to as 1-LTR circles and 2-LTR circles respectively. The 1-LTR circles are 
formed earlier than 2-LTR circles (247), and occur in most abundance compared to other forms of 
unintegrated DNA with the ratio of 2-LTRs to 1-LTRs circles ranging from 0.16-0.43 (248). The 
1-LTRs circles are products of homologous recombination between two flanked HIV-1 LTRs 
(248) or circularization due to defective reverse transcription (249). About 90% of 1-LTR circles 
are products of homologous recombination which occurs after nuclear import and are commonly 
found inside the nucleus (248). Approximately 10% of the total 1-LTR circles population is found 
in the cytoplasm, and these are products of defective reverse transcription (247). Cellular 
nucleases, RAD50, MRE11, and NBS1 have also been implicated in formation of 1-LTR circles 
(248,250).  Another fate of unintegrated linear viral DNA, is autointegration which happens when 
HIV-1 IN mediates 3′ processing of cDNA LTR ends which attack sites within viral DNA (self-
integration), resulting in circularized forms of rearranged or incomplete vDNA genomes (251) 
(Fig. 9).  
The 2-LTR circles are products of non-homologous end joining (NHEJ) pathway (252) and 
autointegration process, and they are exclusively formed inside the nucleus (247). The host NHEJ 
components are involved in double-strand DNA break repair during the G0, G1 and early phase of 
the cell cycle as a protective strategy towards presence of viral ssDNA. The NHEJ pathway 
involves binding and holding of ends of broken DNA by DNA-dependent serine/threonine protein 
kinase (DNA-PK) consisting of autoimmune antigen ku and DNA-PK catalytic subunit (DNA-
PKs). With ku guiding DNA-PKs to cut DNA ends, ligase 4/XRCC4/XLF performs the ligation 
reaction (253,254). In absence of compatible DNA ends for ligation, Artemis nuclease often trims 




of 2-LTRs is shown by decreased abundance of 2-LTRs when Ku, ligase 4 or XRCC4 are 
inactivated and modest reduction is observed upon inhibition of DNA-PKcs (248,256). Two LTR 
circularized DNA forms can still mediate HIV-1 mRNA transcription (257), production of Tat and 




Figure 9. Unintegrated forms of HIV-1 DNA. The translocated cleaved viral DNA has two fates 
in the nucleus; successful integration into the host DNA to form a provirus or failed integration 
which is characterized by mainly two forms of circulating DNA-1 LTR circle or 2-LTR circle. The 
larger portion of 1-LTR circles (90%) is found in the nucleus and the rest is in the cytoplasm. 2-
LTR circles are exclusively found in the nucleus. Another fate of unintegrated linear cDNA is 
autointegration due processed 3′ ends of reverse transcripts cleaving sites within viral DNA 
resulting into truncated and internally rearranged autointegrants. The majority of unintegrated viral 





1.3.7 Transcription, nuclear export of nascent RNA, translation and virus 
assembly 
Transcription of provirus is regulated by the promoter region of HIV-1 5′ LTR which contains 
crucial DNA binding sites; two NFkB sites, three Sp1 sites, and a TATA box. Upon stimulation 
of CD4+ T cell, NFAT and NFkB are activated and recruited to the promoter region of nascent 
RNA transcripts. This leads to recruitment of Tat to the promoter region which trans-activates 
HIV-1 mRNAs expression by interacting with Trans acting response element (TAR) of 5′ HIV-1 
LTR. Tat binding on TAR stabilizes TFIID/TFIIA complex on the TATA box and facilitates 
recruitment of TATA-binding protein, and a cellular P-TEFb and CTD kinases to the HIV-1 
promoter. These kinases include CDK family of CDK2, CDK7, CDK8, CDK9, and CDK11. P-
TEFb is a heterodimer protein made up of cyclin-dependent kinase 9 (CDK9) and its regulatory 
partner cyclin T1. The human cyclin T1 mediates interaction between P-TEFb and Tat (260). In 
presence of Tat, CDK9 phosphorylates the CTD domain of RNA pol II which increases 
processivity of elongating RNA polymerase II (261). In the absence of Tat, only serine 2 of 
heptapeptide repeats is phosphorylated by CDK9 and serine 5 by a component of TFIIH, CDK7 
(261). Tat also interacts with transcriptional cofactors including sp1, cyclinE/cdk2, TFIIH, Tip60, 
polymerase II and transcription activators p/CAF and CBP/p300. In the absence of Tat, the rate of 
HIV-1 transcription initiation is not affected but no elongation of mRNA transcripts is observed 
beyond +59 position due to pausing by RNA pol II (176). 
Alternative splicing of HIV-1 mRNA leads to 47 different RNA species. Depending on extent of 
splicing, there are three categories of HIV-1 RNA transcribed from provirus: 1) partially spliced 
RNA, which are ≈ 4 kb length transcripts of Vpu, Env, one exon Tat, Vpr and Vif; 2) completely 
spliced, ≈ 2 kb transcripts of Tat, Rev, Nef; 3) unspliced RNA, genomic RNA for packaging, Gag, 
and Gag-Pol polyproteins. In the early phase of nuclear export, 9 kb mRNA transcripts are spliced 
to 2 kb RNAs which are exported via normal mRNA pathway and are translated to produce Tat, 
Rev, and Nef. After translation, Rev is imported back to the nucleus via its nuclear localization 
signal(169,262). In the late phase of nuclear export, Rev binds partially spliced and unspliced 
mRNAs at Rev Response element (RRE) located in env coding region before splicing, and exports 
these unspliced or partially spliced messages out of the nucleus to cytoplasm. The leucine rich 




nucleocytoplasmic export. To facilitate nuclear export of cargo, Rev also recruits nucleoporins, 
Nup98 and Nup124 in rev-Crm1 controlled export (263). The partially spliced and completely 
spliced RNAs are shuttled to the ribosome in the cytoplasm for translation into various viral 
proteins.  
The Env and Vpu proteins which are coded by the same mRNA transcript are translated on rough 
endoplasmic reticulum (RER). The Env proteins are glycosylated as they translocate through 
membrane of RER, and they are cleaved by Furin protease to produce SU gp120 and 
transmembrane protein gp41 in the Golgi apparatus, and then transported to the plasma membrane. 
At budding site (cell membrane), the intracellular tail of the transmembrane Env gp41 interacts 
with MA region of the Gag and Gag-Pol precursor proteins. Gag also binds, interacts with, and 
packages other components into a newly formed core.  These include (264,265) cellular proteins, 
ICAM-1, HLA-II, cyclophilin A, actin-binding proteins, lysyl tRNAs-synthetase, and ubiquitin 
(266). HIV-1 Gag preferentially binds and incorporates/encapsidates two copies of the genomic 
HIV-1 RNA while the Gag-Pol is involved in the preferential packaging and placement of the 
tRNALys3 on the genomic RNA. During assembly, Env protein, PR, RT and IN viral enzymes are 
incorporated into the immature virion. The HIV-1 particle later buds off of the cell surface as an 
immature virion mediated by the host endosomal sorting complexes required for transport 
(ESCRT) machinery.  
 
1.3.8 Maturation of viral proteins 
Maturation of HIV-1 particle occurs simultaneously with or immediately after budding from the 
cell surface and is triggered by proteolytic cleavage of Gag and Gag-Pol precursor proteins by 
HIV-1 PR. During virion maturation, the PR subunit in the Gag-Pol precursor autocleaves itself 
out and proceeds to cleave the rest of Gag-Pol and Gag polyproteins at twelve different sites into 
mature structural MA, CA, NC, P6, small spacer peptides p1 and p2, and catalytic enzymes PR, 
RT, and IN (45). This cleavage at these different sites occurs sequentially and at different rates 
with e.g. the first cleavage occurring between spacer peptide p2 and NC and intermediate cleavage 
occurring between CA/MA and p1/p6 sites, and final cleavage at the NC/p1 and CA/p2 sites 




within the viral particles to form the mature viral particles. Following its release from the Gag-Pol 
polyprotein, CA forms hexameric lattice that forms the conical viral core containing viral RNA 
genome, mature NC, RT, and IN proteins (Fig 1). The sequential maturation process of Gag and 
Gag-Pol is described in Figure 3.  
 
1.4 Antiretroviral therapy 
The first report of a new deadly disease found in men who have sex with men in 1981 and then 
among hemophiliacs and intravenous drug users in the USA (2,271,272) led to the rapid search for 
a drug to block this unknown disease.  The discovery that AIDS was caused by HIV-1 in 1983 
then led to the rapid testing of nucleoside analogs that had been shown to inhibit avian and murine 
retroviruses.  Among the nucleoside analog class, only acyclovir, an acyclic nucleoside analogue 
against herpes simplex was approved for therapy by the FDA and was the only effective antiviral 
agent available on market (273,274).  
3'-azido-3'-deoxythymidine (AZT), first synthesized in 1964, was the leading agent among 
nucleoside reverse transcriptase inhibitors (NRTIs)  (275,276) and was rapidly approved in 1987 
(Fig. 10) for HIV-1 treatment after undergoing a small exploratory study (277) and a double blind-
placebo controlled trial. Drug resistance quickly emerged in patients taking AZT (278). In 
subsequent years, more NRTIs were available for HIV-1 treatment including didanosine (2',3'-
dideoxyinosine) (279) and zalcitabine (2',3'-dideoxycytidine) (280) which allowed comparison of 
dual NRTIs to monotherapy. Better outcomes in antiretroviral therapy (ART) naïve patients were 
recorded with dual nucleoside analog therapy (281–284) which paved a way for triple therapy-
highly active antiretroviral therapy (HAART) in 1996 after a number of studies including ACTG 
320 which showed adding two new drugs (indinavir (IDV) and lamivudine (3TC) with AZT in 
AZT experienced patients was more effective than adding a single drug (285). HAART 
combinations differ in each geographical location and largely attributed to the disproportional 
ability to access the most potent antiretroviral drugs for the most effective treatment regimens by 
countries of different economic means. This inequality for HIV-1 treatments across the globe 




Currently, there are over 34 individual and 23 HIV-1 drug combinations approved by Food and 
Drug Authority (FDA) for therapeutic treatment and one ART combination for HIV-1 prevention 
(Fig. 10). Over the years, cART have become more potent, formulated in a single daily pill, are 
easier to tolerate with few adverse events, and high barrier to drug resistance, all of which has 
improved treatment outcomes. These new formulations include fixed dose combinations which 
contain two or more drugs from two or more drug classes in a single tablet. Long acting injectables 
which are dosed once per week or month are tolerable and improve adherence to ART (US national 
library of medicine). These may include long acting injectable, cabotegravir/rilpivirine (in late 
phase III clinical trial), dapivirine within a vaginal ring, and tenofovir alafenamide as a subdermal 
implant (286–288) (289). ART regimens reduce viral replication by targeting different stages of 






Figure 10. FDA approved HIV-1 treatment drugs and combinations. A) Regimens approved 
for HIV-1 treatment, in blue, nucleoside reverse transcriptase inhibitors; orange, non-nucleoside 
reverse transcriptase inhibitors; green, protease inhibitors; red, integrase inhibitors; yellow, 
pharmacokinetic enhancer; brown, post attachment inhibitors; and black, fusion inhibitors. B) 
Brand names of fixed-dose tablets with drug abbreviations. In blue, combinations consisting of 
reverse transcriptase inhibitors; green, combinations of protease inhibitors; black, combinations 
with more than one class of ART.  
There are mainly 5 classes of ART; reverse transcriptase inhibitors target reverse transcription 
step, protease inhibitors target cleavage of polyprotein gag-pol and gag by protease, integrase 
inhibitors target strand transfer step, fusion inhibitors target fusion of gp41 onto host cell 
membrane, and binding inhibitors target HIV-1 coreceptor CCR5. Along with a novel long acting 
anti-CD4 monoclonal antibody, Ibalizumab, new agents targeting capsid assembly, glycoprotein 





1.4.1 Classes of ART and mode of action 
1.4.1.1 HIV-1 integrase strand transfer inhibitors 
HIV-1 integrase strand transfer inhibitors (INSTIs) target HIV-1 IN to stop viral replication. HIV-
1 IN catalyses HIV-1 integration by 3′ endonucleolytic processing of vDNA ends in the cytoplasm 
and strand transfer process in the cell nucleus where vDNA is covalently linked to cellular DNA. 
The discovery of integrase inhibitors depended on screening compounds using assays where 
recombinant HIV-1 IN catalyzed the first step of dinucleotide cleavage on the end of viral DNA 
and/or the strand transfer reaction. The safety of HIV-1 IN is largely based on the fact that the host 
does not produce an enzyme with this type of endonucleolytic processing and strand transfer event. 
After this enzymatic assay screen, an effective IN inhibitor had to meet four basic preclinical 
development criteria in cell culture:  (1) efficacy in vitro that was comparable to blocking HIV-1 
replication in tissue culture (also suggesting cell penetration by the drug) (290–293), (2) 
accumulation of 2-LTRs and reduced integration into host chromosome (290,292,294), (3) with 
dose escalation experiments, the emergence of drug resistant viruses with mutations in integrase 
(290,293,294), and confirmation that the presence of DRMs in recombinant IN showed reduced 
susceptibility to the inhibitor in vitro (290,294).  
The two strategies considered in development of HIV-1 IN inhibitors were; binding to free 
unbound HIV-1 IN or to HIV-1 IN-vDNA complex. Both strategies were attempted, however, the 
high stability of HIV-1 IN-vDNA complex characterised by slow catalytic activity makes it 
difficult for HIV-1 IN inhibitors to bind free HIV-1 IN (295). The complex of HIV-1 IN CCD and 
shionogi inhibitor 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone-5CITEP, 
formed a platform for design of HIV-1 IN inhibitors. The 5CITEP inhibitor binds centrally 
between D-D-35-E motif and forms hydrogen bonds with residues Thr 66, Gln 148, Asn 155, Lys 
156, and Lys 159 (296) (Fig. 11). Some of these residues Lys-156, Lys-159, and Gln-148 are 
involved in vDNA binding (297,298). 5CITEP does not chelate cationic ions at the active site but 
tends to mimic DNA substrate/IN interaction and therefore seems to prevent binding of the second 
divalent cation by occupying the DNA-substrate binding site that inhibits the formation of HIV-1 
IN/DNA complex (296,299) (Fig.11). The assays to identify ligands that bind to HIV-1 IN-vDNA 






Figure 11. The HIV-1 IN CCD and 5CITEP complex. The crystal structure (PDB ID 1QS4) 
(296) shows three HIV-1 IN CCD monomers with HIV-1 IN inhibitor, 5CITEP (red) binding to 
one of the CCD monomers. The three catalytic residues (D64, D116 and E152) are depicted in 
blue and magnesium ion (green) being coordinated by D64, and D116 residues in presence of four 
water molecules (cyan). The HIV-IN residues which form hydrogen bond with 5CITEP inhibitor 
are shown in black.  
 
Following this initial discovery and preclinical development of HIV-1 IN inhibitors at Merck, most 
INSTIs in development and all those approved for treatment target HIV-1 IN protein by 
specifically inhibiting strand transfer process not 3′ processing (300–304). HIV-1 IN requires a 
metallic cationic cofactor to be active and these are coordinated by a triad of acidic residues called 
DDE motif (D64, D116, and E152) in the catalytic domain of HIV-1 IN. INSTIs target the Mg2+ 
chelating groups due to the fact that Mg2+ is a cofactor required in vivo and is less tolerant to 
sequence variations in LTRs (305), and several mutations affect IN activity in Mg2+ dependent 
assays for instance mutations in zinc coordinating motif, HHCC of N-domain of HIV-1 IN (306). 




vDNA to form stable complexes with LTR DNAs (PIC). The confirmation change as a result of 
HIV-1 IN binding to vDNA allows the binding of INSTIs (307).  
INSTIs bind to the CCD domain on IN, involved in chelated Mg2+, and compete with host DNA 
substrate (307).  They typically bind to IN/DNA complex close to 3′ end of vDNA in the enzyme 
and thus inhibits binding of donor DNA to the target host DNA (300,308) (Fig. 12).  
 
 
Figure 12. The crystal structure of DTG bound to prototype foamy virus integrase and 
vDNA. The structure shows DTG binding at active site of CCD of PFV IN with catalysis residues 
D128 (HIV-1, D64), D185 (HIV-1, D116) and E221 (HIV-1, E152) depicted in blue and divalent 
Mg2+ shown in yellow. DTG is shown in red binding to 3′ end of PFV vDNA. The common INSTIs 
associated resistance residues, Y212 (Y143, HIV-1), N224 (N155, HIV-1), and S217 (Q148/G140, 
HIV-1) are shown in magenta. The image was made in Pymol using x-ray crystallography structure 
(PDB ID 3S3M) (308).  
 
For the INSTIs compounds to be active pharmacophores, they must have a chemical group of three 
oxygen atoms in same geometric plane and halogenated phenyl group in their chemical structure 
(Fig.13). The halobenzyl moiety fit within a tight catalytic pocket of HIV-1 IN made available 
after 3′ processing, and interact with G:C proceeding the terminal adenine of 3′ HIV-1 LTR viral 
end, and with residues 145 and 146 of HIV-1 IN. This interaction results in displacement of the 
reactive adenine (309,310) and eventually of 3′ hydroxy group from the active site which 




vDNA complex due to displaced 3′ hydroxy group is further elucidated by increased rate of 
association of INSTIs binding to HIV-1 IN-vDNA complex on deletion of this adenine base (311). 
The three oxygen atoms of β-hydroxy ketone moiety chelate divalent cations within the catalytic 
pocket which impedes catalytic triad D-D-35-E from participating in strand-transfer process (312–
315).  
Raltegravir (RAL), formerly known as MK-0518, was the first INSTI to be approved by the FDA 
in 2007 (316,317), followed by elvitegravir (EVG) (JTK-303/GS-9137) in 2012, dolutegravir 
(DTG) in 2013 (S/GSK1349572), bictegravir (BIC) (GS-9883)  in 2018 and cabotegravir (CAB) 
formerly S/GSK 1265744 or GSK 744 in 2021. Both first generation INSTIs, RAL and EVG are 
effective against WT HIV-1 but the genetic barrier to drug resistance was less than that observed 
with the second generation of INSTIs (DTG, BIC and CAB). DTG and BIC remains effective in 
the presence of some HIV-1 resistant to RAL and EVG (318,319). The structural differences 
between DTG and RAL or EVG may explain high potency seen with DTG. Contrary to EVG/RAL, 
the chelating motif of DTG is located on a tri-cyclic scaffold (319,320). The linker region joining 
metal chelating motif to halogenated group of DTG is further extended compared to RAL and 
EVG (308) (Fig.13) which allows deeper access into the pocket vacated by displaced vDNA 
allowing a closer interaction with vDNA. In addition, presence of RAL/EVG resistant viruses, 
DTG can adjust its position and conformation in response to structural changes at the IN active 
site.  
INSTIs, BIC, and CAB, are the latest second generation INSTIs. BIC a structural analog of DTG 
was approved in 2018 as a fixed-dose combination of BIC/FTC/ tenofovir alafenamide (TAF) in 
ART naïve and suppressed patients (<50 copies/ml) (321). BIC is a potent, un-boosted, once daily 
INSTI, with higher in vitro barrier to resistance against RAL and EVG and with a few drug-drug 
interactions. CAB is another analog of DTG from a class of carbamoyl pyridones that has recently 
been approved by FDA and European Union as long-acting injectable, CAB/rilpivirine for use in 
HIV patients with undetectable viral loads, stable on current ART, and no drug resistance. 9–11 The 
unique physicochemical and pharmacokinetic properties of the CAB formulation allows its use as 
a single-daily tablet or long-acting nanosuspension for monthly or quarterly via subcutaneous or 
intramuscular administration. CAB was recently approved as a fixed-dose long-acting injectable 




individuals. 12,13. BIC and CAB are structurally and chemically similar to DTG both having tri-
cyclic central pharmacophore, though metal-chelating scaffold for CAB is 5-membered (more 
rigid) compared to 6-membered ring (more flexible) for DTG (Fig.13) (325). Overall, BIC seems 
to be more effective than either CAB or DTG which may be explained by further flexibility of 
oxazepine ring allowing accommodation to structural changes of IN active site in presence of 
resistant mutations.   
 
 
Figure 13. HIV-1 integrase strand transfer inhibitors (INSTIs). Currently, there are two groups 
of INSTIs, the first generation (RAL and EVG) and second generation INSTIs (DTG, BIC, CAB). 
All currently approved INSTIs are characterized by three coplanar oxygen group for chelating 
magnesium ions at active site of HIV-1 IN and halogenated benzyl group which seats in pocket 
left by cleaved ‘GT’ dinucleotide and eventually displacing the terminal adenosine of 3′ end of 
viral DNA to terminate integration process. 1) Elvitegravir, 2) Raltegravir, 3) dolutegravir, 4) 
cabotegravir, and 5) bictegravir. The coplanar oxygen atoms are highlighted in red and green circle 
highlights extended linker a common feature to all second generation INSTIs. MarvinSketch was 






1.4.1.2 Nucleoside reverse transcriptase inhibitors 
HIV-1 reverse transcriptase catalyses reverse transcription of viral RNA into complementary 
DNA. Nucleoside reverse transcriptase inhibitors (NRTIs) halt viral replication by inhibiting 
reverse transcription. NRTIs bind to a hydrophobic pocket away from RT active site and exert 
inhibition by competitive inhibition, where modified nucleotide (nucleoside triphosphates) lacking 
3′-hydroxyl group on deoxyribose moiety compete with natural deoxynucleotide for incorporation 
into new strand of DNA (326). Inside the cell, the NRTIs are activated by phosphorylation of 
deoxyribose moiety by cellular kinase enzymes into active metabolite triphosphates (327–329). 
When modified deoxynucleotides are incorporated, the incoming deoxynucleotides cannot form 
5′-3′ phosphodiester bond required to extend DNA chain (330). The chain termination stops 
formation of DNA synthesis which halts viral replication (326). The NRTIs have been screened to 
have highly selective incorporation into the HIV-1 RT over the normal host DNA synthesis to 
minimize drug toxicity and side effects. 
 
1.4.1.3 Non-nucleoside reverse transcriptase inhibitors 
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) do not compete with HIV-1 RT for 
incorporation of normal deoxynucleotides but bind directly to a pocket near the active site of HIV-
1 RT enzyme (41,331). A NNRTI hydrophobic RT complex forms only in the presence of NNRTIs 
(332,333) and the NNRTIs causes conformational change of substrate-binding site which impairs 
RT enzyme polymerisation (41,334). The NNRTIs make contacts with hydrophilic residues, K101, 
K103, S105, D192, E224, and E138; and hydrophobic residues, Y181M Y188, F227, W229, and 
Y232 (335). The approved NNRTIs for treatment and their abbreviated names in the subsequent 
text are listed in figure 10. 
 
1.4.1.4 Protease inhibitors 
The HIV-1 protease enzyme is relatively small (11 kDa).  It is a homodimer of two identical 
symmetrical subunits of 99 amino acids. It has two mobile flaps which form a cleft, the middle of 




polyproteins Gag-Pol and Gag from translation of mRNA by ribosome are cleaved by HIV-1 
protease enzyme into viral enzymes, RT, PR and IN and structural proteins of matrix, capsid, 
nucleocapsid, p1, p2 and p6 respectively (336,337) as described in sections 1.2.1 and 1.3.8. The 
protease inhibitors inhibit PR activity through interaction between hydroxyl group of inhibitor and 
carboxyl group of PR active site residues, Asp 25 and Asp 25’ contacting relatively conserved 
residues Asp 29, Asp 30, Gly 27 and Gly 48 of PR enzyme. This prevents cleavage of Gag-pol and 
Gag polyproteins which results in formation of immature non-infectious virion particles (338). The 
PIs are potent regimens with high genetic barrier to resistance but to inhibit fast metabolism and 
to increase drug’s intracellular half-lives, they need to be co-administered with pharmacokinetic 
enhancers. Ritonavir is a protease inhibitor and also a pharmacokinetic enhancer now commonly 
used to inhibit cytochrome P450 3A4 isoenzyme to increase the intracellular half-lives of protease 
inhibitors as well as many drugs used for treatment of various diseases (339,340). Cobicistat 
(Tybost -GS 9350) is an inhibitor designed to specifically inhibit the cytochrome P450 3A 
(CYP3A) isoforms including CYP3A4 subtype. Low dose Cobicistat increases systemic exposure 
and ultimately reduces adverse side effects of atazanavir (ATV), darunavir (DRV), tenofovir 
(TDF), EVG, and other antiretroviral agents used in treatment of HIV-1. It has also been shown 
that Cobicistat increases intestinal adsorption of substrates including ATV, DRV and TDF (341). 
The first PI, saquinavir, was approved by FDA in 1995. The approved PIs for treatment and their 
abbreviated names in the subsequent text are shown on figure 10.  
 
1.4.1.5 Fusion inhibitors 
The HIV-1 envelope consists of surface membrane gp120 and transmembrane protein gp41 which 
anchors the HIV-1 on to the target cell surface. The binding of gp120 to CD4 receptor triggers 
disassociation of gp120 from gp41 and gp41 undergoes a conformational change which allows 
fusion of viral and cellular membranes (342). The essential role of gp41 in anchoring HIV-1 to the 
cell surface makes it a target for inhibition. The gp41 is predicted to have two hydrophobic helices 
termed ‘heptad repeat’ sequences, HR1 and HR2 that are positioned at the base of HIV-1 env 
trimer. The two heptad repeat domains, HR1 and HR2, interact to form a stable six-helical bundle 
of N helices (interior trimeric coiled coil) and trimeric C helices (342,343) and this interaction 




Analysis of gp41 using x-ray structure shows a small pocket in conserved hydrophobic groove of 
N-peptide bound to isoleucine, tryptophan, and 3 hydrophobic residues which makes it attractive 
to entry inhibitors (342,345). A non-pocket binding peptide, T-20 is the only fusion inhibitor 
approved by FDA. T-20 is a synthetic peptide of 36-amino-acid peptide corresponding to C-
terminal HR2 sequence of gp41 (181). T-20 disrupts interaction between HR1 and HR2 which 
disrupts formation of 6-helix bundle required for membrane fusion (181). T-20 has shown potency 
in patient studies (346,347), and has similar viral inhibition to that of reverse transcriptase and PI 
(346). However, T-20 is more affected by resistance compared to binding-pocket analogues (348).  
Mutations against T-20 are known to reduce viral replication fitness (349,350) and result in  
hypersensitivity to neutralising of monoclonal antibodies targeting gp41 (349). Resistance 
mutations against T-20 include, G36DEVS, V38EAMG, Q40H, N43DKS, I37V, N42T, L44M, 
and L45M (Stanford HIV-1 database, IAS-USA). Resistance mutations to synthetic peptide DP178 
early version of T-20 cluster more in first heptad repeat (HR1) than other regions of gp41. 
 
1.4.1.6 HIV-1 coreceptor antagonists 
HIV-1 entry into the CD4+ cells requires binding to chemokine receptors CCR5 (178,351) or 
CXCR4. CCR5 is expressed by lymphocytes, astrocytes, brain microglia, neurons, capillary 
endothelial cells, epithelium, vascular smooth muscle, fibroblasts, and subpopulations of 
monocytes (352). The ligands for CCR5 include, macrophage inflammatory protein 1 (MIP-1),α, 
MIP-1β, RANTES, and HIV-1 gp120 (353,354). CXCR4 is constitutively expressed by lymphatic 
tissues, spleen, thymus, small intestines and brain (355). The critical role of coreceptors to 
effective HIV-1 infection is underscored by observation that peripheral blood mononuclear cells 
(PBMCs) isolated from individuals deficient of CCR5 are not infected by HIV-1 (356–360). 
Naturally occurring point mutations don’t reduce HIV-1 infection (361), but CCR5 missing 32 
base pairs (CCR5∆32) leads to resistance to HIV-1. Individuals homozygous for CCR5 deletion 
mutation (CCR5∆32) are resistant to HIV-1 (359,360) and heterozygous individuals for CCR5∆32 
may be protected from numerous abnormalities including, AIDS associated lymphoma (362,363), 
multiple sclerosis (364–366), rheumatoid arthritis (367,368) and Crohn’s disease (369). 




T cells (358). The CCR5∆32 allele frequencies is around 0%-14% across Eurasia but absent in 
individuals with Asian or African origin (359,370,371). 
CCR5 antagonists bind to a hydrophobic pocket formed by transmembrane helices of CCR5 (372). 
This allosteric interaction results into locks the receptor into a conformation that is unrecognisable 
by HIV-1 Env (373). There are four CCR5 analogues which have shown potency as CCR5 
antagonists; maraviroc, aplaviroc, vicriviroc, and leronlimab (PRO 140). Maraviroc was approved 
in 2007 (374,375), Vicriviroc was not filed for FDA approval following a successful phase III 
clinical trial, Aplaviroc was discontinued due to severe liver toxicities (376), and Leronlimab is a 
monoclonal antibody that binds to CCR5 receptor on the CD4+ T cells that has emerged as 
treatment following clinical trials. 
Maraviroc is recommended in treatment experienced patients infected with CCR5 usage viruses. 
Use of CCR5 antagonist in patients infected with CCR5/CXCR4 dual tropic viruses may 
encourage emergence of CXCR4 virus and rapid virological failure. Therefore, it becomes 
paramount to screen patients with HIV-1 showing even minimal usage of the CXCR4 coreceptor 
before prescription of MVC, a CCR5 antagonist. Resistance to CCR5 antagonists is mainly 
through 3 mechanisms; ability of HIV-1 Env to bind CCR5 bound to MVC (377,378), selection of 
CXCR4 by originally CCR5 viruses (379,380), and increased affinity of CD4 resulting in HIV-1 
remain bound to cell surface in a confirmation to engage CCR5 when MVC dissociates (based on 
its on-off binding). Generally, most mutations against CCR5 occur in V3 loop of gp120 (Maraviroc 
Viiv healthcare) though resistance mutations have also been observed in gp41 (381). Serial passage 
assays show selection of resistant mutations, T316A, V323I in V3 loop, contrary to resistant 
mutations against aplaviroc which preferentially cluster in C1-5, V1, V3 of gp120 and in gp41 
protein. The CCR5 antagonist functions by binding to CCR5 which leads to conformational change 
in coreceptor, in particular, the second extracellular loop (ECL2) which terminates binding to V3 
loop of HIV-1 gp120 (382,383). Some inhibitors like aplaviroc bind directly to ECL2. The CXCR4 
antagonists halt HIV-1 entry by inhibiting interaction between CD4-gp120 complex with ECL2 
region of CXCR4. Resistance emerging through enhanced CD4 interactions is conferred by the 
N425K mutation in the CD4 binding pocket in gp120.  This mutation provides a gain in replicative 
fitness but never emerges in patients with or without MVC treatment which may relate to exposing 




1.5 HIV-1 drug resistance 
HIV-1 drug resistance (HIVDR) is characterized by active viral replication in presence of ART, 
and it is the major reason for treatment failure (385). All currently available drugs for treatment of 
HIV-1 can select for HIVDR with first generation inhibitors more susceptible to HIVDR compared 
to newer generation of inhibitors. There are a number of factors which can lead to development of 
HIVDR; poor drug levels in patients taking the prescription but subtherapeutic blood drug levels 
is related to poor drug absorption, drug-drug interaction or possible genetic polymorphisms 
impacting drug metabolism.  Emergence of drug resistance is rare in patients adherent to the drug 
regimen and the latter factors appear a low frequency in the patient population.  Instead, HIVDR 
is primarily related to poor treatment adherence (Fig. 14) due to fatigue in maintaining life-long 
daily treatment, drug stock outs, taking “holidays” from drug treatment, avoiding the stigma or 
hiding treatments from others, and taking wrong dosages.  
 
 
Figure 14. The role of patient adherence to ART. 1) Adequate adherence to ART (>90%) allows 
viral suppression within first 3 months of starting ART in most patients. 2) Suppressed viral load 
inhibits selection of drug resistant variants in presence of ART. 3) Patients starting ART and not 




viral replication in presence of suboptimal drug dosage leads to preferential selection drug resistant 
variants in presence of ART. 
 
The HIV-1 mechanism(s) behind the emergence of drug resistance is rather simple compared to 
the sociodemographic and physiological factors that set the stage for treatment failure.  Compared 
to all other RNA and DNA polymerases in nature, HIV-1 RT has one of the highest 
misincorporation rates of nucleotides and does not possess repair mechanism such that replication 
of each HIV-1 genome can have been 1 and 10 mutations.  With a turnover rate of approximately 
a billion HIV-1 particles/day within an infected individual, nearly every possible mutation 
encoding for a replication competent virus emerges every day.  The survival of each mutant HIV-
1 strain forming a swarm of clones or “quasispecies” is based on the replicative fitness of each 
strain.  Under drug selective pressure, the strain with a specific mutation conferring reduced 
susceptibility to the drug is immediately selected in the population.  In general, the current 
generation of antiretroviral drugs select for HIV-1 mutants with low replicative fitness and of very 
low frequencies in the quasispecies of a patient.  Alternatively, the mutations conferring resistance 
are lower in the “fitness valley” and require multiple compensatory mutations to emerge for 
effective drug resistance and treatment failure. 
 
1.5.1 Mode of resistance to HIV-1 inhibitors 
1.5.1.1 Resistance to entry inhibitors 
Though sparsely used compared to other classes of ART, the clinical use of entry inhibitors has 
led to emergence of resistance to these inhibitors mainly through a coreceptor shift from CCR5 to 
CXCR4, and changes in the viral envelope which allows viral replication to continue in presence 
of inhibitors. HIV-1 resistance mutations against CCR5 antagonists are scattered in different 
regions of gp120 including V2, V3, C2 and C4 (386–388). Resistance mutations to many CXCR4 
antagonists have been observed on V3 domain of gp120; however, mutations against SDF-1α 
analogue in V1, V2, C2, and 5 amino acids deletion in V4 loop of gp120 have also been observed 
in resistance selection assay (389). No coreceptor usage switch from CXCR4 to CCR5 been 




1.5.1.2 Resistance to NRTIs 
Resistance to NRTIs mainly occurs in two ways; discrimination and excision pathways (326). 
During discrimination pathway, the HIV-1 RT enzyme affinity to bind to NRTIs is decreased due 
to mutations in the N-terminal domain of polymerase while retaining the ability to recognise 
natural deoxynucleoside triphosphate (dNTP) substrate e.g. RT mutations M184V and V75T. In 
another form of discrimination, there is a decrease in rate of incorporation of analogue over natural 
nucleotides, e.g. K65R, K70E, L74V, and Q151M. In the second mechanism to NRTIs resistance, 
the incorporated chain terminating analogues get excised from the 3′-terminus after it has been 
added into the viral DNA through pyrophospholysis. This allows DNA chain elongation to 
continue resulting in viral replication. The mutations may affect phosphorolytic activity of RT 
overcoming activity of NRTIs in a process called primer unblocking. The mutations which 
enhance loss of phosphorolytic activity of RT include those against thymidine analogues, AZT 
and d4T (stavudine), exhibit this form of antagonism; D67N, K70R, L210W, T215Y/F, K219E/Q. 
 
1.5.1.3 Resistance to NNRTIs 
The NNRTIs inhibit viral replication by non-competitive inhibition; where analogues bind the p66 
subunit of HIV-1 RT at a hydrophobic pocket near active site of RT which terminates elongation 
of DNA chain. The mutations result in conformational changes of the binding pocket through 
disruption of specific contacts between inhibitor and binding pocket, e.g. K103N, K101N; 
disruption of interactions inside pocket e.g. Y181C, Y188L; and overall conformational change of 
pocket e.g. G190E which makes a steric bulk in the pocket leaving no space for NNRTI binding. 
NNRTIs mutations, K103N against nevirapine (NVP), and efavirenz (EFV); and Y181C, against 
NVP, EFV, rilpivirine (RPV), and etravirine (ETR) are the most commonly selected in treated 
patients (390–392). HIV-2 and half the isolates of HIV-1 group O are intrinsically resistant to most 
NNRTIs (393). The drug resistance mutations observed in patients failing NNRTIs regimen all 
reside in the NNRTI binding pocket. NNRTIs have better tolerability profiles than NRTIs, but 
have lower genetic barrier to resistance since a single mutation in HIV-1 RT hydrophobic pocket 
confers high resistance to most NNRTIs with minimal or no impact on replicative fitness. 




administered as monotherapy which suggests that pre-existing mutations are quickly selected 
under NNRTIs pressure (394–397). Again, since mutations conferring NNRTI resistance don’t 
cause substantial loss to viral replication fitness (392,398), NNRTI resistant HIV-1 remain 
detectable in patient’s viral population many years after stopping a failing NNRTI-based treatment 
regimen. Non-subtype B viruses may be intrinsically more resistant to NNRTIs due to pre-existing 
background polymorphisms (399,400). Paradoxically, NRTIs resistance mutations for example, at 
codons 118, 208, and 215 were shown to cause hypersensitivity to NVP, EFV and DLV (401). 
 
1.5.1.4 Resistance to PIs 
The symmetrical structure of HIV-1 PR is crucial for efficient binding of PIs into the substrate-
binding site. The resistance to PIs is a result of mutations near the substrate-binding cleft of an 
enzyme which cause a conformational change, thus preventing the binding of PIs directly or 
indirectly leading to resistance (402–405). Most primary PI resistance mutations (e.g. V82A, I50V, 
G48V, I84V) are located near the enzyme active site. The mutations in the substrate-binding site 
of PR enzyme also affect the binding of normal substrates-Gag-pol and Gag polyproteins which 
affects the normal processing of immature proteins, resulting in impaired viral replication capacity 
(406–408). The loss in viral replication capacity (RC) is usually compensated by emergence of 
compensatory mutations which increase resistance to PIs (409–411) and restores the RC (410–
412). Thus, mutations in the PR cleavage sites within the Gag and Gag-Pol precursor proteins may 
act as compensatory mutations to ensure normal PR-mediated processing and HIV-1 core 
formation (337,408,413–415). The resistance mutation against one particular PI usually affects 
nearly all other first-generation PIs due to similar chemical structures and the substrate binding 
site in PR.  
Mutations in HIV-1 Gag located in close proximity to, but not within the canonical seven amino 
acids of cleavage sites have been associated with evolution of HIV-1 PR resistance mutations, for 
instance mutation I47V downstream of the NC/sp2 cleavage site, and P453L downstream of the 
sp2/p6 site (416,417). The mutations in HIV-1 Gag cleavage sites have also been shown to reduce 
susceptibility to HIV-1 PIs. The presence of NC/p1 cleavage site substitutions, K436E and/or 




1.5.1.5 Resistance to INSTIs 
Resistance to INSTIs occurs mainly through mechanisms involving conformational change of 
HIV-1 IN affecting the binding of INSTIs, charge effects, loss of stabilising IN and INSTIs 
interactions, and steric hindrance. The residues involved in INSTIs resistance are highly conserved 
in HIV-1 IN protein. The common resistance pathways to RAL and EVG observed in vivo and in 
vitro are commonly seen at positions N155, Q148, Y143, and E138 of HIV-1 IN (Fig. 15). Second 
generation INSTIs, DTG and BIC are commonly associated with mutations at positions R263 and 
Q148 in combination with other mutations. Resistance mutations at position Q148 are also 
associated with CAB, the long-acting derivative of DTG. Most of the residues involved in 
resistance are in proximity of surface α4 helix of CCD (Fig. 15) and some make direct contact with 
INSTIs. Thus, the binding of INSTIs to the HIV-1 IN-DNA complex and crucial connections by 
these residues within the complex may explain the occurrence of these mutations in HIV-1 IN. 
   
HIV-1 drug resistance to RAL portrays three major mutation pathways, Y143R/C, Q148R/K/H 
and N155H (419). Mutations, N155H and Q148H/K/R confer 10-fold and 25-fold resistance to 
RAL respectively (420). Other mutations against RAL observed in vivo include: L74M, E92Q, 
E138K, G140S/A and G163R (420). The mutation Y143H/C/R is specific to RAL (421,422) and 
F121Y is selected by RAL only in-vitro. Drug resistance to EVG occurs mainly through primary 
mutations, T66A/I/K, E92Q, N155H, S147G, and Q148H/K/R and G140S/A/C (423–425). 
Mutations S147G confers resistance exclusively to EVG. Secondary mutations conferring 
resistance to EVG include: H51Y, Q195K, Q146P, E138K/A/T, and G118R, (425,426) with 
F121Y, P145S, Q146P, and R263K reducing EVG susceptibility in vitro. Mutations T66I and 
E92Q reduce susceptibility to EVG by >30-fold and Q146P, S147G, H51Y, Q95K, and E157Q by 






Figure 15.The common INSTIs DRMs in different domains of HIV-1 IN. A) In the CCD, the 
majority of INSTIs associated DRMs (red) are observed in proximity to the three catalytic triad 
residues of IN active site (blue) and surface α4 helix (cyan). B) Residue R263 in CTD that is 
commonly associated with DTG resistance. C) Currently no INSTIs associated mutations been 
observed in NTD of HIV-1 IN. 
 
Mutations Y143R/C, Q148R/K/H and N155H are located within the CCD and in close 
juxtaposition to the catalytic triad of D64, D116 and E152 in CCD. Though Y143 lies slightly 
outside the catalytic pocket, Q148 is located close to the DDE residues and N155 is surrounded by 
D64 and E152 residues. In the co-crystal structures, there is no direct contact observed between 
residues Q148 and N155 with bound INSTIs (Fig. 12). However, owing to their critical position 
in active site, substitutions at these positions may trigger a conformational change within the 
catalytic pocket which impairs INSTIs binding (310). The α4 helix residues Y143 and Q148 make 
crosslinks with 3-processing site CA GT3’/5’ ACTG of U5 and U3 of HIV-1 LTR and may confer 
resistance by facilitating accurate positioning of target and vDNA substrates. The small and 
flexible amino acid G140 has been shown to accommodate movement of the His side chain at 
position Q148 enabling INSTIs to bind with a less significant conformation change of IN. This 
probably explains the increased resistance seen with Q148H+G140S/A compared to single Q148H 




impairs binding of INSTIs. Disruption of the His-phosphate interaction by INSTIs may explain 
resistance at residue N155 (310). The resistance associated with Y143 may be due to direct 
interaction with the oxadiazole group and phenol ring of bound RAL forming face-to-face π π 
stacking interaction that is abrogated when this residue is mutated (310,427). INSTIs, EVG, DTG, 
BIC and CAB which don’t have an oxadiazole group are not much affected by substitutions at 
Y143 position. The residues E92 and F121 are located close to bound EVG which may explain 
resistance at these positions. The primary resistance mutations to EVG are scattered around the 
catalytic triad surrounded by secondary mutations. Residues G118 and S153 associated with DTG 
resistance, are in close proximity to catalytic triad residues D116 and E152 respectively. G118R 
may confer resistance by altering geometry of catalytic triad affecting INSTI chelation of divalent 
cations in active site (428) or through causing steric hindrance to drug binding due to bulky 
arginine compared to glycine residue (308). R263K is located far from active site and reduce DTG 
susceptibility by reducing on vDNA binding (429).  
Contrary to EVG and RAL, DTG possess a higher resistance barrier (430,431) and is generally 
less affected by mutations known to cause cross resistance in RAL and EVG (432,433). DTG 
selects a rare R263K mutation in vitro (434) and in vivo (435) but at a cost of reduced RC 
(319,429,435) and ultimately impaired infectivity (436). Other resistance mutations associated 
with resistance to DTG have also been found in both patients failing EVG and RAL-based 
treatments and in vitro assays at positions F121, S153, G118, and E138 (319,429).  
Resistance mutations R263K, G118R, H51Y and E138K confer low level resistance to DTG in 
vitro (429,437). These mutations alone or combined with secondary mutations do impair RC. A 
combination of R263K and mutations at positions 143 and 148, leads to a drastic reduction of 
enzyme activity (434). R263K can tolerate the presence of two mutations, E92Q and N155H of all 
other mutations associated with RAL and EVG (436). In the presence of R263K or G118R and 
secondary mutations, H51Y, M50I, and E138K, the RC is significantly impaired or not restored 
(434,438,439). R263K mutation has influence also on accessory mutations to N155H pathway 
under DTG pressure. Despite viruses containing N155H and R263K in presence of DTG causing 
low level resistance against DTG, surprisingly, no change in resistance level against DTG is 
observed when R263K/N155H is added to L74M, E92Q, T97A, E157Q and G163R, common 




S153F/R263K mutations shows >100-fold resistance to DTG, RAL, EVG, BIC, and CAB in vitro 
(441). However, emergence of S153F and R263K as minority variants does not seem to translate 
into virological failure in a patient on DTG treatment over 24 weeks (441). 
Clinical trials, SINGLE (DTG/3TC/abacavir (ABC) vs TDF/FTC/EFV) (442), FLAMINGO (once 
daily DTG vs ritonavir boosted DRV)(443), and SPRING-1 and 2 ([once daily DTG versus EFV 
and twice-daily RAL respectively] drugs given with coformulated TDF/FTC or ABC/3TC) (444) 
assessed efficacy of DTG-based regimens in ART naïve patients, and no emerging DTG resistance 
was observed in patients given DTG-based regimens. In highly ART experienced patients with IN 
resistant virus to RAL and EVG, DTG (50mg) twice daily showed efficacy with 69% of patients 
achieving HIV RNA <50 copies/ml at week 24 but Q148HRK+ ≥ 2 mutations reduced odds of 
achieving HIV-1 RNA <50 copies/mL by 96% (318). In a study which compared once daily DTG 
versus twice daily RAL in ART experienced but INSTIs naïve patients (SAILING study), no 
emerging resistance mutations with genotypic and phenotypic resistance to RAL or DTG was 
observed in DTG arm but RAL-associated genotypic resistance emerged in 42% patients with 
virological failure taking twice daily 400mg RAL (435). Nevertheless, there are case reports and 
clinical studies reporting cases of DTG resistance. A case report shows virologic failure in an ART 
naïve patient on DTG/FTC/TDF and rifampicin and failure was associated with reduced DTG drug 
levels based on interactions with rifampicin (445). In this patient, virologic failure coincided with 
the emergence of R263K and E157Q in IN and the M184I in RT, i.e. conferring resistance to FTC 
(445). Another case report reported a patient on TDF/3TC/DTG regimen who had virologic failure 
associated with I151V, G163R, and Q148K in IN and M184V in RT (446). In ART experienced 
but INSTIs naïve patients in the SAILING study and a retrospective cohort study (DTG vs RAL 
vs EVG), DTG resistance has been observed with IN T66I and R263K mutations emerging DTG-
based arm (435,447). In HIV-1 infected patients, high RNA copies >100,000 copies/ml, CD4 T 
cell of < 200 cells/ul, adherence <80% (416), and coinfection with Mycobacterium tuberculosis 
(420), have been shown to be risk factors to emergence of DTG resistance. Despite these anecdotal 
cases, emergence of DTG resistance is rare following initiation of a new DTG-based cART among 
treatment experience patients and extremely rare in treatment naïve taking DTG-based cART. 
These observations, the high genetic barrier for DTG resistance, and the low replicative fitness of 
DTG-resistant HIV-1 prompted the field to consider use of DTG in monotherapy. DTG resistance 




when switched to DTG monotherapy.  DTG resistance was conferred by Q148H/R (3-patients), 
N155H (3-patients), G118R (2-patients), S230R (2-patients) and R263K (1-patient) (448,449).  
Interestingly, INSTIs mutations against DTG may have an inhibitory effect on NRTIs and NNRTIs 
mutations. The presence of H51Y/R263K delays the emergence of NNRTI resistance mutation, 
V106A by 5 weeks while R263K delays NRTI resistance mutation, M184V/I by 2 weeks (450). 
Emergence of NNRTI resistance (Y181C) required more viral passages and a delay between 15 to 
25 weeks when comparing wild type HIV-1 versus HIV-1 harboring INSTI resistance mutations 
G118R, H51Y/G118R (450). The emergence of V106A mutation was delayed from week 6 to 25 
weeks in viruses carrying H51Y/R263K vs wild type in presence of NVP. With 3TC, there was 
delay in emergence of M184I to week 25 in presence of H51Y/R263K mutations (450). In addition, 
presence of the INSTI-resistance mutations, R263K with either the NRTI resistance mutations, 
M184V/I or K65R mutations further reduce viral replicative capacity of the viruses with any one 
of these mutations alone  (451). The R263K mutation progressively reduces HIV-1 integration 
(452) and there is no detectable levels of integrated HIV-1 DNA in cell culture assays in presence 
of R263K/H51Y and M184I/V, L74V, K103N, E138K (451). Together, these observations may 
explain why cases of DTG failure with NRTI resistance mutation is rare, i.e. DTG resistant 
mutations cannot emerge or are slow to emerge due to additive reduction in replicative fitness. 
These observations also indicate impaired capacity of HIV-1 to develop resistance mutations in 
different genes at the same time under drug pressure. Combination of mutations in RT and IN 
genes also seem to interfere with interaction between these two genes leading to reduced RC. HIV-
1 IN mutations being pleiotropic, they have been described upon multiple viral steps including 
reverse transcription. HIV-1 INSTI drug resistant mutations have been found in all three domains 
of HIV-1 IN enzyme (453) and disruption of binding residues of RT on HIV-1 IN led to 
downregulation in synthesis of cDNA (454). Interestingly, presence of RT mutations M184I/V or 
K65R impair the emergence of DRMs against DTG but not EVG or RAL (455).  
BIC has resistance pathway involving R263K, S153F/F, H51Y, Q146L in cell culture (456,457), 
and Q148H. BIC generally retains activity against mutations T97A, T66I, E92G/Q, Y143R, 
Q148H/K/R, Q148H/G140S, and N155H, conferring resistance to EVG, RAL (458,459), and DTG 
associated mutations, G118R, R263K, H51Y/R263K (459). In phase 3 clinical trials investing 




patients, no emerging resistance to BIC was observed in any of the study patients (460,461). In 
GS-US-380-4030 study investigating efficacy of single-tablet regimen BIC/FTC/TAF in 
virologically suppressed patients with documented or suspected NRTI resistance, no emerging 
resistance to BIC was reported in the study (462).  
CAB an analog of DTG shows activity in presence of RAL, EVG, and DTG mutations, Y143R, 
N155H, T66I, E92Q, H51Y and E138K/R263K with EC50 of <5 nM (458), and Q148H/K/R, 
G140S/Q148H/K/R, (FC <7) (463). The oral formulation of CAB demonstrated a higher genetic 
barrier to resistance than RAL and EVG (absence of mutations at residues, 138, 140, 148, and 155 
) in a first time-in-human and phase IIa study involving healthy and HIV infected individuals 
(464). The long-acting CAB has also shown activity in vitro in viruses from ART naïve patients 
(mean EC50 FC, 0.91) and those harboring dual N155H/E92Q (4-fold) and Q148H/G140S (11-
fold) mutations in a panel of subtype B, A1, D, C, and recombinant AE recombinant viruses (465). 
In a randomized, phase 2b, open-label clinical trial of ART naïve patients investigating 
intramuscular CAB, resistance mutation Q148R emerged in one of the three patients who 
experienced virological failure (286), and Q148R has also been observed in patient failing -oral 
CAB (325). So far, long-acting injectable CAB has been tested in two phase III clinical trials, 
FLAIR and ATLAS. In these trials investigating non-inferiority of monthly CAB+RPV compared 
to current oral regimens, there was no emergence of resistance FLAIR study (466) and N155H 
mutation which reduced CAB susceptibility by 2.7-fold was observed in ATLAS study (289). In 
LATTE-2 trial comparing infectable CAB/RPV and oral CAB/3TC/ABC, R269R/G and Q148R 
emerged in 2 patients with protocol-defined virological failure in CAB/RPV arm and only Q148R 
showed phenotypic resistance to CAB (286). Overall, BIC, CAB, and DTG have higher genetic 
barrier to resistance than EVG and RAL, but DTG and BIC show broader efficacy against resistant 
viruses compared to CAB (457,459). 
 
1.6 HIV-1 subtypes and recombinants 
The HIV-1 epidemic is a result of zoonotic viral transmission of SIV from nonhuman primates to 
humans mainly in regions of Western and Central Africa. Transmission from lentiviral strains, 
SIVcpz (chimpanzees) and SIVgor (gorilla) resulted in HIV-1 groups M&N and groups O&P, 




jump to humans. HIV-2 originated from SIVsmm (Sooty mangabey). The high error prone HIV-1 
RT and high turnover of HIV-1 virions within infected humans ultimately resulted into high 
genetic diversity of HIV-1 circulating worldwide. HIV-1 is mainly divided into 4 main groups, 
group M (major), O (Outlier), N (non M, non-O) and N (11). Group M is the most widely 
distributed and is further divided into 9 subtypes: A-D, F-H, J and K (11). Globally, subtype C 
accounts to the majority of HIV-1 infections (48%), subtype A (12%), subtype B (11%), 
CRF02_AG (8%), CRF01_AE (5%), G (5%) and D (2%) of HIV-1 infections (467). HIV-1 
subtype A is predominant in regions of Eastern Africa (468), Asia and other former Soviet Union 
countries (469). HIV-1 subtype C is commonly found in Southern Africa, Eastern Africa, Brazil, 
China, and India and has been increasing in regions of Brazil, Southwest China, Malaysia, 
Scotland, and Uruguay. HIV-1 subtype B predominates in regions of North America (470), South 
America (471), Australia (472), Europe (473), Middle East and Northern Africa (474). Subtype F 
is mainly in regions of Eastern Europe and southern America. Subtypes E, G, H, J, and K are 
mainly in countries of Central and West Africa. It is important to note that all of these HIV-1 
subtypes had their origins in the Congo Basin, likely due to an unreported emergence of HIV-1 
infections following the “opening” of this tropical rainforest region with Colonist expansion into 
this region following the turn of the 19th century. 
HIV-1 like all retroviruses has two copies of genomic RNA (diploid) on which RT can jump 
between strands during reverse transcription to complete the proviral DNA (see section 1.3.3).  In 
cases of dual or super infection by two different HIV-1 strains within an individual human, these 
two HIV-1 strains can dually infect a cell and produce a heterodiploid virus (a copy of an RNA 
genome from both strains) which can then lead to recombinant HIV-1. Thus co-circulation of 
different HIV-1 subtypes in the same geographical region will eventually lead to stable circulating 
and unique recombinant forms (CRFs and URFs). A strain is recognized as CRF if it is isolated 
from at least two unrelated individuals, fully sequenced and plays a role in HIV-1 pandemic. The 
unique recombinant form (URFs) result from a mixture of subtypes found only in one HIV-1 
infected individual (475). Approximately 20% of group M viruses found in the epidemic are not 
“pure” subtypes but are recombinant forms (476). These recombinations are widely distributed in 





Originally known as subtype E, CRF01_AE, has subtype A genes and subtype E env, circulates in 
South-East Asia and accounts to >80% HIV-1 infections in Thailand and 5% globally. 
CRF01_AE/B is mainly found in Thailand, Georgia, and Malaysia. The CRF02_AG, which is 
commonly found in Western Africa, accounts for 60% HIV-1 infections in Cameroon and nearly 
5% of global HIV-1 infections. The former subtype I now classified as the CRF04_cpx, a subtype 
A/G/H/K recombinant (477,478)(479), accounts for 2-10% of HIV-1 infection in Greece (480), 
Cyprus and Mediterranean regions. CRF06_cpx from parental fragments of subtypes A, G, J, and 
K is responsible for infections mainly in Burkina Faso and Mali; and CRF07_BC, and CRF08_BC 
are the dominant HIV-1 forms in China (12, 13-Bertha 2008). CRF09_cpx from subtypes A, C 
and D accounts for most HIV-1 infections in Senegal. Intermixed recombinant forms have also 
been isolated with CRF18_cpx/CRF19_cpx isolated in Cuba, CRF06_cpx/A in Estonia and 
CRF11_cpx/B in Switzerland.  
The high degree of diversity between group M and O has not hindered occurrence of homologous 
recombination between the two groups with patients carrying intergroup M and O replicative 
competent (481). Recombination between HIV-1 and HIV-2 types has not yet been documented 
probably because of wide diversity between the two groups, however, patients infected with HIV-
2 can subsequently be infected with HIV-1 (482).  
HIV-1 Groups O, N, and P all appeared within or in the vicinity of Cameroon and never attained 
the same foothold in the human population as HIV-1 group M. There is less than reported 
infections with N and P while HIV-1 group O is responsible for ~50,000 infections worldwide.  
HIV-2 strain shows low infectivity characterized by low viral loads and slow disease progression 
in humans and this may explain its limited circulation/expansion in areas of Western Africa.  
 
1.6.1 HIV-1 subtypes and drug resistance  
Patients respond similarly to ART treatment irrespective of the HIV-1 subtype (483–485), 
however, HIV-1 subtype may still influence ART outcomes and emergence of HIVDR. For 
instance, despite susceptibility of HIV-1 subtype C and B strain-derived IN enzymes to the current 




infections on INSTIs (486). There is also less chance of subtype B viruses developing resistance 
against DTG compared to subtype A/G and C viruses (429). HIVDR against NRTIs and PIs has 
been shown to occur more frequent in subtype B compared to subtype C (26% vs 8% and 54% vs 
23%) respectively. Faster emergence of HIVDR to NRTIs and PIs in subtype B vs C has been 
shown in ART naïve and experienced patients (487). In Uganda, ART drug resistance and 
treatment failure is more prevalent in subtype D compared to subtype A or subtype C infected 
patients (488). The variability of INs at amino acid level between different HIV-1 subtypes is 
relatively low ~8-12% however, higher entropy scores or amino acid variability is observed at sites 
where mutations are selected for primary or secondary INSTI resistance. 
Subtype-specific resistance mutations to INSTIs: Among HIV-1 subtypes, residues associated 
with IN catalytic activity and common INSTIs mutations sites, N155, Q148, Y143 are highly 
conserved, however there is variability at secondary resistance mutations sites among different 
HIV-1 subtypes (489) (Fig. 16). HIV-1 subtype specific amino acid differences have been 





Figure 16. HIV-1 IN of different subtypes. Across HIV-1 integrase gene there are a number of 
differences in naturally occurring polymorphisms in different HIV-1 subtypes. These 
polymorphisms may function as compensatory mutations in specific subtypes which may influence 
differential selection of major mutations. HIV-1 integrase sequences of ART naïve patients were 
downloaded from HIV-1 sequence database (http://www.HIV-1.lanl.gov/). Alignment, annotation, 
and visualization was done in Bioedit (491). Blue represents the three catalytic triad residues of 
CCD (D64, D116, and E152), green represents major resistance mutation positions, and red is the 
natural polymorphisms naturally occurring between different HIV-1 subtypes. General consensus 
of amino acids at a particular position between HIV-1 subtypes is represented by (.). 
 
HIV-1 mutations at position G140 of HIV-1 IN occur more frequently in subtype B than non-
subtype B infected individuals (492) which also increases the frequency of Q148H/K/R mutations 
in subtype B viruses (Table 1). This is attributed to the high genetic barrier to the emergence of 




coded commonly by GGT or GGC thus requiring a single transition G to A to replace glycine with 
serine (G140S) or transversion G to C for the alanine (G140A).  In contrast, glycine is commonly 
coded by either GGG or GGA in non-B subtypes requires two nucleotide substitutions to change 
to codon G140 mutants. In cell culture assays, R263K mutation selected by DTG and EVG is 
frequent in HIV-1 subtype B and CRF02_AG, whereas G118R conferring resistance to DTG, RAL 
and EVG is common in CRF02 A/G and C subtypes (429). Whereas G118R causes low-level 
resistance to RAL in subtypes B and C, there is increased resistance to RAL by G118R in 
CRF02_AG in cell culture and patient samples (437,493). E138K mutation which confers 
resistance to RAL, EVG, and DTG in presence of Q148 mutations shows increased level resistance 
to RAL in CRF02_AG compared subtype B viruses (437) (Table 1). Double mutation 
E92Q/N155H in HIV-1 subtype C backbone shows 10-fold more susceptibility to RAL and EVG 
compared to the same mutations in subtype B virus (486).  On effect of subtype on IN enzyme 
activity, H51Y causes significant loss in IN enzyme activity in CRF02_AG and B but not in 
subtype C, and E138K leads to >55% reduction in enzyme activity in CRF02-AG but not in 
subtype B and C (437).  Strand transfer efficiency is restored by addition of E138K+H51Y to 




Table 1. The INSTIs associated resistance mutations frequency and impact on 








a  A, C, D, F, G, CRF01, CRF02, CRF01, CRF05, CRF35; b A, C , D, F, G, H, J, CRF01_AE, 
CRF02_AG, CRF03, CRF06, CRF09, CRF11, CRF12_BF, CRF13, CRF14_BG, CRF15, CRF18, 
CRF19; c A, C, D, F, G, CRF01_AE, CRF02_AG. In bold, major INSTIs DRMs. In brackets, INSTIs for 
which there is increased resistance in presence of respective DRMs.  
 
Subtype-specific resistance mutations to PIs: Natural polymorphisms, M36I, V82I, L10I, L63P, 
L10V, K20R, and V77I in protease gene of non-subtype HIV-1 in ART naïve patients are known 
to reduce susceptibility to PIs in HIV-1 subtype B viruses (487,494). Substitutions at position 36 
of HIV-1 protease seem to have differential impact on susceptibility of ART in different subtypes. 
I36 appears as an accessory mutation and enhances resistance to ritonavir, ATV, and nelfinavir as 
a natural polymorphism in non-B HIV-1 subtypes, specifically subtype C and CRF02_AG (83%) 
but appears at only a 6% occurrence in subtype B ART naïve patients (495). In contrast, M36 has 
this accessory/secondary resistance effect to PIs in HIV-1 subtype B (496).  
Primary DRM, V82A/F/T/S selected by IDV and LPV does appear more frequently in subtype F1 
than subtype B HIV-1 infected patients (497).  In contrast, D30N results in highly impaired viral 
replication in HIV-1 subtype C whereas this D30N is a primary PI resistant mutation in HIV-1 
subtype B infected patients receiving a PI-based treatment (498). Lack of DRM D30N in some 
subtypes may relate to lack of natural polymorphisms, L63P and V77I in subtype B compared to 
non-B subtypes (495) necessary to compensate for D30N fitness loss. Mutation/natural 
polymorphism L63P has been shown to compensate loss in viral fitness by the primary PI resistant 
mutation, L90M mutation (499) found at lower frequency among subtypes C, F1, and intersubtype 
BF compared to subtype B (500–502). Finally, emergence of M89T mutation which causes 
phenotypic resistance to ATV, NFV (nelfinavir) and LPV is influenced by presence of 
polymorphism M89 in subtypes A, C, and CRF01_AE, and L89 in subtype B viruses (503). The 
mutation L89M increases genetic barrier for emergence of L90M and reduces susceptibility to 




of IDV (504).  In-vitro assays also reveal possible polymorphisms associate with hyper 
susceptibility to PIs.  For example, CRF02_AG viruses carrying protease polymorphisms G17E 
and I64M confer hypersusceptibility to NFV, ATZ, and IDV inhibition (505). Accessory 
mutation/polymorphism I93L is also associated with hypersusceptibility to LPV in subtype C 
viruses compared to HIV-1 subtype B viruses (506).  
Subtype-specific resistance mutations to NRTIs and NNRTIs: Generally, amino acid substitutions 
conferring resistance to NRTIs in subtype B match those of non-subtype B  (507). However, there 
is more rapid emergence of the K65R in RT coding region in patients infected with subtype C 
compared to individuals infected with subtype B, G, and CRF02_AG (508). Lysine 65 of HIV-1 
RT confers resistance to TDF, ABC, didanosine (DDI), and d4T and is coded by AAG in subtype 
C and AAA in subtype B such that a single versus double transition G to A mutation (respectively) 
is necessary for the Arginine.  Contrary, K65R is less frequent in subtype A compared to subtype 
B and C HIV-1 in patients on ART (509). Otherwise, the frequency of thymidine analog drug 
resistance mutations (D67N, K70R, L210W, T215F/Y) is similar in patients infected with HIV-1 
subtype A, B and C and receive a thymidine analog (D4T or AZT) in a treatment regimen (509), 
though M41L has been found to be more frequent in subtype B than C infected patients (497). 
In relation to NNRTI resistance, mutations in HIV-1 pol associated with NVP and EFV, K103N, 
V106M and, A98S occur more frequently in those infected with HIV-1 subtype C compared to 
subtype B.  This was observed in both ART naïve and experienced patients receiving an NNRTI-
based treatment regimen (510). Mutation K103N associated with NVP, and EFV, is less frequent 
in subtype A and D compared to HIV-1 subtype C (511), and Y181C mutation which reduces 
susceptibility to NVP, EFV, etravirine, and rilpivirine shows more prevalence in subtype B and C 
compared to subtype A (509). Minority species of K103N or Y181C detected by ultrasensitive 
PCR were found in 42% of subtype A/AE compared to 70-87% of subtype C HIV-1 infections 
(512). V106M is preferentially selected in subtype C under NVP/EFV therapy compared to V106A 
commonly seen in subtype B viruses (399,513). N348I mutation in connection domain of HIV-1 
RT reduces susceptibility of NVP, EFV, AZT, and DDI and is commonly associated with M184V 
and TAMs in HIV-1 infected patients (514–517). There seem to be decreased susceptibility for 
EFV and NVP in subtype A and D viruses than for subtype B and C when N348I mutation is 




in vitro (519) but with reduced susceptibility in presence of E138A/K/Q mutations (520). In HIV-
1 ART naïve and experienced patients, E138A/K/Q mutations are found at a higher frequency in 






Chapter 2  
2 HIV-1 treatment, drug resistance and subtypes in Uganda  
2.1 Preface 
Uganda is one of the countries which has overcome a historical high prevalence of HIV-1 infection 
from 30% in 1992 when 18% of population was infected to the current 5.7% reported in 2018 
(522,523). Uganda was also one of the first countries in Africa to access/distribute cART and with 
Dr. Anthony Fauci, was the primary architect of the U.S. President's Emergency Plan for AIDS 
Relief (PEPFAR) treatment plan. Despite the success of NNRTI-based first-line therapy under 
PEPFAR and UNAIDS/Global Fund in Uganda, there has been increasing prevalence of HIVDR 
leading to the implementation of PI-based second-line and RAL-based third-line treatment 
regimens (always with two NRTIs). Uganda has recently surpassed the WHO threshold of >10% 
prevalence of pretreatment HIV-1 drug resistance (PDR) to NNRTIs (524). WHO recommends a 
change of first-line regimens with PDR prevalence > 10% and Uganda has switched from 
NNRTIs+2NRTI for first-line to DTG/3TC/TDF regimen for patients initiating cART (525). DTG 
not only prevents the rapid emergence of resistance with first line cART but is also effective in 
viruses harboring most DRMs. Uganda is among few countries with a very diverse population of 
HIV-1 strains which makes studying HIV-1 subtype dynamics possible. Indeed, HIV-1 subtypes 
have been shown to influence rate of replication, pathogenesis, and occurrence of HIVDR in some 
HIV-1 infected populations. In this chapter, we describe ART options, HIVDR, and role of HIV-
1 subtype distribution on treatment outcomes in the Uganda population. 
 
2.2 HIV-1 history in Uganda 
For many years, HIV-1 spread in Uganda without knowledge of what exactly was causing the 
“slim” body stature in individuals who were immunocompromised. By the time HIV-1 was 
recognized as a causative agent for AIDS, the rate of HIV-1 prevalence had already skyrocketed 
with over 18% of general population harboring HIV-1. HIV-1 was first recognized in Rakai district 
in South west part of Uganda in 1982 by a young resident doctor who was seeing 29 patients 




sarcoma, lymphadenopathy, and genital warts. All these patients had uniform characteristic of 
extreme weight loss which was locally referred to as “slim” (3,526). In 1986, 900 cases were 
reported in the country (Uganda AIDS control program, 1989). Despite the first HIV-1 cases being 
described in 1982, HIV-1 epidemic in Uganda likely originated in 1960 (1950-1968) for subtype 
A1 and 1973 (1970-1977) for subtype D in regions of Masaka (South-West of country) and then 
spread to the Kampala capital region (527). The 1970s-1980s was likely the period of exponential 
growth and by 1985, HIV-1 prevalence was reported to be 11% among population of pregnant 
women (528) and 18% in the general population. By 1992, HIV-1 prevalence in pregnant women 
receiving antenatal care had risen to 30% and 3% in urban and rural areas, respectively. Through 
public sensitization and behavioral changes including reduction of casual sex patterns and use of 
condoms, there was a sharp decrease in HIV-1 prevalence among pregnant women from 30% in 
1992, to 21% in 1998 and 6% in 2000 (523). The rate of HIV-1 in adults has been steady over the 
last few years with prevalence of 7% in 2001, 6.5% in 2009, and most recently 6.8% in 2019 
(529,530).  
 
2.3 ART treatment in Uganda 
The government of Uganda in collaboration with UNAIDS launched a two-year pilot program, 
Drug Access Initiative (DAI) in 1997 with mandate of improving HIV-1/AIDS care access for 
individuals living with HIV-1. The initiation of DAI program allowed over 912 HIV-1 infected 
individuals to access ART through the program (531,532). However, the extremely high annual 
cost of HIV-1 drugs to the tune of US $ 12,000 in 1997 to about US $7,200 in 1999 for first-line 
regimen was a huge stumbling block to the program (531). The ART program in Uganda only 
changed trends of HIV-1 infections after importation of generic drugs by the Joint Clinical 
Research Centre (JCRC) in 2000 which allowed patients to access ART at an end-user price of US 
$ 31/month for generic ARVs (AZT/3TC/NVP) produced by Cipla in India breaking the 
inequitable international TRIPS agreement (531,532). This allowed more patients access ART 
with some economic means. Despite the multinational pharmaceutical companies signing an 
agreement to lower the cost of ART for developing countries in May 2000, the most significant 
reductions in cost of ART coincided with importation of generic drugs from Cipla by JCRC in 




increased from 912 in 2000 to 3,400 in 2002 (532). Further progress was made with initiation of 
PEPFAR program in 2004. By 2005, 75% of HIV-1 infected patients were receiving ART in 
Uganda (533). JCRC being one of major PEPFAR grantee, 19,000 HIV-1 infected patients were 
receiving ART in the first 18 months of PEPFAR including 2,000 orphans and pregnant women 
(533). JCRC kept playing a critical role with over 60,000 HIV-1 infected patients receiving 
treatment through the JCRC by the mid-2000s and nearly 200,000 through clinics across the 
country. In 2017, the Uganda government adopted 2015 WHO recommendation of “test and treat” 
which entailed initiating ART for all individuals testing HIV-1 positive, irrespective of their CD4 
count or clinical stage.  
First-line regimens in Uganda: In 1997-2000, cART consisted of three affordable choices for 
patients with high personal incomes: 2 NRTIs + either NNRTI or PI; or 2NRTIs + hydroxyurea 
(the latter showing only partial suppression and never used widespread in high income countries). 
In 2002, treatment guidelines recommended use of triple therapy of AZT or D4T plus 3TC/NVP 
as first line in Uganda despite limited access to this treatment for vast majority of Ugandans (534). 
The revised ART guidelines of 2008 recommended first line of AZT/3TC/NVP or EFV in both 
adults and children/infants but EFV was not recommended in children <3 years and <13 kgs (526). 
By 2008, if an infected individual had access to a clinic and had CD4 cell counts <200/mm3, this 
treatment was available for free through the PEPFAR, the Global Fund, or the Clinton Foundation.  
Since first roll-out of ART in Uganda in 2002, ART regimen constituted NNRTIs+ NRTIs with a 
number of transitions including d4T replacing AZT in 2008 and TDF replacing d4T (or AZT if 
still in use) by 2012.  D4T and AZT had long since been abandoned by the high income countries 
due to mitochondrial toxicity, anemia and peripheral neuropathy (526,531,535). Due to favourable 
properties of DTG including high potency, low toxicity, higher genetic barrier to resistance, and 
increased circulation of NNRTI resistance, there was a switch in the cART naïve from an NNRTI-
based treatment to the TDF/3TC/DTG combination (525).  In March 2018, Uganda transitioned 
from NNRTIs-based to once-daily fixed dose of TDF/3TC/DTG for all patients initiating ART and 
eligible ART experienced patients except women and adolescents of childbearing potential or on 
effective contraception (525). In children 3<10 years and less than 35 kg ABC/3TC/LPVr is 
recommended (525). The updated 2020 HIV-1 treatment guidelines now recommend initiation of 
TDF/3TC/DTG in all adults and adolescents ≥ 30kg including pregnant and breastfeeding women 




ABC/3TC/DTG is recommended first-line with LPV/r, EFV, RAL, or triple NRTIs use when DTG 
is contraindicated (536). A study at one of the HIV-1 treatment specialized centers in Uganda, 
shows possible increased prevalence of hyperglycemia in patients who transitioned to DTG though 
this group had significantly higher number of older, male, and long-term ART experienced patients 
compared to patients who did not transition to DTG (537).  
Second-line regimens in Uganda: ART expansion phase starting in 2002, recommended a second-
line of AZT or d4T plus DDI/LPV/r (534). The revised cART treatment and care guidelines of 
2008 recommended ABC/DDI/LPVr, FTC/LPVr, or AZT(or ABC)/DDI/LPVr as second-line 
regimen in adults and children/infants respectively (526). In 2018 national HIV-1 treatment 
guidelines recommended second-line of AZT/3TC/ATVr in adults and AZT/3TC/RAL or DTG in 
children 3<10 years (525). The 2020 HIV-1 treatment guidelines recommend TDF/3TC/LPV/r 
second-line in ≥ 30kg patients failing on DTG-based first-line, TAF or ABC/3TC/LPV/r in 
children ≥ 20Kg - <30Kg, and ABC/3TC/LPV/r in children weighing <20Kg (536). 
Third-line regimens in Uganda: Viral load of <1000 copies/ml with evidence of >95% adherence 
to treatment warrants a switch to third-line regimen under guidance of genotyping test (525). The 
choice of third-line regimen is guided by HIV-1 genotype testing, and regimens are selected by 
national third-line ART team basing on genotypic profile, available ART options and patient 
treatment history (525). Third-line treatment consists of regimens active against resistant viruses 
and commonly DRV/r, RAL, and ETR, or two recycled NRTIs are used in these highly treatment 
experienced patients. Third-line cART remains the last line of treatment due to inaccessible CCR5 
or fusion inhibitors in Uganda. Ugandan children (<18 years) carrying multiple DRMs after failure 
on second-line, responded well to RAL-based third-line after ~5 years of follow up (538).  
 
2.4 Distribution of HIV-1 subtypes in Uganda  
HIV-1 subtypes A and D account for the majority of HIV-1 infections in Uganda (539,540), with 
subtype C (541–543), B (542,544,545), and G (546) only rarely reported in the country. The A/D 
unique and stable recombinant forms (URFs and CRFs) account for 9% to 30% of HIV-1 infections 




HIV-1 subtype A emerged in Uganda earlier than subtype D (549) and it was shown to have 
originated from Congo which then spread from East to West in the country with subtype A now 
predominant in HIV-1 infections of Kenya. HIV-1 Subtype D in Uganda is said to have originated 
from Tanzania but originated in the Congo Basin like all HIV-1 group M strains.  Subtype D now 
predominates the Southwest of the country and has had more limited spread to the North and East 
(550–552).   Consequently, distribution of HIV-1 subtypes vary in different geographical locations 
in the country. In central regions of the country-areas of Kampala and Entebbe, subtype A is only 
slightly more prevalent than D (50 and 30% respectively) (539,548,553) with subtype A becoming 
more prevalent near the Kenyan border; and subtype D reaching a peak in prevalence (>70%) in 
the Southern Rakai district (550,554). Despite HIV-1 subtype D being of the highly prevalent HIV-
1 strains, its prevalence has been steadily decreasing while subtypes A, C, and A/D and A/C URFs 
have been increasing in Uganda (555). HIV-1 subtype A is easily spread through personal and 
community transmission (556), however, with increased access to more potent cART, the 
incidence rates of subtype A will also likely decrease in the population. By using phylogenetic 
analyses, HIV-1 transmission dynamics through clusters has been studied through a cohort of HIV-
1 patients in Southwestern Uganda. In a 7-year (2004-2010) study of 94 participants, 37% of 
sequences (partial gag and env) accounted to 13 transmission clusters and revealed a possible high 
sexual risk behavior and super transmitters in the community (552). Phylogenetic analysis of 3796 
HIV-1 pol sequences from HIV-1 infected patients in Southwestern Uganda, identified 524 
clusters and clustering was largely associated with being a female and staying within general 
population cohort set up previously to analyze trends in HIV-1 prevalence and incidence, their 
determinants and pathogenicity. The clustering dynamics revealed significant viral spread from 
general population cohort without viral introduction from outside the cohort (557).  
 
2.5 Role of HIV-1 subtype on body response to infections 
In Uganda, HIV-1 subtype is associated with different clinical and disease manifestations. HIV-1 
subtype D is associated with faster disease progression than subtype A in a Uganda population 
(558). In ART naïve and experienced HIV-1 infected patients, cART failure is more frequent in 
subtype D compared to subtype A infected individuals (488). Subtype D infected is also associated 




(539,558). Subtype D also shows significantly lower transmission rate than subtype A among HIV-
1 discordant couples (556). Increased ability to use both CXCR4 and CCR5 coreceptors during 
diseases progression with subtype D (559), contrary to an almost exclusive use of CCR5 by HIV-
1 subtype A (558,560) may perhaps explain the high virulence of subtype D. HIV-1 infected 
Ugandans infected with CCR5 viruses have higher CD4 cell count than CXCR4 or CCR5/CXCR4 
viruses (561). However, independent of co-receptor usage, HIV-1 subtype D isolates have higher 
replicative fitness in primary human T cells when compared with HIV-1 subtype A isolates and 
higher replicative fitness of subtype D HIV-1 directly correlated to the faster rate of disease 
progression as measured by a sharper decline of CD4 T cells in blood (562). This faster decline 
CD4 T cells was observed without any usage of CXCR4 by subtype D HIV-1.  
Subtypes A and D infected Ugandans also have increased CD4+ and CD8+ T cell activation 
compared to subtype B infected counterparts (563). CD4 dysfunction characterized by higher 
expression of programmed cell death receptor -1 (PD-1) and increased cell apoptosis is more 
pronounced with subtype D compared to subtype A in ART naive Ugandans (564).  Subtype D 
infected patients also exhibit pronounced loss of invariant natural killer T (iNKT) cells whereas 
FoxP3+ regulatory T cells (Tregs) loss is more frequent in subtype A infected Ugandans (565). On 
contrary, there seem to be no difference in the initial cART response among patients infected with 
HIV-1 subtype A, C and D (566).  
 
2.6 HIV-1 drug resistance in Uganda 
In Uganda, the high prevalence rates of HIV-1 infections (~5.7%) (567) and frequent use of low 
genetic barrier to resistance regimens have led to increased levels of HIVDR. Uganda much more 
like the rest of Africa countries, first generation NNRTIs, NVP and EFV have constituted first-
line combination (531,568) and difficult to take LPV has frequently been used in second-line 
treatment (526). The high prevalence of HIVDR can also be explained by early roll out of ART in 
2002 compared to other African countries (534). Overall, over 10% of HIV-1 infected Ugandans 
on ART harbor drug resistance variants, and over 15.4% initiate ART already carrying HIV-1 




HIVDR in ART naïve patients and those with previous exposure to ART has been increasing in 
Uganda (569). Over the years, the frequencies of HIVDR in patients initiating ART in Uganda has 
increased from 0% (2006–2007) (570), to 8.6% (2009–2010) (571) and 15.4% from WHO survey 
(2014–2016) (524). This is largely contributed by NNRTIs-associated TDR compared to other 
classes of ART. HIV-1 infected patients carrying TDR can achieve viral suppression on first-line 
(572), however, escalating TDR beyond 10% threshold, called for substitution of NNRTI 
component following WHO treatment guidelines (524). In ART naïve children  and > 12 years, 
HIVDR to first-line between 2010-2011 was found at 7.7% (573), and 16.9% (574). Among 
different patient groups, TDR among fisher folks has been observed between 5-15% for NNRTIs 
and <5% for NRTI and PI regimens (575), 3% for NNRTIs among female sex workers (576), and 
<5%  for NRTI, NNRTI and PR among women attending antenatal care (570).   
HIVDR to thymidine (AZT, d4T) and non-thymidine analogues used in first-line regimens has 
been observed in 58.8-95% HIV-1 infected Ugandans (540,577). Thymidine associated mutations, 
M41L, D67N/G, T215I/F/Y/T, and K219N/K/E/Q, are frequently selected in HIV-1 infected 
Ugandans failing on first-line ART (540,577,578). Non-TAM, M184V/I, K65R/K,  are the most 
prevalent mutation observed in patients failing first-line regimens (540,577,579,580). NNRTIs 
associated resistance account to the majority of first-line resistance with 73.2-96% of first-line 
failures harboring NNRTIs-associated resistance (540,577,581). The major frequently selected 
NNRTIs mutations include, K101E/Q, K103N/S, G190A/S/E/G, and Y181C (540,577–579,582). 
NNRTIs major resistance mutations, K103N, G190A, and Y181C have low fitness cost and 
therefore frequently observed even after many years after switching to non-NNRTI regimen 
(583,584). We have shown previously that over 55% of patients failing PI-based second-line in 
Uganda harbor NNRTIs- resistance mutations (540). There has also been a challenge of using NVP 
monotherapy to prevent mother to child transmission which may predispose women to HIVDR. 
Indeed the risk of HIV-1 resistance after a single-dose NVP has been estimated to be 32% among 
Ugandan women (585,586). Starting babies with prior exposure to single dose NVP to NNRTIs 
(due to lack of pediatric PI formulations) further exposes them to NNRTIs resistance. HIVDR has 
been observed in over 35.7% of children in prevent mother to child transmission program in 
Uganda (573). In some cases, children failing first-line and some with pre-exposure to single dose 
NVP, all have been found to harbour NRTI and NNRTIs resistance (587) and impact of HIVDR 




(574). Children failing first-line and harboring common M184V, K65R/N, and K103N mutations 
may respond well on boosted LPV containing second-line regimens (588). At first-line failure, 
CD4 cell count at baseline <250 cells/ul and viral load > 100,000 copies/ml have been shown as 
independent predictors of HIVDR at 12 months in HIV-1 infected Ugandans (554,577). The type 
of NRTI+ NNRTIs-first-line regimen has been associated with accumulation of TAMS and 
K103N, and poor adherence predicts emergence of K103N and reduced virological response to PI-
based regimens in Ugandan children (588). Starting HIV-1 patients on AZT containing first-line 
compared to TDF, and ART duration of >82 weeks have been shown to be independent predictors 
of acquired HIVDR (589).  
Following two consecutive viral load of <1000 copies/ml with 3-6 months apart and adherence 
support after first viral load test, patients failing on first-line are switched to PI-based second-line, 
regimens (525). The boosted LPV has been commonly used in second-line combination until 
recently when the country switched to boosted ATV and 2 NRTIs (525). PIs have higher genetic 
barrier to resistance compared to NNRTIs or NRTIs. In patients failing PI-based second-line, PI 
resistance has not or nearly observed (578,581) but also detected at 18.5% (590), and 19.4% (579) 
in Ugandan patients. Major PIs mutations, V82A, I54A, M46I/L are frequently observed in 
patients failing PIs-based second line in the Uganda (540,579,590). In patients failing second-line 
and carrying PI-resistance, DRV remains the only active part of PI cocktail for third-line treatment 
(579). PI resistance at first-line failure is very low in children (<12 years) and over 20% fail 
second-line but lacking PI resistance (580). PI resistance has also been shown to be rare in children 
(<20 years) failing second-line (588). Sub-optimal adherence and less weight have been associated 
with HIV-1 treatment failure of second-line in Ugandan children (<12 years) (580).  
Data on HIVDR to third-line regimens in Uganda is very limited. In patients failing RAL-based 
third-line, over 48% of patients carry RAL/EVG associated primary DRMs (540). About 5% of 
patients failing RAL-based third-line regimens carry DTG-associated DRMs and 2-10% harbor 
secondary mutations against INSTIs. Among major DRMs against INSTIs, N155H mutation is 
most frequently selected and Q148R/K least selected INSTIs associated mutation in HIV-1 
infected Ugandans failing third-line regimens (540). In INSTIs naïve HIV-1 patients, major 
INSTIs mutations, Y143H, and Q148R only are observed at low frequency (1.1-1.6%) (578). HIV-




first-line regimen, 9% were found with RAL/EVG resistance but no high-level DTG resistance 
(591). Primary INSTIs associated DRMs in ART naïve patients in Uganda and other 4 African 
countries have been detected only at <20% frequency (592).  
Despite higher entropy scores or amino acid variability at sites where INSTIs mutations are 
selected for primary or secondary INSTI resistance between subtype B and non-B HIV-1 subtypes, 
there is very limited data on prevalence, genotype, and impact on susceptibility to INSTIs by these 
DRMs in non-B HIV-1 subtypes. Observations in the subsequent chapters show absence of INSTIs 
associated mutations in INSTIs naïve (n=366) but in 47% of patients failing on RAL-based 
regimen. Among the 47% with INSTIs DRMs, 4% (2/51) of patients (subtype A and D) had 
multiple primary INSTIs DRMs conferring resistance DTG, BIC, and CAB, a unique observation 
in both LMICs and HICs. The viruses harboring single RAL/EVG primary INSTIs mutations 
(~50%) remained susceptible to DTG, BIC, and CAB with fold-change in EC50 values nearly 
equivalent to that of wild-type. We confirmed that subtype A with E138A/G140A/G163R/Q148R 
and subtype D with E138K/G140A/S147G/Q148K viruses on RAL-based regimen are highly 
resistant to all currently available INSTIs in LMICs. Emergence of INSTIs resistance appears in 
part to be subtype specific with even N155H reducing DTG susceptibility more so in subtype A 
and D than in subtype B HIV-1. In contrast to commonly observed G140S/Q148H mutations in 
subtype B viruses, non-B HIV subtypes commonly carried G140A/Q148KR mutations. The 
potential novel resistance mutations to INSTIs, I203M and I208L, did not singly reduce 
susceptibility to either RAL or DTG, further analysis is warranted to determine how these novel 
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Currently there are over 37 million people infected with HIV-1 worldwide and over 35 million 
people have died due to HIV-1 related complications. Since the introduction of the first ART 
regimen, AZT in 1987, there have been tremendous progress in different ART regimens to the tune 
of 40 different regimens available today. In the due course, more potent ART regimens with better 
tolerability, safety, and activity with resistant viruses have been made accessible. This achievement 
has to the great extent been realized in HICs which have capabilities to get access to these better, 
high-cost drugs. INSTIs are the latest class of ART in this category of drugs with high potency 
and yet good safety profile.  
Dolutegravir, one of the second generation INSTIs, was approved in 2013 by FDA but Uganda 
much more like other LMICs could only have DTG widely accessible in late in 2018. DTG was 
introduced in Uganda in form of a triple combination of DTG/3TC/ABC in 2019. Yet still, data 
on DTG susceptibility in subtype A, D, C and recombinant viruses commonly circulating in 
Uganda is not available. The study presented herein, tacked this challenge by screening for DTG, 
RAL and EVG associated DRMs in HIV-1 infected individuals on different lines of ART in 
Uganda. I selected this cohort of patients, carried out laboratory assays, and completed the 











3.2  Abstract 
Objectives: To screen for drug resistance and possible treatment with Dolutegravir (DTG) in 
treatment naïve patients and those experiencing virologic failure during first, second, and third line 
combined antiretroviral therapy (cART) in Uganda.  
Design: Samples from 417 patients in Uganda were analyzed for predicted drug resistance upon 
failing a first (N=158), second (N=121), or third line (all 51 involving Raltegravir [RAL]) 
treatment regimen.    
Method: HIV-1 pol gene was amplified and sequenced from plasma samples. Drug susceptibility 
was interpreted using the Stanford HIV-1 database algorithm and SCUEAL was used for HIV-1 
subtyping.  
Results: Frequency of resistance to nucleoside reverse transcriptase inhibitors (NRTI) (95%) and 
non-NRTI (96%) was high in first-line treatment failures. Despite lack of NNRTI-based treatment 
for years, NNRTI resistance remained stable in 55% of patients failing second line or third line 
treatment and was also at 10% in treatment naïve Ugandans. DTG resistance (n=366) was not 
observed in treatment naïve or individuals failing first and second line cART and only found in 
two patients failing third line cART while 47% of the latter had RAL and Elvitegravir (EVG) 
resistant HIV-1. Secondary mutations associated with DTG resistance were found in 2% to 10% 
of patients failing third line cART.    
Conclusion: Of fourteen drugs currently available for cART in Uganda, resistance was readily 
observed to all antiretroviral drugs (except for DTG) in Ugandan patients failing first-, second-, or 
even third-line treatment regimens.  The high NNRTI resistance in first line treatment in Uganda 
even among treatment naïve patients, calls for the use of DTG to reach the UNAIDS 90:90:90 







By 2016, there were 36.7 million people living with HIV-1 infection worldwide, and 1.8 million 
new infections diagnosed in the same year (593). Uganda is among the countries with the highest 
burden of HIV-1 infections, with approximately 1.5 million (7.1%) people living with HIV-
1/AIDS and 57% of them receiving combined antiretroviral therapy (cART)(594). Unfortunately, 
due to various sociological and economic factors, HIV-1 drug resistance has been rapidly emerging 
in patients receiving cART such that HIV-1 drug resistant variants are now responsible for at least 
9% of the new infections(488).  
In Uganda, as most of sub-Saharan Africa, over 57% of patients have access to TDF- and EFV-
based first line regimen recommended by the World Health Organization (WHO), while less than 
50% of patients are receiving the DTG- and DRV-based first-line regimens recommended by the 
International Antiviral Society – USA(595). However, rapid emergence of HIV-1 drug resistance 
to first line B1a rated treatment regimens argues for increasing access to more effective cART, 
which may lead to better treatment outcomes, lower adverse events/drug toxicity, and higher 
barriers for drug resistance.  DTG, a second-generation Integrase Strand Transfer Inhibitor 
(INSTI), Elvitegravir/cobicistat (EVG/cobi) or Raltegravir (RAL) are three “backbone” INSTIs 
recommended for first line treatment regimens in combination with tenofovir disoproxil 
fumarate/emtricitabine (FTC) (or with tenofovir alafenamide/FTC when combined with 
EVG/cobi)(596). DTG/abacavir/lamivudine is also employed if the patients are screened to 
exclude those with an HLA B57 allele.  Rilpivirine along with the latter NRTIs are used for new 
first line treatment regimens.  Despite these preferences for treatment in HICs, at the JCRC in 
Uganda, currently less than 1% of the 60,000+ patients receive this first line cART recommended 
by the CDC for HICs.   
Equally important, in vivo DTG resistance has rarely been observed even in those few patients 
showing virological failure in NRTI-experienced but INSTIs-naïve patients(435). In vitro studies 
characterizing the DTG-associated R263K mutation in subtype B, C, and CRF02_AG HIV-1 
strains, showed early emergence of R263K in subtypes B and CRF02_AG, whereas the G118R 
substitution was only observed in subtype C and CRF02_AG (429).  It is possible that HIV-1 
strains from different subtypes may explore distinct paths, selecting for different mutations, to 




(597), the DTG-resistant R263K mutation is even slower to emerge and more debilitating to HIV-
1 replication. The R263K mutation observed in clinical and in vitro studies, and secondary 
mutations such as H51Y, M50I and E138K observed in cell culture studies, do emerge during DTG 
treatment but appear unable to restore replication capacity of the virus (434,598,599). DTG can 
also inhibit most HIV-1 isolates resistant to RAL and EVG which relates to its success in RAL-
experienced patients in the VIKING-3 study (318).    
Despite the strong safety profile and success of DTG in both first and second line treatments, its 
use in LMICs has been minimal.  DTG has been extensively tested in patients infected with subtype 
B, with no difference on DTG susceptibility been observed in non-B subtype HIV-1 strains in 
dose-escalating/selection experiments (600).  However, little is known about DTG treatment 
outcomes in patients infected with subtype A and D HIV-1 primarily found in Uganda (601).   
In this study, we evaluated the possible treatment with DTG in cART to treat HIV-1 infected 
Ugandan individuals based on the current drug resistance profile in treatment naïve and highly 
treatment experience patients.  Drug susceptibility was predicted in 417 plasma samples from 
treatment naïve individuals (N) (n=87), first-line failures (FF) (n=158), second-line failures (SF) 
(n=121) or third line/RAL-based antiretroviral failures (RF) (n=51).  Our results did not predict 
DTG resistance in HIV-1 infected treatment-naïve patients, nor from individuals failing different 
cART regimens, highlighting the suitability of DTG-based therapies to treat HIV-1 infected 




3.4 Materials and methods 
Samples for the study  
This was a retrospective study that assessed the prevalence and impact of DTG associated 
mutations in patients failing on different treatment regimens. Samples were collected from the 
WHO, CAP, and NIH-VQA-accredited Center For AIDS Research (CFAR) Laboratory of the 
Joint Clinical Research Center (JCRC) in Kampala, Uganda. The JCRC is one of the first HIV-1 
treatment centers in the country to roll out cART and currently the only site licensed to provide 
INSTIs in the country. The patient database in the CFAR laboratory was used to access the patient 
demographics, medical, and treatment history of the study samples. A total of 440 plasma samples 
were collected from patients receiving routine treatment care at the JCRC and with virological 
failure, defined by a viral load above 1,000 copies/mL and/or CD4+ T-cell counts below 250 
cells/mm3. These virological failures included plasma samples from 90 N, 165 FF, 125 SF, and 60 
RF patients. Antiretroviral therapy (ART) naïve samples came from the Pan-African Studies to 
Evaluate Resistance (PASER) network (602), the Monitoring Antiretroviral Resistance in Children 
(MARCH) observational cohort study (603), and the Hormonal Contraception and HIV-1 Genital 
Shedding and Disease Progression among Women with Primary HIV-1 Infection (GS) study (604). 
Forty two of 165 FF samples came from the Europe-Africa Research Network for Evaluation of 
Second-line Therapy (EARNEST) trial (605). The rest of the samples were patient samples 
collected during routine Sanger genotyping testing at the JCRC. Ethical clearance was obtained 




RNA extraction and PCR amplification  
Viral RNA was extracted from 440 plasma samples using a QIAamp viral RNA Mini Kit (Qiagen) 
according to the manufacturer’s instructions. Reverse transcription of the full-length HIV-1 
integrase (IN)-coding region from extracted viral RNA and amplification was done with the sense 
primer RTA9F (5′-TATGGGGAAAGACTCCTAAATTTA-3′) and antisense primer 3Vif (5′-
AGCTAGTGTCCATTCATTG-3′) using a Superscript III single RT-PCR system with Platinum 
Taq DNA polymerase kit (Thermo Fisher Scientific) as per manufacturer’s instructions. Nested 
PCR was done using the sense primer INTFEXT1 (5′-
AGAAGTAAACATAGTAACAGACTCACA-3′) and antisense Vif 3 reverse 1 primer (5′-
GTCCTGCTTGATATTCACACC -3′) using a Platinum Taq kit (Thermo Fisher Scientific) as per 
manufacturer’s instructions to generate amplicon of 1433 base pairs. Amplification of protease 
(PR) and reverse transcriptase (RT) regions was done as previously described (488). The amplicon 
was purified using ExoSAP-IT enzyme (Thermo Fisher Scientific) and quantified using a Qubit 
fluorometer (Thermo Fisher Scientific).   
Cycle sequencing and sequence analysis  
The HIV-1 IN as well as the PR and RT coding regions were amplified and analyzed on a Sanger 
sequencing platform. Briefly, quantified and purified PCR product was sequenced with primers 
spanning the full length of the IN gene (1-288 amino acids): Vif 3 reverse1 (5′-
GTCCTGCTTGATATTCACACC-3′), INTREXT (5′-AATCCTCATCCTGTCTAC -3′), and 
INTFEXT1 (5′-AGAAGTAAACATAGTAACAGACTCACA-3′). PCR product was sequenced 
with ABI Big dye terminator (v3.1) (Thermo Fisher Scientific) according to manufacturer’s 
instructions on ABI 3730xl sequencing platform (Life Technologies, Carlsbad, California, USA). 
A total of 417 samples (N = 87, FF = 158, SF = 121, and RF= 51) were amplified and sequenced 





Figure 17. The workflow chart of the patient numbers and their respective groups. FF 
consisted of patients who were on NNRTI-based combination therapy, SF had PI-based 
combination, RF had RAL backbone and N had not been exposed to ART. Abbreviations: INSTIs, 
Integrase Strand Transfer Inhibitors, RT, reverse transcriptase, PR, protease. 
 










The HIV-1 subtype was predicted using SCUEAL subtype classification algorithm. Viral loads were 
assayed using Abbott m2000sp/rt or Roche COBAS Amplicor Monitor ultrasensitive tests, v1.5.  a The total 
number of patients tested for INSTIs resistance in each patient group. bDescription of the ART combinations 
in the study, and the number of patients taking that combination. ND, not determined. Other, the number 
of ART combinations which were less prescribed i.e., only one patient for each of these ART drug 
combinations: (3TC, TDF, NVP) (AZT, D4T, 3TC, NVP) (3TC, EFV, LPVr) (3TC, EFV, ATVr) (ABC, 
DDI, LPVr) (TDF, 3TC, ATVr) (EFV, DDI, LPVr) (EFV, RAL, DRVr) (TDF,3TC, RAL, ETR) (TDF, 
FTC, RAL, DRVr) (RAL, ETR, LPVr). cThe average number of patient viral loads (copies/ml x 105), ND, 
not determined. dThe percentage of patients with HIV-1 unique circulating recombinant forms (CRFs); 
A1/C, A1/AE, D/U, J/A1,C/G, AE/D, A1/U, A3/U and CRF35. Until the time ATVr was available and 
incorporated into national treatment guidelines, LPVr was infrequently provided as second line 
monotherapy if resistance patient had drug resistance to 3TC and AZT.   
 
Stanford resistance predictions were obtained using a Python client, SierraPy 0.1.2, to automate 
transactions with the Stanford HIV-1db Sierra web service algorithm v8.3 (607).   
Subtype classification  
The resulting JSON files were converted into CSV files using an in-house R script. SCUEAL was 
used for HIV-1 subtype classification and recombination detection (608). This algorithm maps 
sequences to a phylogeny of subtype reference sequences by maximum likelihood to classify 
subtypes and detect recombination. Sequences with two or more recombination breakpoints with 
multiple subtype or sub-subtype (e.g., A1, A2) parents are labeled "complex" recombinants. 
Amino acid polymorphisms were extracted by pairwise alignment of the consensus sequence to 
the HXB2 reference integrase gene sequence using an in-house Python script. Insertions relative 




a HXB2 coordinate system. We excluded circulating recombinant forms (CRFs) from the 
phylogenetic analysis and aligned all the data using MAFFT v7.305b(609), including the HIV-1 
subtype reference sequences of HIV-1 subtypes A1, A2, C and D. We manually adjusted the 
resulting alignment using AliView v1.19-beta-3(610). A phylogenetic tree was reconstructed by 
maximum Likelihood using PHYML v20160207 with the default parametric bootstrap support 
analysis(611). The General Time Reversible model incorporating invariant sites and a gamma 
distribution for rate variation across sites (GTR+I+G) was selected using the Akaike Information 
Criterion (AIC) using jModeltest v2.1.10(612). The tree was visualized and manually annotated in 
FigTree (A. Rambaut,  http://tree.bio.ed.ac.uk/software/ figtree) and Archaeopteryx v0.9920 
beta(613).  
Statistical analysis  
Statistical analyses were performed using GraphPad Prism 7.03 (GraphPad Software, La Jolla, 





Based on sequencing of the PR, RT and IN-coding regions, HIV-1 subtype distributions did not 
significantly differ among the four groups (N, FF, SF, and RF). Subtype A virus was the 
predominant subtype found in nearly half of patients in each group followed by subtype D, and C. 
Our observations are consistent with our previous study on Uganda HIV-1 subtype distribution in 
the last 10 years (488) (Fig. 18). As previously described (488), a higher proportion of patients 
failing treatment appeared to be infected with subtype D, but this was not statistically significant 
(Fig. 18).  No subtype C infections were identified in the RAL treated group, most likely due to 
the smaller sample size.  AD recombinants were observed at higher frequency in the naïve than 
treatment failure populations whereas complex recombinants/CRFs comprised the remaining 13-





Figure 18. HIV-1 subtype classification of reverse transcriptase, protease, and Integrase 
regions. (A) The bar graph (Right) and phylogenetic tree (Left) describe the HIV-1 subtype 
classification of the IN gene (percentages) of ART naïve patients, FF, SF and RF. (B) The bar 
graph (Right) and phylogenetic tree (Left) of HIV-1 subtype classification of RT, and PR regions 
of N, FF, SF, and RF. Subtype descriptions are embedded in the figure. An in-house Python script 
was used to label tips with subtype classifications from SCUEAL. A maximum likelihood 
phylogenetic tree was reconstructed from the alignment using PHYML v20160207 with the default 
parametric bootstrap estimation of branch supports given the data. The tree was visualized and 
manually annotated in FigTree (available at: http://tree.bio.ed.ac.uk/software/figtree) and 
Archaeopteryx v0.9920 beta. 
 
On average, 10% of the treatment naïve patients were infected with HIV-1 variants harboring 
primary resistance mutations to at least one NRTI or NNRTI (Fig. 19, Fig. 20). This treatment 
naïve group was recruited from 2007-2011 during chronic disease and tested for HIV-1 drug 





Figure 19.Drug resistance predictions based on pol sequences of treatment naïve, first, and 
second line treatment failures or in patients receiving raltegravir. Genotypic resistance/drug 
susceptibility prediction was performed on 400 HIV-1 pol sequences from Uganda using the HIV-
1db genotypic resistance interpretation algorithm from Stanford University.  Panels A, B, C, and 
D show the level of drug resistance in N, FF, SF, and RF respectively. The first bar in each patient 
group represents total drug resistance in that group, and the first bar in each drug class represent 
total drug resistance in that respective drug class. The rest of description of level of drug resistance 




A 10% incidence of drug resistance in chronically infected patients from 2007-2011 is likely an 
underestimate of current rates of transmitted drug resistance HIV-1 in the treatment naïve 
population.  Recruitment of these patients during chronic disease likely resulted in a loss of drug 
resistance and reversion to wild type HIV-1 following initial infections with a drug resistant HIV-
1 variant.  A recent WHO report 2017 shows pretreatment HIV-1 drug resistance to EFV/NVP in 






Figure 20. HIV-1 genotypic resistance interpretation based on Sanger sequencing. Amino 
acid substitutions was used with HIV-1db program Genotypic resistance interpretation algorithm 
from Stanford university HIV-1 drug resistance database (https://HIV-1db.stanford.edu) to predict 
the levels of susceptibility to PR, RT and INSTIs. A susceptible genotype is shown in green, 
intermediate and high-level resistance is shown in yellow and red respectively. Abbreviations: 
ABC (abacavir), AZT (zidovudine), D4T (stavudine), DDI (didanosine), FTC (emitricabine), 3TC 
(lamivudine), TDF(tenofovir), EFV(efavirenz), ETR (etravirine), NVP (nevirapine), RPV 
(rilpivirine), ATVr (atazanavir/r), DRVr (darunavir/r), FPVr (fosamprenavir/r), IDVr (indinavir/r), 
LPVr (lopinavir/r), NFV (nelfinavir), SQVr (saquinavir/r), TPVr (titranavir/r), DTG 





A slightly higher frequency of NNRTI over NRTI resistance was observed in our treatment naïve 
population, which may be due to higher fitness costs of NRTI over NNRTI resistant mutations and 
faster reversion to wild type HIV-1(614,615). Finally, no PI or INSTI resistance was observed in 
the naïve patients from 2007-2011, which reflects very limited use of these treatments in Uganda 
during this time period.   
Following first-and second-line treatment failures, 97.8% and 81.9% of the HIV-1 sequences 
showed resistance to at least one ART drug, respectively (Fig. 19).  Resistance and presence of 
drug resistant mutations was mainly observed in the NRTI and NNRTI drug classes following first 
line treatment failures due to exclusive use of these drug classes on cART initiation (Figure 19, 
Table 3).  Due to complete absence of PI treatment in the first line treatment regimens, the PR 




Table 3. Frequency of mutations associated with reduced susceptibility to protease, reverse 










aThe number of primary resistance mutations in protease region of HIV-1 found in the study patients. 




in resistance to NNRTIs. dPrimary resistant mutations which confer resistance to INSTIs. n.d, drug resistant 
mutations not determined. Others, drug resistant mutations with one frequency in each patient group. 
   
However, previous studies in Uganda have confirmed the near absence of PR resistant mutations 
in first line treatment regimens involving two NRTIs and an NNRTI (578). PIs typically 
lopinavir/ritonavir (LPVr) or atazanavir/ritonavir (ATVr) were prescribed in nearly all second line 
treatments, hence the appearance of PI resistance upon failure.  Despite the absence of NNRTIs in 
second- or third-line treatment with RAL, NNRTI resistance remained and was still the most 
common in these patients found in 75.5% and 49.0% patients respectively.  Once PIs are 
administered, PIs are typically retained in the regimen even upon treatment failure and emergence 
of PI resistant mutations.  As a consequence, we have little to no data on the potential loss or 
reversion of PI resistant mutations, except that PI resistance is still less frequent than NNRTI or 
NRTI resistance in newly infected or treatment naïve patients.   
 Unlike NNRTI, NRTI, and PI resistance, major drug resistance mutations (DRMs) to INSTIs were 
noticeably absent in N, FF, and SF, i.e., Y143R/C/H, Q148R/K/H/N, N155H, E92Q, E138A/K/T, 
G140S/A/C, S147G, T66A/I/K and R263K conferring resistance to RAL, EVG, and/or DTG. 
Nevertheless, we detected some minor IN mutations described as secondary or compensatory 
mutations: T97A/T (9.6%), M50I (6.7%), L74M/I (3.1%), E157Q (1.43%), V151I/A (2.0%) and 
G163R (2.0%) (Fig. 19, Table 4).  L74M was observed in 0.8% of INSTIs naïve patients (N, FF, 




Table 4. HIV-1 infected patients failing on RAL-based regimen with primary and/or 
secondary (compensatory) INSTI mutations. 
Secondary mutations (not included in the table) found in N, FF, and SF, were classified as follows; M50I 
was found in 12 (7.5%) of FF, 4 (3.3%) of SF, and 7 (8.0%) of N. L74M found in 1(0.8%) of SF, and 1 
(1.1%) of N. T97A was found in 8 (5.0%) of FF, 9 (7.4%) of SF and 7 (8.0%) of N. E157Q was found in 
2(1.2%) of FF, and 1 (1.1%) of N. In bold, the major INSTIs primary resistance mutations which confer 
resistance to INSTIs. Abbreviations: H, high level resistance, I, intermediate level resistance, L, low level 
resistance, S, susceptible genotype. Table 3. Frequency of mutations associated with reduced susceptibility 
to protease, reverse transcriptase, and integrase strand transfer inhibitors. 
It is a polymorphic accessory mutation selected by RAL and EVG (616) and selected by DTG in 




observed in 6.2% of INSTIs naïve patients and 9.8% of RF, and increases resistance to DTG in 
combination with R263K to 5.6-fold in cell culture, though it does not increase the replication 
capacity of the virus. E157Q was found in 0.8% of INSTIs naïve and 5.8% of RF. It has been 
identified as a compensatory mutation for the N115H mutation, but also tends to increase 
susceptibility to DTG. T97A was found in 6.5% of INSTIs naïve and 29.4% of RF. T97A has been 
shown to pre-exist in 5%-10% of INSTIs naïve patients infected with subtype A virus.  
Additionally, T97A was previously co-selected in the presence of primary INSTIs DRMs by RAL 
in many clinical studies (423,617), and by DTG in treatment experienced patients with preexisting 
RAL associated resistance mutations (618). As expected, lack of INSTI resistance is attributable 
to absence of INSTI treatment in Uganda and most of sub-Saharan Africa.  However, previous 
reports and data presented herein also indicate that natural polymorphisms conferring resistance 
to INSTIs are extremely rare in these subtype A and D isolates, also reported as rare in subtype B 
(619).  Predicted DTG resistance was also absent in HIV-1 variants from 366 treatment naïve- or 
experienced patients (FL and SL treatment failures) (Fig. 19, Fig. 20).   
INSTI resistance major mutations Y143R/S (0.9%), Q148K/R (0.47%), N155H (2.1%), E138A/K 
(0.7%), G140A (0.47%), T66A/TAIV (0.47%), and S147G (0.25%) (Fig. 19, Table 4) were only 
observed in RF.  
However, only two patients (DR-206-12, DR-1059-17) in RF had genotypes with potential 
resistance to DTG (i.e., G140A, S147G, Q148K, E138K, and G140A, Q148R, E138A, and G163R 
respectively).  In addition, R263K, the mutation most commonly associated with DTG resistance, 
was not observed.  Over 47% RF had RAL and EVG resistance but only 23.5% were predicted to 





The Ministry of Health in Uganda has implemented the WHO “Treat All” recommendation which 
states that every person tested HIV-1 positive be started on treatment irrespective of his/her 
virological and immunological status. With increasing emergence of drug resistance in treatment 
naïve population in LICs (524,615,620,621), and the number of patients on cART increasing, HIV-
1 drug resistance prevalence will inevitably also rise. More potent antiretroviral drugs, such as 
DTG, have shown to be active in treatment-experienced patients. More importantly, resistance to 
DTG seems to be infrequent in cART-naïve individuals treated with this integrase inhibitor (622). 
The purpose of the study was to screen for drug resistance and possible treatment with DTG in 
treatment naïve patients and those experiencing virologic failure during first, second-, and third-
line cART in Uganda. To our knowledge, this is the first study to look at INSTIs associated drug 
resistance in both cART naïve and experienced patients in Uganda and most other countries in 
sub-Saharan Africa.  
Among minor INSTI resistance mutations, T97A mutation was observed in both INSTIs naïve and 
RF and has been shown to reduce sensitivity of virus to INSTIs and/or rescue viral fitness in 
combination with Y143C/R, Q148+G140S, or N155H. However, a previous study shows T97A 
doesn’t significantly reduce susceptibility to INSTI with up to 94% and 97% viral suppression 
achievable in HIV-1 patients with preexisting and emerging T97A respectively (623). The 
prevalence of the M50I polymorphism observed in INSTI-naïve patients is lower compared to the 
10% found in patients infected with HIV-1 subtype B virus, which shows variation in the evolution 
of INSTI-associated mutations in different viral subtype populations. A relatively small number 
of patients were infected with viruses carrying the E157Q mutation, which has shown to increase 
susceptibility to DTG (624). However, the combination of E157Q and R263K increases DTG 
resistance by 10-fold (624).    
We found neither of the two rare mutations associated with DTG resistance, R263K and G118R. 
R263K has been identified in both clinical samples and cell culture assays (429,435) and G118R 
in cell culture tests. The major mutation pathways for RAL, Y143R/C, Q148R/K/H and 
N155H(419) were not found in INSTIs naïve patients in agreement with previous study done in 




Q148R/K, G140A, E138A, S147G, T66A/TAIV, and N155H INSTI major mutations which could 
explain the virological failure observed in these patients.  
This study shows that accumulation of INSTIs DRMs at positions, G140, S147, Q148, and E138 
after RAL failure can potentially predict the potential loss of susceptibility of the virus to DTG as 
seen previously (626). For example, we found two individuals infected with a virus carrying the 
Q148K/R resistant mutation, which when present alone moderately reduces RAL and EVG 
susceptibility while having a minimal effect on DTG susceptibility; however, in combination with 
G140S/A/C and/or E138K/A, it may reduce DTG susceptibility up to 10-fold (607,627).  In RF, 
N155H had highest frequency 9 (17.6%) compared to other major INSTIs DRMs which may be 
due to early selection of this resistant mutation under RAL pressure as observed previously in a 
phase II study looking at long term efficacy and safety of RAL in patients with limited treatment 
options(628).  Among the six major mutations which reduce susceptibility to EVG, T66I, E92Q, 
T97A, S147G, Q148K and N155H (424), only substitution E92Q was not selected by the virus in 
the study patients which could be due to cross resistance as EVG is currently unavailable in the 
country.    
Based on our analyses of 417 Ugandan HIV-1 pol sequences, DTG would possibly be effective at 
any stage of cART treatment in sub-Saharan Africa.  DTG has become the preferred drug for the 
majority of new FL or salvage treatments in HICs.  In our Ugandan cohort, we did not observe a 
higher frequency of mutations conferring DTG or any other primary INSTI resistance mutations. 
We observed a high frequency of NNRTI resistance in FF (96.4%), and in patients who remain on 
treatment but who have not received NNRTI for years, SF (75.5%) and RF (49.0%). This 
observation complements the fact that over 50% of treatment failures in Uganda retain NNRTI 
resistant virus and often for years following the last dose of nevirapine (NVP) or efavirenz (EFV). 
In contrast, the frequency of NRTI and PI resistance is lower in all of these HIV-1 infected groups 
in Uganda.  With the UNAIDS/WHO 90:90:90 goals, continued use of NNRTIs (EFV or NVP) 
may help increase access to treatment since these drugs are readily available in this setting but may 
not impact treatment outcomes due to associated high drug resistance, high pill burden, and poor 
tolerability profiles. However, to achieve continued viral suppression in 90% of treated 
individuals, we should abandon the continued use of NNRTIs (NVP or EFV) in first line treatment 




in first line treatment regimens in lower income countries (LICs), such as Uganda and other East 
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Raltegravir is commonly used as a salvage therapy in most LMICs in combination with darunavir 
and NRTIs. Though RAL is sparingly used in Uganda, over 50% of patients failing third line 
therapy harbor RAL/EVG associated DRMs with 4% predicted to harbor DTG resistance. DTG 
has a higher barrier to resistance profile and for that treatment failure in DTG naïve or experienced 
patients is rare. Indeed, from our previous study, DTG resistance was only predicted in patients 
with multiple INSTIs associated DRMS failing RAL-based regimen. The prediction was based on 
Stanford HIV-1 drug resistance database interpretation and therefore it was necessary to confirm 
these results by carrying out phenotypic assays on recombinant viruses from patient-derived HIV-
1 integrases.  
E.N, Y.L, A.M, C.T, P.S performed drug resistance assays and experimentation in this article and 
E.N, M.A, A.P, A.S.O, R.M.G, M.E.Q-M performed data analyses. I.N, F.K, C.K recruited all the 
patients for this study. E.J.A and M.E.Q-M procured the funding, and E.J.A designed, supervised, 














4.2 Abstract  
Objectives  
Increasing first-line treatment failures in low-and middle-income-countries (LMICs) has led to 
increased use of integrase strand-transfer inhibitors (INSTIs) such as dolutegravir (DTG). 
However, HIV-1 susceptibility to INSTIs in LMICs especially with previous raltegravir (RAL) 
exposure is poorly understood due to infrequent reporting of INSTI failures and testing for INSTI 
drug resistant mutations (DRMs).   
Methods  
A total of 51 non-subtype B HIV-1 infected patients failing third-line treatment regimen (RAL-
based) in Uganda were initially selected for the study. DRMs were detected using Sanger and deep 
sequencing. HIV-1 integrase genes of 13 patients were cloned and replication capacities (RCs) and 
phenotypic susceptibilities to DTG, RAL, and elvitegravir (EVG) were determined with TZM-bl 
cells. Spearman’s correlation coefficient was used to determine cross resistance between INSTIs.  
Results  
INSTIs DRMs were detected in 47% of patients. HIV-1 integrase-recombinant virus carrying one 
primary INSTI DRM (N155H or Y143R/S) was susceptible to DTG but highly resistant to RAL 
and EVG (>50-fold). Two patients with E138A/G140A/Q148R/G163R or 
E138K/G140A/S147G/Q148K displayed highest reported resistance to RAL, EVG, and even 
DTG.  The former multi DRM virus had wild type RC whereas the latter had lower RCs than wild 
type.  
Conclusions  
In HIV-1 subtype A and D infected patients failing RAL and harboring INSTIs mutation DRMs, 
there is high level resistance to EVG and RAL.  More routine monitoring of INSTI treatment may 
be advised in LMICs considering multiple INSTI DRMs may have accumulated during prolonged 






4.3 Background  
HIV-1 integrase strand transfer inhibitors (INSTIs), the latest class of ART, have changed the HIV-
1 treatment landscape around the world. The second generation INSTI dolutegravir (DTG) has a 
higher genetic barrier to resistance and has proved to be an effective INSTI when used in 
combination therapy for treatment-naïve as well as individuals harboring viruses resistant to 
raltegravir or elvitegravir (318,444). Under 2018 WHO guidelines, a DTG-based regimen is 
preferred for first-line ART for all adults and adolescents except for those women of childbearing 
age who wish to become pregnant.  DTG is also the preferred second-line drug of choice for those 
failing NNRTI-containing treatment regimens (629). For children >4 weeks of age, DTG is favored 
for second-line treatments following failure to NNRTIs or PI containing ART (629). Following 
FDA approval in 2013, and prior to 2014, DTG was rarely administered in low-income and middle-
income countries (LIMCs) but with the rollout of TDF+3TC+DTG at a cost of US $75 annually 
per patient-year (630), over 4 million patients are now receiving a DTG- containing regimen (631), 
eclipsing the number of patients receiving DTG in the high income countries (HICs).  In Uganda, 
the focus site of this study, generic DTG is now part of the preferred first-line regimen 
(TDF+3TC+DTG) in all adults (525).   
RAL performs pivotal role as salvage and pediatric treatment and EVG can be used in ART naïve 
patient in Uganda and other LMICs. However, RAL and EVG resistance has been reported but 
mostly in HIV-1 subtype B due to early use of INSTIs (632). In addition, there is infrequent 
reporting of INSTI failures and testing for INSTI drug resistant mutations in non-B subtypes 
especially subtype A and D. Switching patients to salvage treatment in Uganda is done under 
discretion of a committee by the ministry of health which rely on resistance predictions from HIV-
1 drug resistance databases (525). However, there appears to be subtype specificity associated with 
resistance to INSTIs with some mutations.  For example, substitutions at Q148 of HIV-1 integrase 
which confers resistance to RAL, EVG, and cross resistance to DTG appears more in subtype B 
than non-B subtypes (633). Thus, it becomes imperative to assess the impact of RAL and EVG 





Despite the rapid and large scale roll out of DTG in LMICs, there is very limited data on the 
susceptibility of non-subtype B HIV-1 to INSTIs (592,633), including cross-resistance to DTG 
conferred by raltegravir-resistant variants HIV-1 emerging in non-B HIV-1 subtype infected 
patients failing raltegravir-based regimens (633). In addition, increasing spread of HIV-1 non-B 
subtypes in regions where subtype B previously predominated such as Europe and America (634–
636), calls for the urgent need for more genotypic drug susceptibility testing for INSTI resistance.  
Even with the use of generic DTG for first-line ART in LIMCs, treatment failures to the NNRTI-
based and subsequent boosted PI-based regimens are still followed by raltegravir-based ART.  
Failure to this third-line treatment in LMICs leaves patients with few options since entry inhibitors, 
i.e., enfuvirtide- and maraviroc, are not readily available. In our previous study, we found over 
50% of patients failing on raltegravir-based therapy in Uganda harbored raltegravir-associated 
DRMs (540).   
In this study, non-B HIV-1 integrase (IN) chimeric viruses derived from 11 Ugandan patients 
failing a raltegravir-based third-line regimen showed significant resistance to raltegravir and 
elvitegravir but remained susceptible to DTG when the “common” raltegravir resistance mutations 
were present: N155H, Y143R/S. However, viruses harboring three, or four resistance mutations 
(i.e., E138K/A, G140A, S147G, Q148K/R, and G163R) showed high-level resistance to all 













4.4 Materials and methods  
Samples for the study  
Samples were collected from the WHO, College of American pathologist (CAP) and National 
Institutes of Health-virology quality assurance (NIH-VQA)-accredited center for AIDS Research 
(CFAR) laboratory of the Joint Clinical Research Center (JCRC) in Kampala, Uganda. The patient 
database in the CFAR laboratory was used to retrieve the patient demographic, medical, and 
treatment histories.  A total of 60 plasma samples were collected from patients failing raltegravir-
based third-line regimens. Virologic failure was defined by a viral load above 1,000 copies/ml 
and/or CD4+ T cell counts below 250 cells/mm3 defined immunological failure. Written consent 
was obtained from all patients prior to sample storage. Ethical clearance was obtained from the 
IRBs at the JCRC and University hospitals Cleveland medical center/Case Western reserve 
university (EM-10-07 and 10-05-35). 
RNA extraction and PCR amplification 
HIV-1 viral RNA was extracted from plasma using a QIAamp viral RNA Mini Kit (Qiagen) and 
HIV-1 IN-coding region amplified using a Superscript III single RT-PCR system (Thermo Fisher 
Scientific) as previously described, (540) (Table 5). 
Sanger sequencing and sequence analysis 
The HIV-1 IN coding regions were amplified and analyzed using Sanger sequencing as previously 
described (540). Briefly, a quantified and purified PCR product was sequenced to cover the full 
length of the HIV-1 IN (1–288 amino acids) (Table 5). Sequences were exported and analyzed in 




Table 5. List of primers used in the study 
 
RT, reverse transcription; F, forward; R, reverse  
The Stanford HIV-1db Sierra web service algorithm v8.3 was used to predict resistance phenotype. 
(637) 
Library preparation and deep sequencing  
An amplicon-based deep sequencing method was used to detect variants and confirm presence of 
DRMs originally identified by Sanger sequencing (Table 5). Briefly, two overlapping PCR 
products spanning full-length of HIV-1 IN were purified using (Agencourt AMPure XP; Beckman 


















a,b,c HIV-1 susceptibility to DTG, EVG, RAL respectively. Sanger and Illumina sequences were predicted 
for resistance using Stanford HIV-1 database v8.3 (https://HIV-1db.stanford.edu/HIV-1db/by-sequences/). 
DTG, dolutegravir; EVG, elvitegravir; RAL, raltegravir; H, high level resistance; I, intermediate resistance; 
L, low level resistance; P, potential resistance; S, susceptible; IN, HIV-1 integrase. 
 
The barcodes were added using Nextera XT index Kit v2 (Illumina) (Table 4) and paired-end 
sequencing done on a MiSeq instrument (Illumina). Analysis was performed with MiSeq Reporter 
analysis software version 2.6 (Illumina) and drug resistance interpretation was done using Stanford 
HIV-1db Sierra web service algorithm v8.3 (637).  Samples confirmed by deep sequencing to 
harbor INSTIs associated DRMs (n=11) or having no known INSTIs associated DRMs (n=2) were 




Table 7. Virological and clinical characteristics of patients with INSTIs associated 
mutations in the study 
The HIV-1 subtype was predicted using SCUEAL subtype classification algorithm. Viral loads were 
assayed using Abbott m2000sp/rt or Roche COBAS Amplicor Monitor ultrasensitive tests, v1.5. In bold, 
major INSTIs resistance mutations a The patients accession numbers tested for INSTI resistance. 
bDescription of the ART combinations in the study cThe patient viral loads (copies/ml) dThe predicted 
subtype of study patients ethe resistance mutations detected in study patients cART, combined antiretroviral 
therapy; ND, not determined; INSTI, integrase strand transfer inhibitor; ATVr, atazanavir/r; DRVr, 
darunavir/r; LPVr, lopinavir/r; RAL, raltergravir; 3TC, lamivudine; TDF, tenofovir; FTC, emitricabine. 
 
HIV-1 subtype classification and detection of recombination forms was done using SCUEAL 
program (608).   
Cells and antiviral compounds 
TZM-bl, U87.CD4.CXR4, and HEK293T cell lines were obtained through the AIDS Research and 
Reference Reagent program, division of AIDS, NIAID, NIH. TZM-bl cells, and HEK293T were 
maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 μg/ml penicillin-
streptomycin. U87.CD4.CXR4 cells were maintained in DMEM supplemented with 10% FBS, 
100 μg/ml penicillin-streptomycin, 300 μg/ml G418, and 1 μg/ml puromycin (Invitrogen, 
Carlsbad, CA). All cell lines were subcultured every 3-4 days at 37°C under 5% CO2. The TZM-




expression of HIV-1 tat. Elvitegravir was obtained from (Gilead Sciences, Inc., Foster City, CA), 
raltegravir and DTG (NIH). 
Construction of HIV-1 IN chimeric viruses 
HIV-1 full length IN PCR products were recombined into near full-length HIV-1 
(pREC_NFL_IN/URA3) vector using transfected Saccharomyces cerevisiae MYA-906 cells 
(ATCC) based on yeast homologous recombination-gap repair system (638). Plasmids were 
extracted from the yeast cells using phenol/chloroform (Thermo Fisher scientific) and transformed 
into electrocompetent Escherichia coli Stbl4 cells (Thermo Fisher scientific). Plasmids were 
extracted from the bacteria using Qiagen miniprep kits (Hilden, Germany). The presence of 
mutation (s) in generated plasmid was confirmed by Sanger sequencing. pREC_NFL_INT 
plasmids were cotransfected into HEK 293T cells (3×104 cells/well) along with the complementing 
plasmid pCMV_cplt using Fugene 6 reagent (Promega, Madison, WI) (638). Produced 
heterodiploid virus particles containing one copy of the pREC_NFL_INT and cplt HIV-1 RNAs 
were further propagated on U87.CD4.CXCR4 cells to produce a complete HIV-1 genome. 
Following virus propagation, viral RNA was re-sequenced to confirm the presence of the various 
DRMs. 
INSTIs resistance assays in TZM-bl cells 
The susceptibility of patient-derived viruses to DTG, raltegravir and elvitegravir was determined 
using short-term resistance assays with TZM-bl cells. Briefly, 20,000 cells were seeded to each 
well of 96-well plate and infected with controls, NFL4-3, UG14, UG98, and mutant viruses in 
presence of 10-fold dilutions of DTG, raltegravir, or elvitegravir (100 µM to 10-8 µM) and DEAE-
dextran (1mg/ml). The amount of virus added to each well was normalised to 0.01 MOI based on 
infectious titre. After 48 hr incubation at 37°C and 5% CO2, the infectivity of viruses was 
quantified using X-gal as previously described (639). The stained colonies were counted using 
Cytation 5 plate reader (BioTek USA) and confirmed by manual counting using a fluorescent 
microscope. Drug sensitivity curves were generated using nonlinear regression curve fitting 
features of GraphPad Prism 8.0 software (GraphPad Software, Inc., San Diego, CA). Drug 




controls and mutant viruses basing on at least two sets of experiments each performed in 
quadruplicates.  
X-gal staining assay 
The X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) (40 mg/ml) substrate was used to 
detect β-galactocidase enzyme expression from infected cells (639). The TZM-bl cells infected for 
48 hrs were fixed with glutaraldehyde (0.2%) and formaldehyde (0.8%). The cells were 
sequentially stained with potassium ferrocyanide (0.2M), potassium ferricyanide (0.2M), 
magnesium chloride (2M), and X-gal substrate, and then incubated for 2 hours at 37°C.  
Infectivity assay in TZM-bl cells 
Infectivity of HIV-1 IN chimeric mutant viruses were determined using short-term infectivity 
assay in TZM-bl cells. Briefly, 20, 000 TZM-bl cells in presence of DEAE-dextran (1mg/ml) were 
infected with increasing concentration of either mutant or controls. Cells were fixed, stained, and 
β-galactosidase expression was measured using X-gal protocol as described above. The fold 
decreases in infectivity were expressed as percentage of relative decrease in area under the curve, 
amount of virus needed for TZM-bl cells to produce the maximal level of β- galactosidase in an 
infection.  
Statistical analyses 
Statistical analyses were performed using non-linear regression in GraphPad Prism 8.1.2 
(GraphPad Software, La Jolla, CA). The level of cross resistance was analysed using Spearman’s 










Samples and patient demographics  
Samples were obtained from 60 patients failing a third-line raltegravir-based in Uganda. Of them, 
51 (85%) were successfully amplified and sequenced by Sanger and deep sequencing (540). 
INSTI-associated DRMs were detected in 24/51 (47%) patient samples. Eleven samples with 
INSTIs resistance mutations were subsequently selected for phenotypic assays.  Of the 11 samples 
selected for phenotypic studies, 8 of 11 were obtained from individuals on dual therapy (protease 
inhibitor [PI] + raltegravir) while the other 3 were treated with triple therapy (i.e., NRTI + PI + 
raltegravir). The average viral load count was 454,669 copies/ml (range 850 -2,293,840) (Table 
7).  Seven of 11 (64%) viruses were classified as HIV-1 subtype A, 27% subtype D (3/10) and 1 
sample had a subtype A/D recombinant (Table 6, Table 7). Two patient IN with no INSTI-
associated DRMs, UG98 (subtype D), UG14 (subtype A), as well as NL4-3 HIV-1 (subtype B) 
where included in phenotypic assays as reference strains (Table 7). 
As previously published, (540) nearly 5% (2/51) of the patients failing a raltegravir-containing 
therapy harbored virus with multi-DRMs to INSTIs, i.e the subtype A UG1059 with 
E138A/G140A/G163R/Q148R and subtype D UG206 with E138K/G140A/S147G/Q148K. These 
were selected for cloning and phenotypic assays along with other 9 with INSTIs DRMs. Whereas 
Q148H only emerges in context of G140S mutants in subtype B, the Q148R/K appears associated 
with G140A in non-B subtypes. Overall, N155H was the predominant INSTI DRM found in 9 of 
51 patients. For this study, three IN regions with only N155H (UG1179, UG11, and UG537) and 
two patients’ IN containing N155H with secondary mutations, L74I/T97A or 
M50L/L74I/V151I/E157Q/G163R (respectively) were cloned for phenotypic analyses (Table 6, 
Table 7). Along with these seven, other three had Y143R plus secondary mutations 
M50I/L74IM/T97A, (UG35), or T97AT/G163R, (UG481), and Y143S plus T97A (UG1044). One 






N155H and Y143R/S emergence during raltegravir treatment in subtype A and D confer 
high level resistance to raltegravir and elvitegravir but not to DTG 
The N155H mutation in HIV-1 subtype B confers significant level resistance to both raltegravir 
and elvitegravir. In drug susceptibility assays, the three subtype D and circulating recombinant 
form A/D patient derived recombinant viruses (UG11, UG537 and UG1179) carrying only N155H 
had a 10- to 19-fold decrease in susceptibility to raltegravir, 63- to 78-fold to elvitegravir, but only 
1.3-fold change to DTG susceptibility when compared to susceptibility of wild type NL4-3 (Fig. 
21, Fig. 22, Fig. 23).  Slightly higher levels of resistance were observed with these N155H viruses 





Figure 21.The susceptibility of viruses with drug resistant mutations to INSTIs. The log 
values of drug concentrations were plotted against percentage of infections in TZM-bl cells 
detected by x-gal assay. The colonies were counted using elispot and they are from 2-3 independent 
experiments each run in quadruplets. The change in EC50 relative to wild type (NL4-3) is shown. 
Ral: raltegravir, evg: elvitegravir, dtg: dolutegravir.    
 
When L74I and T97A was found in addition to N155H in a subtype A IN, there was no effect on 
susceptibility to DTG (FC 1.57-fold change or FC) but increased resistance to raltegravir (FC 39) 





Figure 22.The susceptibility of mutants by subtype. The fold change values in EC50 of DTG, 
RAL and EVG relative to each subtype was determined in short term infection assay in TZM-bl 
cells. Each value represents the mean fold change of EC50 from 2-3 independent experiments each 





Presence of secondary mutations, E157Q, G163R, M50L, L74I and V151I in addition to N155H 
in the subtype D integrase resulted in a low 2.8-fold resistance to DTG but high-level resistance to 
elvitegravir (FC 70) and raltegravir (FC 56).  
 
Figure 23.The susceptibility of HIV-1 mutants relative to NL4-3 strain. The fold change values 
in EC50 of DTG, RAL and EVG relative to NL4-3 was determined in short term infection assay in 
TZM-bl cells. EC50 fold changes of wild type A, D relative to NL4-3 are also shown. Each value 
represents the mean fold change of EC50 from 2-3 independent experiments each done in 
quadruplets.    
 
The Y143R/S mutation only emerged in HIV-1 subtype A infected patients and conferred slightly 
higher levels of resistance to raltegravir than to elvitegravir in subtype A HIV-1. The T97A, M50I, 
and L74I/M secondary mutations had minimal or no impact on INSTI resistance. Susceptibility to 
DTG was not affected by Y143R/S with the other secondary mutations (Fig. 21, Fig. 22, Fig. 23). 




Multiple INSTI DRMs with secondary mutations confers high level resistance to DTG, 
raltegravir and elvitegravir  
Q148H/K/R alone typically has minimal effect on DTG susceptibility. In patients failing a 
raltegravir-based treatment in Uganda, the Q148R mutation in subtype A HIV-1 was found in 
combination with primary INSTI DRMs, E138A, G140A, and in subtype D, a Q148K with E138K, 
G140A, and S147G. With the IN from both patients, the chimeric viruses were highly resistant to 
elvitegravir, raltegravir (both >1000-fold), and DTG (>100-fold) (Fig. 22, Table 8, Fig. 23).  
Table 8. The mean EC50 of different HIV-1 integrase strand transfer inhibitors against 
recombinant viruses in the study 
 
 
DTG, dolutegravir; RAL, raltegravir; EVG, elvitegravir; EC50, effective concentration 50; CI, confidence 




Finally, chimeric virus from HIV-1 subtype A infected patient with secondary mutations T97A, 
V151A, and E138A had resistance to elvitegravir (45-fold) and low-level resistance to raltegravir 
(12-fold) but wild type sensitivity to DTG (Fig. 21, Fig. 22, Fig. 23). 
For all the chimeric viruses studied for drug susceptibility, the IN genes of HIV-1 subtype A and 
D infected patients containing INSTI DRMs were cloned into a subtype B backbone.  Despite the 
concerns with complementation compatibility, the same level of resistance with these IN chimeric 
viruses was observed when compared to wild type NL4-3 or the NL4-3 containing the wild type 
subtype A and D IN coding regions (Fig. 24). 
 
Figure 24. Effects of IN complementation in an NL4-3 chimeric virus. The correlation of fold 
change values relative to subtype A, D, and nfl4-3. Each value represents the fold change of means 
from each subtype. Correlation was determined using spearman’s rank order with p=0.001 
significant. 
 
INSTI DRMs can impair replicative capacity regardless of subtype 
Using TZM-bl cells replication capacity (RC) of these IN chimeric HIV-1 (all with NL4-3 
backbone) were compared to wildtype NL4-3, UG14, and UG98 references. All the IN chimeric 
HIV-1 with INSTI DRMs had significantly reduced RC compared to the reference wild type 
strains. Reduced RC exhibited by the viruses was not simply due to poor complementation 
considering the IN of the subtype A and D in a NL4-3 backbone had slightly higher replication 
rates than wild type NL4-3. Viruses, UG138-A (N155H; secondary mutations, T97A/L74I,), and 




<30% of the subtype A and D references.  UG206-D, with four primary DRMs, E138K, G140A, 
S147G, and Q148K also had a low RC (29%). However, there was no clear patterns of reduced 
replication rates based on any of the primary or secondary DRMs (Fig. 25). UG23-A, UG1044-A, 
and UG35-A replicated at 40 to 45% of the references, while UG119-A, UG537-A/D, UG42-D, 
and UG11-D were at 50 to 60% of wild type HIV-1s.  
 
Figure 25. Relative viral infectivity of recombinant viruses. The viral infectivity of resistant 
mutants compared to controls and wildtype was determined using short-term infection assay in 
TZM-bl cells. Area under the curve was used to measure the relative decrease in infectivity. The 
data shown represent means and standard deviation from independent experiments performed in 
triplicates. 
 
The other chimeric HIV-1 with four primary DRMs in IN (E138A, G140A, Q148R, G163R) had 






Cross resistance observed between DTG and elvitegravir 
Correlation coefficient of FC values for DTG, raltegravir, and elvitegravir were assessed to 
determine the level of cross resistance between the INSTIs. DTG FC values for resistance were 
found to correlate with elvitegravir FC values for resistance (P=0.0073, R=0.8), but not with FC 



















Resistance to INSTIs is well characterized in HIC with a 12, 7 year, and 6-year history of 
employing raltegravir, elvitegravir, and DTG, respectively. The typical 4 major pathways to 
INSTIs resistance involve N155H, Q148H/K/R, and Y143R/H/C to raltegravir and elvitegravir, 
and R263K to DTG and bictegravir as primary INSTI DRMs. Both in vitro and in vivo selection 
of DTG resistance is conferred by either an accumulation of INSTI DRMs or the emergence of 
R263K. Both pathways confers low-level DTG resistance, significant reductions in RC, and often 
requires the emergence of compensatory mutations, e.g. H51Y with R263K (434).   
In this study, we produced 11 chimeric viruses harboring the IN genes of Ugandan patients failing 
third-line raltegravir-based treatment and with known DRMs.  Chimeric IN HIV-1 produced with 
single DRMs resulted in significant resistance to elvitegravir and raltegravir and 43 to 68% 
decrease in RC. Even these single DRMs with compensatory/secondary mutations emerging in 
subtype A and D IN do not confer cross resistance to DTG.  HIV-1 containing IN of two patients, 
UG1059 and UG206 with three and four DRMs (respectively) showed high-level resistance to 
elvitegravir and raltegravir and over 100-fold cross resistance to DTG.  The level of INSTI 
resistance by these two patient derived viruses are among the highest ever recorded with 
phenotypic tests.  Although the subtype D UG206 had a 70% reduction in RC, the RC for UG1059 
was not significantly different from wild type.   
Few studies have assessed phenotypic INSTI resistance using the IN derived from INSTI failures 
in Uganda or in Sub Saharan Africa. One study describes resistance to INSTIs, even DTG in 
subtype A, B, C, D, F, G, CRF01, CRF02, and other CRFs related to Q148H/K/R resistance 
pathway but these Q148H/K/R were infrequent in this cohort when compared to INSTI failures in 
subtype B infected patients (633,640,641). There are, however, several genotypic studies 
describing common INSTI DRMs in untreated and in INSTI treated patients of Sub-Saharan 
Africa.  For nearly 10 years raltegravir-based treatment has been recommended by WHO for third-
line regimens (642) and as such is rarely used in treatment within LIMCs. In just 4 years,  generic 
DTG and TDF/3TC/DTG is now accessible to 3.9 million HIV-1 infected individuals in sub-
Saharan Africa and other developing countries (629,631).  This important roll out of DTG was 




DTG treatment from the time of conception (643). Nonetheless, there has been no extensive screen 
for susceptibility of African non-subtype B HIV-1 to DTG and especially not with HIV-1 derived 
from those failing a raltegravir-based regimen.  This study suggests that 5% of raltegravir failures 
may harbor DTG resistant HIV-1. Even this frequency of DTG cross resistance in raltegravir 
failures in subtype A and D infected individuals could be a cause of concern. Furthermore, a recent 
study by our team suggests that 28% of raltegravir failures harbor raltegravir / elvitegravir resistant 
viruses with previously uncharacterised INSTI DRMs related to subtype A and D (reference 
submitted for now). Half of these new INSTI-resistant genotypes in subtype A and D HIV-1 
displayed cross resistance to DTG.   
HIV-1 IN mutation N155H is selected early under raltegravir pressure (644). We have previously 
shown predominant selection of N155H (17.6%) in HIV-1 patients failing third-line raltegravir -
based regimen in Uganda (540), and thus, understanding the susceptibility of viruses with single 
N155H is important in assessing if DTG could be utilized in a fourth-line regimen given the limited 
availability of other salvage drugs like enfuvirtide or maraviroc in Uganda. In our study, three 
viruses with a single N155H mutation were susceptible to DTG (FC, 1.6-2.4) two of these 
comparable to N155H in subtype B HIV-1 (FC, 1.2) (319). Given the low-level phenotypic 
resistance associated with DTG failure in subtype B infected individuals, even our modest 2.4-fold 
decreased susceptibility with N155H to DTG may predict potential treatment failure with DTG-
containing ART use as fourth-line treatment in Uganda.   
Prolonged exposure to INSTI following treatment failure can lead to an accumulation of primary 
DRMs and compensatory secondary mutations to increase INSTI resistance and/or restore viral 
fitness (645). Achieving viral suppression with DTG in patients failing raltegravir or elvitegravir 
is reduced with each added primary INSTI DRM (G140H/A/S, E138A/K/T) in association with 
substitutions at Q148, as seen in VIKING-3 study (318).  Viral suppression with DTG was also 
reduced with INSTIs mutations, E138K, G140A, S147G, Q148R and T97A in a subtype C 
infected, raltegravir-experienced patient from Botswana (646). However, this accumulation of 
INSTI DRMs is extremely rare in HICs due in part to frequent patient visits, viral load monitoring, 
and drug resistance testing.  In Uganda like many other LIMCs, less frequent clinic visits and viral 
load testing, intermittent adherence, and limited drug resistant testing could contribute to multi-




this Ugandan cohort had E138A, G140A, Q148R, and G163R in a subtype A virus and E138K, 
G140A, S147G, Q148K in subtype D. The presence of these four primary INSTI resistance 
mutations within IN has never been observed in subtype B infected patients, naïve to or failing 
INSTIs (421). A combination of two primary INSTI DRMs (Q148H, G140S) with secondary 
mutations, T97A, L74M conferred resistance to DTG in subtype B viruses (647). The loss of RC 
observed with UG206 could as well be compensated by emergence of secondary mutations to 
support active infection in presence of drug. Thus, the frequent appearance of multi-DRM HIV-1 
in subtype A (as with UG1059) and subtype D (with UG206) upon INSTI treatment failure could 
have devasting consequences for future roll out of DTG. Hopefully, a 11% frequency of multi-
DRM will not persist with larger cohorts on raltegravir-based treatment in sub-Saharan Africa. 
Conclusions 
In this study, we show that INSTIs resistant viruses in the majority of patients in Uganda failing 
raltegravir-based third-line treatment remain susceptible to DTG and have impaired RC. However, 
accumulation of primary INSTI DRMs mutations leads to high level resistance to all INSTIs 
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Accumulation of primary HIV integrase mutations in ART experienced patients infected failing 
RAL leads to high-level resistance to DTG, RAL, and EVG. However, we have shown previously 
that DTG remains active against viruses with single primary mutation or combination of secondary 
mutations.  N155H within IN may confer higher resistance to DTG in subtype A and D compared 
to subtype B viruses. BIC is newly approved second generation INSTI that is becoming available 
in LMICs, and CAB INSTI is in phase III clinical trial as daily oral and long acting parenteral 
nanosuspension for monthly or quarterly administration. CAB and BIC have activity against many 
resistant HIV strains to EVG and RAL and some resistant variants to DTG. Due to wide roll out 
of INSTIs in LMICs, the number of patients failing INSTIs will also likely increase limiting the 
available ART options. Therefore, to ascertain possibility of switching ART experienced patients 
to BIC or CAB, we carried out drug susceptibility assays in-vitro and tested the level of resistance 















The second-generation integrase strand transfer inhibitor (INSTI) bictegravir (BIC) is becoming 
accessible in low- and middle-income countries (LMICs), and another INSTI (cabotegravir, CAB) 
has recently been approved as long-acting injectable. Data on BIC and CAB susceptibility in 
raltegravir (RAL)-experienced HIV-1 subtype A and D infected patients carrying drug resistance 
mutations (DRMs) remains very scarce in LMICs.  
Patients and methods 
HIV-1 integrase (IN) recombinant viruses from eight patients failing RAL-based third-line therapy 
in Uganda were genotypically and phenotypically tested for susceptibility to BIC and CAB. Ability 
of these viruses to integrate into human genomes was assessed in MT-4 cells.  
Results 
HIV-1 IN-recombinant viruses harboring single primary mutations (N155H or Y143R/S) or in 
combination with secondary INSTI mutations, T97A, M50I, L74IM, E157Q, G163R, or V151I 
were susceptible to both BIC and CAB. However, combinations of primary INSTI-resistance 
mutations such as E138A/G140A/G163R/Q148R or E138K/G140A/S147G/Q148K led to 
decreased susceptibility to both CAB (fold change in EC50 values from 429 to 1,000x) and BIC 
(60 to 100x), exhibiting a high degree of cross resistance.  However, these same IN-recombinant 
viruses showed impaired integration capacity (14% to 48%) relative to the wild type HIV-1 NL4-
3 strain in the absence of drug.  
Conclusions 
Though not currently widely accessible in most LMICs, BIC and CAB offer a valid alternative to 
HIV-infected individuals harboring subtype A and D HIV-1 variants with reduced susceptibility 





HIV-1 drug resistance remains a global threat, even in the era of second-generation HIV-1 strand 
transfer integrase inhibitors (INSTIs). In low- and middle-income countries (LMICs), the 
increasing prevalence of HIV-1 drug resistance in the treatment naïve population has required the 
reduced use of a first-line non-nucleoside reverse transcriptase inhibitors (NNRTI)-based 
combined antiretroviral therapy (cART), such as efavirenz or nevirapine, to a 
tenofovir/lamivudine/dolutegravir regimen (629). Nevertheless, prolonged virological failure is 
common in LMICs due to limited virological monitoring of HIV-infected individuals, leading to 
accumulation of even INSTI-resistance mutations and reduced susceptibility to dolutegravir 
(DTG), raltegravir (RAL), and elvitegravir (646,648,649).  
Bictegravir (BIC, formally GS-9883) and cabotegravir (CAB, formally S/GSK 1265744 or GSK 
744), both structural analogues of DTG, are the latest second generation INSTIs. Two clinical 
trials in ART-naïve individuals and two trials in virologically suppressed patients (321,457,650) 
led to approval of BIC in 2018 by FDA as a fixed-dose combination of BIC/FTC/TAF in cART 
naïve and suppressed patients (<50 copies/ml) with no history of drug resistance. BIC is a potent 
unboosted once-daily INSTI with a higher in vitro barrier to resistance than RAL and EVG, and 
with limited drug-drug interactions. Its structure has a distinct oxazepane ring attached to a metal 
chelating scaffold (Fig. 1), which increases flexibility allowing for more adaptability in presence 
of drug resistance mutations (651). CAB is another analog of DTG from a class of carbamoyl 
pyridones that has recently been approved by FDA and European Union as long-acting injectable, 
CAB/rilpivirine for use in HIV patients with undetectable viral loads, stable on current cART, and 
no drug resistance (652–654). The unique physicochemical and pharmacokinetic properties of the 
CAB formulation allows its use as a single-daily tablet or long-acting nanosuspension for monthly 
or quarterly via subcutaneous or intramuscular administration. CAB was recently approved as a 
fixed-dose long-acting injectable combination of CAB plus the NNRTI rilpivirine after successful 






Figure 26. The chemical structures of different INSTIs. 1) Elvitegravir, 2) Raltegravir, 3) 
dolutegravir, 4) cabotegravir, and 5) bictegravir. The coplanar oxygen atoms are highlighted in red 
and green circle highlights extended linker a common feature to all second generation INSTIs. 
 
BIC has shown broad activity in vitro as an INSTI against recombinant viruses and clinical isolates 
carrying primary mutations associated with resistance to RAL and elvitegravir (459,656). 
However, mutations at position Q148 of the HIV-1 integrase (IN) confer a wide range of resistance 
to BIC in vitro when combined with other amino acid substitutions (657). Selection of the Q148R 
mutation was observed in two patients on either oral or long injectable CAB in the LATTE clinical 
trials (655,658); however, CAB has shown activity against viruses harboring T66I, Y143R, 
N155H, E92Q, Q148H/K/R and G140S/Q148H/K/R (<7-fold) (463). 
By mid-2020, transition to generic DTG-based first line had been implemented in 100 LMICs, 
however, the distribution of DTG at large scale in LMICs has coincided with the emergence of 
SARS-CoV-2, responsible for the COVID-19 pandemic (659,660). Unfortunately, this may lead 
to increasing emergence of INSTI-resistance mutations associated with poor therapy adherence 
due to reduced access to pharmacies and healthcare providers, or disruptions in the distribution of 




switched to optimized dosage of DTG. Twice-daily DTG dosage of 50mg or 100mg may rescue 
viral suppression in patients carrying resistance mutations at residue G140 and Q148 of IN 
(318,662). However, some cART experienced patients infected with subtype B or non B HIV-1 
strains with multiple DRMs are already resistant to DTG (646,648,649,657). With prevailing 
challenge of access to more potent antiretrovirals options in LMICs, it becomes very crucial to 
assess susceptibility of viruses harboring diverse INSTI-associated mutations to BIC and CAB 
(663).  
In this study, non-B IN recombinant viruses derived from eight Ugandan patients failing RAL-
containing regimens and carrying single or multiple primary INSTIs mutations with or without 
secondary INSTIs mutations, were phenotypically tested for susceptibility to CAB and BIC. 
Although patient-derived IN-recombinant viruses carrying single primary INSTI mutations (or in 
combination with secondary INSTI mutations) were susceptible to BIC and CAB, viruses 
harboring multiple primary INSTI-resistance mutations (i.e., E138A/G140A/G163R/Q148R and 
















The study patients n=8 failing RAL-based third-line therapy with INSTIs-resistance mutations 
were part of a cohort of n=51 HIV-1 infected patients failing RAL-based third line at the Joint 
Clinical Research Center (JCRC) in Kampala, Uganda as described previously (540,649). JCRC 
was the first center to provide generic cART in Uganda starting in early 2000 (531,533) and has 
since provided HIV-1 treatment to over 200,000 HIV-1 patients in Uganda and other African 
countries since 1990. Samples of patients with virological failure detected during routine checkups 
are sent to Case Western Reserve University -Center for AIDS Research (CFAR) laboratories at 
JCRC for sanger HIV-1 genotyping tests (488). The CFAR laboratory is a World Health 
Organization (WHO), College of American Pathologist (CAP), and National Institutes of Health-
virology quality assurance (NIH-VQA)-accredited laboratory. HIV-1 patients who provided 
written consent and were experiencing virological or immunological failure described as plasma 
HIV-1 RNA load >1,000 copies/ml and/or CD4+ T cell counts below 250 cells/mm3 were included 
in the study. Ethical clearance was obtained from the IRBs at the JCRC and University Hospitals 
Cleveland Medical Center/Case Western Reserve University (EM-10-07 and 10-05-35). 
RNA extraction and PCR amplification 
Plasma samples from all eight patients were used to extract HIV-1 viral RNA (QIAamp viral RNA 
Mini Kit, Qiagen) and the IN-coding region was amplified using a Superscript III single RT-PCR 
system (Thermo Fisher Scientific) as previously described (540). 
Sanger sequencing analysis 
Purified and quantified IN amplicons were cycle sequenced using Big Dye Terminator v3.1 
(Thermo Fisher scientific) and analyzed as previously described (540). Briefly, PCR products were 
sequenced on an ABI 3730XL to cover the full length of the IN (288 amino acids). Raw sequences 
were exported and analyzed in RECall (beta v3.02) program as recommended by the WHO (606). 
To check for presence of DRMs, analyzed sequences were exported to Stanford HIV-1db Sierra 




Library preparation and deep sequencing  
To confirm the presence of drug resistance mutations originally identified by Sanger sequencing, 
an amplicon-based deep sequencing method was used as previously described (540). Briefly, two 
overlapping PCR products spanning full-length of INT were purified using (Agencourt AMPure 
XP; Beckman Coulter) and quantified using (Quant-iT Picogreen dsDNA assay kit; Thermo 
scientific). The barcodes were added using Nextera XT index Kit v2 (Illumina) and paired-end 
sequencing done on a MiSeq instrument (Illumina). Analysis was performed with MiSeq Reporter 
analysis software version 2.6 (Illumina) and drug resistance interpretation was done using the 
Stanford HIV-1db Sierra web service algorithm v8.3 (637).   
Cells and antiviral compounds 
TZM-bl, U87.CD4.CXR4, MT4, and HEK293T cell lines were obtained through the AIDS 
Research and Reference Reagent Program, division of AIDS, NIAID, NIH. TZM-bl cells, and 
HEK293T were maintained in DMEM supplemented with 10% FBS, 100 μg/ml penicillin-
streptomycin. U87.CD4.CXR4 cells were maintained in DMEM supplemented with 10% FBS, 
100 μg/ml penicillin-streptomycin, 300 μg/ml G418, and 1 μg/ml puromycin (Invitrogen, 
Carlsbad, CA). MT4 cells were maintained in RPMI supplemented with 10% FBS. All cell lines 
were sub-cultured every 3 to 4 days at 37°C under 5% CO2. CAB and BIC were purchased from 
Selleck chemicals (Houston, TX). 
Construction of HIV-1 integrase recombinant viruses 
Full-length IN- PCR products were recombined into near full-length HIV-1 
(pREC_NFL_IN/URA3) vector using transfected Saccharomyces cerevisiae MYA-906 cells 
(ATCC) based on the yeast homologous recombination-gap repair system as previously described 
(638). Briefly, plasmids were extracted from the yeast cells using phenol/chloroform (Thermo 
Fisher scienfific) and transformed into electrocompetent Escherichia coli Stbl4 cells (Thermo 
Fisher scienfific). Plasmids were then extracted from the bacteria using Qiagen Miniprep kit 
(Hilden, Germany). The presence of mutation(s) in the generated plasmids was confirmed by 
Sanger sequencing.  pREC_NFL_IN plasmids were co-transfected into HEK293T cells (3×104 




Madison, WI) (638). Produced heterodiploid virus particles containing one copy of the 
pREC_NFL_IN and cplt HIV-1 RNAs were further propagated on U87.CD4.CXCR4 cells to 
produce a complete HIV-1 genome. Following virus propagation, HIV-1 RNA was RT-PCR 
amplified and Sanger sequenced to confirm the presence of the different DRMs. 
 
Virus titration 
The titers of the IN-recombinant viruses were measured using short-term infectivity assays in 
TZM-bl cells using Galacto-Star chemiluminescent reporter gene assay (Thermo Fisher 
Scientific), which measures expression of the β galactosidase enzyme under HIV-1 Tat expression. 
Briefly, 20,000 TZM-bl cells were seeded in the presence of polybrene (1mg/ml) to each well of 
96-well plate. The cells were infected with 3-fold serially diluted virus and cultured in 37°C and 
5% CO2 incubator for 48 hrs. The cells were washed with 200µl of 1X PBS and lysed with 10µl 
of lysis buffer for 10 mins. To the cell lysate, 100µl of reaction buffer and Galacton-star substrate 
was added and incubated for 1 hr at room temperature. The expression of β-galactocidase enzyme 
was measured on Cytation 5 plate reader (BioTek USA). 
INSTI susceptibility assay  
The susceptibility of patient-derived IN-recombinant viruses to BIC and CAB was determined 
using short-term resistance assays based on TZM-bl cells. Briefly, 20,000 cells were seeded to 
each well of 96-well plate and infected with the IN-recombinant viruses, or three control HIV-1 
strains (i.e., subtype B NL4-3, subtype A UG14, and subtype D UG98) in the presence of 10-fold 
dilutions of BIC and CAB (100 µM to 10-8 µM) and polybrene (1mg/ml), at an MOI of 0.05 IU/ml 
in quadruplicate. After 48 hr incubation at 37°C and 5% CO2, virus replication was quantified 
using Galacto-Star chemiluminescent reporter gene assay as described above. Drug dose response 
curves were generated using nonlinear regression curve fitting features of GraphPad Prism 8.0 
software (GraphPad Software, Inc., San Diego, CA). Drug resistance was expressed as fold change 





HIV-1 integration assay 
The relative HIV-1 integration into cellular DNA was determined by carrying out Alu-gag qPCR 
as previously described (428),(664), with some modifications. Briefly, 30,000 MT-4 cells were 
infected with normalized viruses (MOI of 0.05 IU/ml) in the presence of 1mg/ml polybrene.  
 
 
Figure 27. The Alu-Gag PCR workflow. In the first round of PCR, primer Alu forward aligns to 
the alu repeats which exist randomly in human genome. The reverse primer, Gag reverse aligns at 
U5 of 5′ end of HIV genome. In the second round of PCR, LTR (R) forward primer aligns at R 
and reverse primer LTR (U5) at U5 of 5′ end of HIV genome to produce 129bp product that is 
quantified by qPCR machine. 
 
The HIV-1 protease inhibitor darunavir (1µM) was added to allow one round of infection and cells 
were cultured in 37°C and 5% CO2 incubator for 72 hours. Genomic DNA was extracted using 
DNeasy Blood and Tissue kit (Qiagen) and normalized using β-globin gene using primers 
described previously. The DNA was amplified using Alu-Gag PCR with first round PCR primers, 




GTT CCT GCT ATG TCA CTT CC-3′) and kinetic PCR primers, LTR (R) forward, (5′-TTA AGC 
CTC AATAAA GCT TGC C-3′), LTR (U5) reverse, (5′-GTT CGG GCG CCA CTG CTA GA-3′) 
and probe (5′-FAM-CCA GAG TCA CACAAC AGA GGG GCA CA-TAMRA-3′) previously 
described (664). The first round PCR was done using platinum taq DNA polymerase High fidelity 
(ThermoFisher scientific) and reaction mix consisting of 10X High fidelity PCR buffer, 50mM 
Mgcl2, 10mM dNTP mix, 20µM of each primer and water. The PCR gram was done as follows: 
initial denaturation at 94°C for 2 mins, denaturation at 94°C for 15 secs, annealing at 55°C for 15 
secs, extension at 68°C for 3 mins and final extension at 68°C for 7 mins. The kinetic PCR was 
done using TaqMan Fast advanced master mix (ThermoFisher scientific), 20µM of each primer 
and probe, water, and template. QuantStudio real time system (ThermoFisher scientific) was used 
under the following conditions, UNG incubation at 50°C for 2 mins, polymerase activation at 95°C 
for 10 mins, denaturation at 95°C for 15 secs and annealing/extension at 60°C for 1 min. The 
relative HIV-1 integration was quantified using a standard curve generated by dilution series of 
DNA from infected MT-4 cells (dilution using DNA from uninfected cells).  
Global occurrence of Q148H/K/R mutations  
To assess global occurrence of Q148H/K/R mutations and associated INSTIs primary resistance 
mutations in patients failing RAL, we analysed all the available HIV-1 INSTI-associated mutations 
from the Drug Resistance HIV Stanford Database (https://hivdb.stanford.edu/). All sequence data 
with original reference, patient identifier, isolate name, accession number, and treatment history 
was retrieved for the analysis. The search was conducted on August 28, 2020 and search terms 
used were, “integrase, raltegravir, HIV-1 and subtypes.” 
Statistical analyses 
Statistical analyses were performed using non-linear regression in GraphPad Prism 8.1.2 
(GraphPad Software, La Jolla, CA). The level of cross resistance between INSTIs was analyzed 
using Spearman’s rank order test. The means of EC50 for BIC, CAB, DTG, RAL, and elvitegravir, 







Individuals failing ART with INSTI-associated mutations 
We previously described a cohort of sixty HIV-1-infected patients failing RAL-based third-line 
regimen in Uganda (540).  From this group of individuals, we identified eight patients carrying 
HIV-1 strains with a variety of mutations associated with resistance to INSTIs (the most common 
being N155H), as well as two patients infected with HIV-1 strains lacking INSTI-associated 
mutations (Table 9). The patients median age was 30.5 years [Interquartile range (IQR), 26.25-
36.25 years] and the median plasma HIV-1 RNA load was 85,091 copies/ml with (IQR, 3687.5-
570,480 copies/ml). As expected, most patients were infected with subtype A HIV-1 strains 
(62.5%), followed by subtype D (25%) and recombinant A/D (12.5%). Five of the eight patients 
were treated with RAL/LPV/RTV, while the other three individuals were RAL/DRV/RTV, 





Table 9. The clinical characteristics of study patients 
 
The HIV-1 subtype was predicted using SCUEAL subtype classification algorithm. Viral loads were 
assayed using Abbott m2000sp/rt or Roche COBAS Amplicor Monitor ultrasensitive tests, v1.5. In bold, 
major INSTIs resistance mutations. Abbreviations: cART, combined antiretroviral therapy; ND, not 
determined; INSTI, integrase strand transfer inhibitor; DRVr, darunavir/ritonavir; LPVr, 
lopinavir/ritonavir; RAL, raltergravir; 3TC, lamivudine; TDF, tenofovir; FTC, emitricabine 
 
BIC and CAB retain activity in presence of single N155H or Y143R and added secondary 
mutations. 
In this study, IN recombinant viruses carrying diverse INSTIs-associated resistance mutations 
from patient-derived IN (n=8) were tested for their susceptibility to BIC and CAB (Table 9). The 
RAL and elvitegravir -resistant mutant N155H remained susceptible to both BIC (1-2.3-fold) and 




V151I in context of N155H, did not affect susceptibility to BIC (0.8-fold) and CAB (1.3-fold) 
respectively (Table 10, Fig.28, and Fig.29). Viruses carrying the primary mutation to RAL, Y143R 
in combination with secondary mutations T97AT, G163R, M50I, and L74IM remained susceptible 
to BIC (FC, 1.2-1.3) and CAB (1.7-2.6). 
Table 10. The mean EC50 and fold-change in EC50 of recombinant viruses 
 
The EC50 and 95% CI for EC50 was determined using nonlinear regression analysis in GraphPad prism. The 
nfl4-3 was used as wild type in the assays. Abbreviations: BIC, bictegravir; CAB, cabotegravir; EC50, 50% 
effective concentration; CI, confidence interval. The fold-change values are relative to NL4-3 wild type. 
 
The mutation E138A selected by RAL, elvitegravir, and DTG did not reduce susceptibility to 
either BIC (0.8-fold) or CAB (3.3-fold) in presence of secondary mutations T97A and V151A 
(Table 10, Fig.28, and Fig.29).  
Combination of multiple primary INSTI-associated mutations leads to high-level resistance 




Prolonged virological failure on same HIV-1 regimen can result in accumulation of HIV-1 drug 
resistance mutations in a patient viral population (665). Severe reduced susceptibility to DTG 
(>100-fold) was previously shown with IN-recombinant virus UG1059 carrying the primary 








Figure 28. The EC50 (nM) and fold-change in EC50 of recombinant viruses by subtype. The 
susceptibility of IN-recombinant viruses, UG537 (with mutation N155H), UG1179 (N155H), 
UG481 (Y143R, T97AT, G163R), UG23 (E138A, T97A, V151A), UG42 (N155H, E157Q, 
G163R, M50L, L74I, V151I), UG35 (Y143R, T97A, M50I, L74IM), UG1059 (E138A, G140A, 
Q148R, G163R), and UG206 (E138K, G140A, Q148K, S147G) to BIC and CAB was determined 
using TZM-bl cells. The mean EC50 (nM) values from independent experiments run in 
quadruplicates were used to determine fold-change in EC50 (nM) of recombinant viruses harboring 
INSTIs-resistance mutations relative to subtype B, A, and D references (panels A, B, and C). The 
error bars represent ± SD in EC50 values between replicates of independent experiments. The 
horizontal line represents fold-change of 1.  
 
In context of BIC and CAB, UG1059 showed a decreased susceptibility to BIC (60-fold), and 
>100-fold to CAB. 
 
Figure 29. The susceptibility of recombinant viruses to CAB and BIC. The susceptibility of 
recombinant viruses to INSTIs, BIC and CAB was determined using short-term infectivity assay 
in TZM-bl cells. Each experiment was done in quadruplicates. The change in EC50 (nM) of 
recombinant viruses harboring INSTIs- resistance mutations was determined in reference to NL4-
3 wild type.  Panel A- UG206, B- UG1059, C- UG537, D- UG42, E- UG35, and F- UG481, drug 
susceptibility to BIC (left panel) and CAB (right panel) respectively. 
 
Interestingly, the subtype D virus UG206 also resistant to DTG, carrying E138K, G140A, Q148K, 




respectively (Table 10, Fig.28, Fig.29, and Fig.30). The NL4-3 alone or subtype B HIV-1 carrying 
a wild type subtype A or D IN coding region showed no difference in susceptibility to BIC and 
DTG with EC50 values previously reported for wild type HIV-1. (458,463) Overall, BIC showed 
more potency against viruses carrying various INSTIs-associated resistant mutations compared to 
CAB (p=0.03). IN-recombinant viruses carrying multiple primary INSTIs- resistance mutations 
showed substantial reduced susceptibility to both BIC and CAB but EC50 values for BIC were 




Figure 30. The fold-change (FC) in EC50 of recombinant viruses. A) the FC in EC50 (nM) of 
recombinant viruses UG206 relative to wild type NL4-3 for BIC, CAB, DTG, RAL, and EVG. B) 
the FC in EC50 of recombinant virus UG1059 relative to wild type NL4-3 for BIC, CAB, DTG, 
RAL, and EVG. C) the FC in EC50 (nM) of BIC and CAB for recombinant virus UG206, D) 
UG1059. The FC in EC50 (nM) of recombinant viruses harboring INSTIs-resistance mutations 




EC50 of CAB and BIC were compared using nonparametric two-tailed t-test, p=0.005 was 
considered statistically significant. 
 
Both BIC and CAB are second generation INSTIs targeting IN gene for inhibition of HIV-1 
replication. To determine degree of cross resistance between BIC and CAB for different viral 
genotypes tested, log FC in EC50 values for BIC resistance were correlated with log FC in EC50 
values for CAB resistance. Significant cross resistance was observed as shown by strong 
correlation coefficient, r= 0.995, p= 0.0001, and slope, 0.69 between BIC and CAB (Fig. 30). 
 
 
Figure 31. The correlation of fold change values in EC50 between BIC and CAB for the same 
patient sample. The correlation of resistance between BIC and CAB was determined by spear 
man’s correlation coefficient. The fold change (FC) values are relative to NL4-3 wild type. 
 
IN-recombinant viruses carrying single or multiple primary INSTIs-resistance mutations 




HIV-1 integration into host chromatin strongly favors active transcription sites (231). To test 
impact INSTIs-resistance mutations may have on integration, we quantified the relative amounts 
of viral integration using a quantitative Alu-gag qPCR (Fig. 32) as described previously. (664) 
Viruses UG35 and UG42 carrying the primary N155H or Y143R mutations with additional 
secondary mutations showed only 25%-29% of the capacity to integrate into the host genome 
compared to wild type NL4-3 or NL4-3 carrying the wild type subtype A or D IN.  Presence of a 
single N155H mutation in the UG537 or UG1179 viruses led to a 50% reduction in integration. 
The UG1059 virus carrying mutations E138A, G140A, Q148R, and secondary G163R had the 
lowest capacity of integration with only 14% compared to wild type NL4-3 (Fig. 32).  
 
 
Figure 32. The relative integration capacity of recombinant viruses harboring diverse 
INSTIs associated DRMs. The ability of recombinant viruses to integrate into host chromatin was 
determined in MT-4 cells using Alu-gag assay and percentage of integration by mutant relative to 





Prevalence of Q148HRK mutations in RAL failing patients infected with subtype B and non-
B HIV-1 isolates  
Viruses, UG1059 and UG206 with high-level resistance to both BIC and CAB carry Q148K/R 
with additional E138A, G140A, G163R and E138K, G140A, and S147G INSTI-associated 
mutations, respectively (Table 10, Figs.28, Fig.29, and Fig.30).  However, this combination of 
INSTI resistance mutations have not be previously reported which prompted us to assess global 
prevalence of Q148HRK and other mutations in subtype B and non-subtype B infected individuals 
failing RAL (Table 11, Fig 33). We used Stanford HIV database (https://hivdb.stanford.edu/) to 
















Table 11. Prevalence of Q148HKR and associated primary mutations in patients failing on 
raltegravir. 
INSTIs associated resistance mutations in patients failing on RAL containing regimens were retrieved 
from Stanford HIV drug resistance database (https://hivdb.stanford.edu/). a HIV-1 subtype A, C, D, F, G, 
H, J, K, CRF01_AE, CRF02_AG, CRF12_BF, CRF05_DF, CRF47_BF, CRF06_cpx, CRF11_cpx, 
CRF09_cpx. b Q148HKR and associated primary mutations observed once in patient database: S147G, 
Q148R; T66TK, G140GS, Q148QR; E138EK, S147G, Q148R; E138K, Y143YCHR, Q148QR; E138EA, 
S147SG, Q148QR, N155NH; G140S, Q148H, V151VA; G140GS, Y143YR, Q148QH, N155NH; and 
E92EQ, G140GS, Y143YR, Q148QR, N155NH. 
HIV-1 subtype B comprised the majority of sequences carrying Q148HRK (87%, 1442/1653) 
while non-B HIV-1 subtypes represented 13% of sequences (211/1653). The single Q148HRK or 




but only 5.2% (11/211) of non-B subtypes infected patients failing RAL-based treatments. The 
Q148HRK, G140SCA combination was most dominant in HIV-1 subtype B (19.5%) and non-B 
subtypes (4.9%), with Q148HRK, E138AKT, G140SCA combination occurring in (3.7%) of 
subtype B and (1%) of non-B HIV-1 subtypes infected patients. The combination of Q148HRK 
and N155H are uncommon in all HIV-1 derived INs from patients failing RAL (1.8%) regardless 
of subtypes (Table 11, Fig 33). 
 
Figure 33. The prevalence of Q148HRK and associated primary INSTIs-resistance 
mutations in HIV-1 subtype B and non-B subtype viruses in patients failing RAL-based 
regimens. The number of HIV-1 infected patients failing on RAL with single Q148HKR with or 
without other primary INSTIs mutations was assessed from HIV drug resistance database by 
Stanford University (https://hivdb.stanford.edu/). 
 
Our detection of these multiple INSTI resistance mutations in two HIV-1 infected individuals 
would appear to be a chance and rare discovery. However, it is important to point out that our IN 
sequences represents 51 of 71 of subtype A and D sequences in the Stanford HIV database and 51 






Increased prevalence of drug resistance in the treatment naïve HIV infected population of many 
LMICs has led to switch from the administration of two NRTIs + an NNRTI (efavirenz or 
nevirapine) to the TDF/3TC/DTG regimen for individuals initiating cART. Current WHO 
guidelines also recommend switch of patients on first line with no history of INSTI treatment to 
TDF/3TC (or FTC)/DTG (666). Despite wide roll out of DTG in LMICs, there is increasing case-
reports of DTG failure in patients started on DTG-based regimens, and in INSTIs experienced 
patients carrying mutations including Q148HKR (318,649).  
The recently approved second generation INSTI BIC is available as a part of single-fixed dose 
formulation of TAF/FTC/BIC (Biktarvy).  This TAF/FTC/BIC treatment is indicated in ART naïve 
and virologically suppressed patients (viral load <50 copies/ml) with no history of treatment failure 
and drug resistance (667). As previously reported with DTG (308,319,649), BIC also shows potent 
inhibition of a broad range of drug resistant viruses in vitro. (668,669) Before recent CAB approval 
as long-acting injectable, CAB was tested in combination with rilpivirine in both ART naïve and 
virologically suppressed patients as oral or long acting injectable in the LATTE 1, LATTE 2, 
ATLAS and FLAIR clinical trials. In LATTE 1 and 2, INSTIs associated Q148R mutation 
emerged while in the FLAIR study, G140R, Q148R, E138A/T/K, and ATLAS, N155H mutation 
were observed in patients with virological failure (289,655,658,670).  
In this study, we tested the HIV inhibition profiles of CAB and BIC using virus carrying patient-
derived subtype A and D INs. Recombinant viruses carrying either single primary INSTI resistance 
mutations (N155H, Y143R, E138A) remained susceptible to both BIC and CAB. We have 
previously shown that N155H as a predominant INSTIs-resistance mutation (17.6%) in HIV-1 
patients failing third-line RAL-based regimen in Uganda (540). Viruses carrying N155H in 
subtype A or D IN were susceptible to BIC (1-2.3-fold), comparable to that observed with HIV-1 
subtype B virus (1-fold) (668). In HIV-1 infected patient failing RAL, Q148HRK mutation 
emerges later in the course of infection replacing N155H mutation of higher replication fitness but 
exhibiting lower resistance to RAL (671). In our study, subtype A recombinant virus carrying 
E138A, G140A, Q148R, and G163R mutations and subtype D virus carrying E138K, G140A, 




presented herein, the triple and quadruple INSTI resistance mutations emerged in two different 
patients infected with subtype A and D HIV-1 (respectively) and failing a RAL-based treatment 
regimen.  The high level cross resistance to BIC and CAB by this patient-derived HIV-1 has been 
confirmed with the same set of mutations in a study screening for BIC and CAB using a subtype 
B HIV-1 with these mutations introduced in vitro (459). Despite high level resistance to both drugs 
by the RAL selected primary mutations, Q148KR, G140A, E138KA and S147G, the fold-change 
cross resistance to CAB was more pronounced.  BIC, compared to CAB appears to be better 
accommodated in the binding pocket of IN even with these mutations, possibly due to the 
oxazepane ring attached to metal chelating scaffold of BIC (651). The superiority of BIC compared 
to CAB to inhibit viral replication in viruses carrying substitutions at G140 and Q148 has also 
been reported in studies of mainly subtype B viruses (457,459,647).  
Multiple INSTIs-resistance mutations (>3) emerging in HIV-1 infected patient is rare but its 
detection during RAL failure is not surprising in highly cART experienced patients, especially if 
RAL failure is prolonged due to limited virological monitoring common in LMICs (646,648). 
Despite increasing reporting of patients failing INSTIs with multiple primary mutations in non-B 
HIV-1 subtypes, we found most occurrence of Q148HKR and associated primary mutations to be 
in subtype B viruses. This may be associated with early use of INSTIs in high income countries 
where subtype B virus is predominant. The HIV-1 genotypes with Q148HKR in association with 
multiple INSTIs primary mutations is currently < 3% in Uganda and 5.2% in non-B HIV-1 
subtypes which encourages use of BIC and CAB, but increased INSTIs resistance surveillance will 
be required as INSTIs become accessible in LMICs.  
IN-catalyzed integration into cellular DNA is a two-step process of 3′-processing and strand 
transfer process and is required for viral replication and infectivity (672). IN-resistance mutations 
including N155H and E138K and added mutations reduce efficiencies of 3′ processing and strand 
transfer activities which impairs HIV-1 integration capacity (437,440). We find that all IN-
recombinant viruses tested exhibited <50% capacity to integrate into cellular DNA which may 







Emergence of multiple INSTIs-resistance mutations after prolonged virological failure on RAL 
presents a huge threat to the efficacy of BIC, CAB, and DTG regimens, the latter previously 
reported. (649) BIC and CAB retain potency in patients carrying most single primary INSTI 
resistance mutations with or without secondary mutations.  However, with common use of RAL-
based regimens for third line treatments, failure to a prolonged RAL-based treatment as well as 
spread of RAL resistance viruses carry multiple INSTI resistance mutations could impact the use 
of these second generation INSTIs. Given the infrequent use of drug resistance genotyping in 
almost all LMICs, we have not determined the prevalence of the specific INSTI drug resistance 
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Based on our previous studies, only about 5% of HIV-1 infected patients in Uganda have drug 
resistance mutations (DRMs) which could impact efficacy of dolutegravir (DTG) especially when 
used as salvage therapy. Contrary, over 50% of patients failing raltegravir (RAL)-based regimen 
have resistant viruses to RAL and elvitegravir (EVG). In addition, around 38% of patients failing 
RAL-based regimen lack any DRM associated with reduced RAL susceptibility. These patients 
still fail on treatment which could be related to poor adherence and/or due to a novel resistant 
mutation(s) currently unrecognized in HIV-1 drug resistance interpretation algorithms.  
Support vector machine (SVM) analysis can be used to identify association between groups of 
population sharing specific traits. SVM was employed to identify novel resistance pathways to 
RAL resistance in patients found not to harbor any putative DRMs using deep sequencing data. 
After generation of plasmids with these candidate mutations, recombinant viruses were made and 
tested for susceptibility on RAL and DTG. In the chapter presented herein, Dr. Mariano Avino the 
lead author for the manuscript carried out computational analysis for the deep sequencing data. I 
recruited the patients for the study, carried out all the laboratory assays, and analyzed Sanger 














The global HIV-1 pandemic comprises many genetically divergent subtypes. Most of our 
understanding of drug resistance in HIV-1 derives from subtype B, which predominates in North 
America and Western Europe. However, about 90% of the pandemic represents non-subtype B 
infections. Here, we use deep sequencing to analyze HIV-1 from infected individuals in Uganda 
who were either treatment-naive or who experienced virologic failure on ART without the expected 
patterns of drug resistance. Our objective was to detect potentially novel associations between 
mutations in HIV-1 integrase and treatment outcomes in Uganda, where most infections are 
subtypes A or D. We retrieved a total of 380 arcHIV-1ed plasma samples from patients at the Joint 
Clinical Research Centre (Kampala), of which 328 were integrase inhibitor- naive and 52 were 
RAL-based treatment failures. Next, we developed a bioinformatic pipeline for alignment and 
variant calling of the deep sequence data obtained from these samples from a MiSeq platform 
(Illumina). To detect associations between within-patient polymorphisms and treatment outcomes, 
we used a support vector machine (SVM) for feature selection with multiple imputation to account 
for partial reads and low-quality base calls. We subsequently introduced the I203M, I208L 
mutations through site-directed mutagenesis, and used patient-derived integrases carrying I208L 
or I203M and I208L to evaluate susceptibility of these mutants to INSTIs in vitro. Recombinant 
viruses with mutations, I203M, I208L or I203M and I208L were generated and phenotypically tested 
to determine susceptibility to RAL and DTG in TZM-bl cells. Novel resistance mutations, I208L, 
I203M or I203M and I208L identified by SVM did not show reduced susceptibility to RAL or 
DTG compared to wild-type virus with 1.3-1.8-fold and 1.1-1.4-fold observed, respectively. 
 
Author summary 
There are many different types of HIV-1 around the world. Most of the research on how HIV-1 
can become resistant to drug treatment has focused on the type (B) that is the most common in 
high-income countries. However, about 90% of infections around the world are caused by a type 
other than B. We used next-generation sequencing to analyze samples of HIV-1 from patients 
in Uganda (mostly infected by types A and D) for whom drug treatment failed to work, and 




learning to detect mutations in these virus populations that could explain the treatment 
outcomes. Finally, we experimentally added two candidate mutations identified by our analysis 
to a laboratory strain of HIV-1 and confirmed that they conferred drug resistance to the virus. 
Our study reveals new pathways that other types of HIV-1 may use to evolve resistance to drugs 





There are currently six classes of antiretroviral drugs approved for treatment of HIV-1 infection, 
with protease inhibitors (PIs) and nucleoside and non-nucleoside reverse transcriptase inhibitors 
(NRTIs and NNRTIs) in most widespread use (673). Integrase strand transfer inhibitors (INSTIs) 
are a more recent class of antiretroviral drugs targeting the virus-encoded integrase (IN) protein, 
which is responsible for inserting complementary DNA derived from the viral RNA genome into 
the genome of the host cell (674). INSTIs are increasingly being used for individuals in low and 
middle-income countries (LMICs) for whom first- and second-line antiretroviral treatment (ART) 
regimens have failed, due to the emergence of drug resistance mutations (DRMs) to the PIs, NRTIs 
and/or NNRTIs that comprise these regimens (642). With the exception of boosted PIs, there is 
typically a greater genetic barrier for HIV-1 to develop resistance to second-generation INSTIs, 
such as dolutegravir (DTG) and bictegravir (BIC), relative to other drugs (671,675). Even so, there 
are multiple well-characterized mutations conferring major and accessory resistance to INSTIs 
(676), where we employ the Stanford HIV-1 Drug Resistance (HIV-1db) guidelines for 
categorizing DRMs (677). Most DRMs with major effects cause some level of cross-resistance 
to all drugs in this class— DTG, BIC, raltegravir (RAL) and elvitegravir (EVG) — with higher-
level resistance to RAL and EVG compared to DTG and BIC. 
 
Until recently, HIV-1 drug resistance studies have generally focused on individuals receiving ART 
in high income countries. The expansion of ART to over 18 million worldwide has turned 
attention to finding affordable methods for scaling up treatment monitoring and drug resistance 
testing. With the high volume of tests,  some LMICs have  adopted drug resistance genotyping  
by next generation sequencing (NGS) technologies (678,679), in place of the more common but 
less scaleable Sanger sequencing approaches (680). In addition to the ability to multiplex large 
numbers of patient samples into a single run (681), NGS has an added advantage of deep 
sequencing — where the same region of the virus genome is covered by sequences from hundreds 
or thousands of individual viruses in the sample — making it possible to reproducibly identify 
minority HIV-1 variants below the detection threshold of Sanger sequencing (682). Despite their 




anticipate the emergence of drug resistance and treatment failure (683). Deep sequencing 
analysis of clinical HIV-1 samples in LMICs also provides a unique opportunity to identify 
potentially new HIV-1 polymorphisms associated with drug resistance in diverse HIV-1 strains 
(684–686). These opportunities also present significant bioinformatic challenges. Enormous 
amounts of sequence data must be processed accurately and efficiently, where sequencing error 
rates still exceed conventional Sanger methods (687). The task of identifying novel associations 
between treatment outcomes and minority variants in diverse HIV-1 populations remains an open 
problem, and research has focused largely on HIV-1 coreceptor tropism (688,689) in populations 
predominantly affected by subtype B. . 
 
The global diversity of HIV-1 is structured into four phylogenetic groups, denoted by letters M-
P (690). The vast majority of infections worldwide are caused by group M viruses, which are 
further separated into subtypes that have distinct geographic distributions, possibly owing to early 
‘founder effects’ in sub-Saharan Africa (691). The majority of research on DRMs has historically 
been carried out on HIV-1 subtype B, owing in part to the predominance of this subtype in North 
America and western Europe — this subtype represents only about 10% of the global HIV-1 pan- 
demic (692,693). Fortuitously, clinical outcomes on first- and second-line ART appear to be 
largely independent of HIV-1 subtype (483,484,694). However, several studies (reviewed in (695) 
have shown that non-subtype B infections can accumulate DRMs in response to treatment along 
mutational pathways that are distinct from subtype B. For example, a novel DRM in HIV-1 RT 
(V106M) has been reported to confer resistance to the NNRTI efavirenz (EFV) that is 
characteristic of HIV-1 subtype C (513). More recently, investigators determined that the HIV-1 
integrase mutation G118R confers a high level of resistance to RAL in the circulating recombinant 
form CRF02 AG, where the glycine is highly conserved across subtypes (493). According to that 
study, G118R had only been previously observed in cell culture on exposure to another second-
generation INSTI (MK- 2048). 
 
Historically, Uganda has had one of the highest burdens of HIV-1/AIDS in the world, with an 
estimated 1.3 million people living with HIV-1. The majority of infections in Uganda are caused 
by HIV-1 subtypes A and D, followed by A/D inter-subtype recombinants and subtype C (696). 




an estimated 5% to 9% of treatment- naive individuals carrying at least one primary DRM (488). 
The majority of individuals starting ART in Uganda are prescribed a first-line regimen based on 
EFV, tenofovir (TDF) and a second NRTI, whereas almost no one had received the World Health 
Organization-recommended (666) INSTI + 2 NRTIs initial regimen that is more common for first- 
line therapy in higher income settings (540,697). DTG was recently introduced into new first line 
treatment regimens across sub-Saharan Africa, but treatment with any INSTI still represents less 
than 1% of active first line treatments in LMICs (698). In most LMICs, INSTIs have generally been 
reserved for those requiring a third-line treatment regimen, with RAL-based regimens being quite 
successful in treatment-experienced individuals with multidrug-resistant HIV-1 (628,699,700). 
Several mutational pathways reducing susceptibility to RAL have been described, including the 
major DRMs T66K, Y143R, Q148H/K/R, and N155H in HIV-1 integrase (433,617,671,701). 
Notably, all of these studies were carried out in predominantly (≥ 90%) HIV-1 subtype B cohorts 
or in vitro with a subtype B laboratory clone. 
 
Here, we describe a bioinformatic approach to detect potential novel DRMs from NGS data sets 
that include all within-host polymorphisms above a frequency of 1%. We have applied this method 
to HIV-1 NGS data from a cohort of individuals with HIV-1 non-subtype B infections in Uganda, 
of whom a subset had experienced treatment failure on RAL-containing salvage regimens. 
Addition- ally, we have experimentally verified the resistance effects of the novel DRMs predicted 
by our bioinformatic analysis by drug susceptibility assays in vitro, and characterized these 












6.4   Methods 
 
Data collection 
The study samples were collected from the Center for AIDS Research Laboratory at the Joint 
Clinical Research Centre (JCRC) in Kampala, Uganda (540). Written informed consent was pro- 
vided by all study participants. Ethical approval was obtained from JCRC and University Hospitals 
Cleveland Medical Center/Case Western Reserve University Institutional Review Boards (EM-
10- 07 and 10-05-35). All investigations have been conducted according to the principles 
expressed in the Declaration of Helsinki. Patient samples were assigned to one of four categories 
based on treatment history and clinical outcome records in the JCRC database: treatment- naive, 
first-line treatment failures, second-line treatment failures, and treatment failures on RAL-based 
salvage regimens (RAL failure). Treatment failure was defined by the presence of either a viral 
load above 1,000 copies/mL and/or a CD4 cell count below 250 cells/mm3 in the period following 
treatment initiation. Although current definitions of treatment failure tend to focus on viral load 
measurements, we retained the criterion based on CD4 cell counts for consistency with historical 
practice in this treatment population.  
RNA extraction and PCR amplification 
For each sample, viral RNA was extracted from 200µL of plasma using a QIAamp viral RNA Mini 
Kit (Qiagen) according to the manufacturer’s instructions. Reverse transcription of the full-length 
HIV-1 integrase (IN)-coding region from extracted viral RNA and amplification was performed 
with the sense primer RTA9F (5-TATGGGGAAAGACTCCTAAATTTA-3) and antisense primer 
3Vif (5-AGCTAGTGTCCATTCATTG-3) using a Superscript III single RT-PCR system with Plat- 
inum Taq DNA polymerase kit (Thermo Fisher Scientific) as per the manufacturer’s instructions. 
The complementary DNA product was purified using a Quant-iT Picogreen dsDNA assay kit 
(Thermo Fisher Scientific) and quantified using a Qubit fluorometer (Thermo Fisher Scientific). 
The region encoding integrase was amplified in two parts by nested PCR using the following sets 
of primers: (1) sense primer INTF1B (5’-AGGTCTATCTGGCATGGGTACC -3’) and antisense 
primer INTR1B (5’-GATTGTAGGGAATTCCAAATTCCTGCT-3’); (2) sense primer 





Library preparation and deep sequencing 
Two overlapping IN-PCR regions corresponding to the 288 amino acids of HIV-1 IN were 
sequenced with the MiSeq NGS platform (Illumina). The amplicons were purified with Agencourt 
AMPure XP (Beckman Coulter) and quantified using the Quant-iT Picogreen dsDNA assay kit 
(Thermo Fisher Scientific), prior to adding adapters using the Nextera XT sample prep kit (Illu- 
mina) with dual indexing for a maximum of 384 unique tags. The resulting libraries were 
quantified, normalized and pooled for paired-end sequencing (2×300 nt) on the Illumina MiSeq 
platform. Signal processing, base calling and structural variant analysis were performed with the 
MiSeq Re- porter Software (version 2.6, Illumina). We deposited the unprocessed FASTQ data in 
the National Center for Biotechnology Information (NCBI) Short Read ArcHIV-1e (BioProject 
accession number PRJNA554675). 
 
Site directed mutagenesis of I203M and I208L 
The I203M and I208L mutations were created in HIV-1 INT gene from pREC-NFL (NL4-3) 
back- bone using in-house site directed mutagenesis protocol. Briefly, the HIV-1 IN coding regions 
were amplified with the following primers: Vif 3 reverse 1 (5′-
GTCCTGCTTGATATTCACACC-3′); INTREXT (5′-AATCCTCATCCTGTCTAC-3′); and 
INTFEXT1 (5′-AGAAGTAAACATAGTAACAGACTCACA-3′). The I203M mutation was 
created using sense primer 5′-gcaggggaaaga atagtagacATGatagcaacagacatacaaac-3′ and the 
antisense primer 5′-gtttgtatgtctgttgctatCATgtctac tattctttcccctgc-3′); I208L was created using the 
sense primer 5′-gaatagtagacataatagcaacagacTTG caaactaaagaattacaaaaa-3′ and antisense primer 
5′-tttttgtaattctttagtttgCAAgtctgttgctattatgtctactatt c-3′. The presence of the mutation in the 
plasmid and the propagated virus was confirmed by PCR followed by Sanger sequencing. 
Cells and antiviral compounds 
TZM-bl, U87.CD4.CXR4 and HEQ293T cell lines were obtained through the AIDS Research and 
Reference Reagent Program (Division of AIDS, National Institute of Allergy and Infectious 




(DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 µg/ml penicillin-
streptomycin. In addition, U87.CD4.CXR4 cells were maintained in the presence of 300 µg/ml 
G418 (an amino- glycoside antibiotic) and 1 µg/ml puromycin (Invitrogen, Carlsbad, CA). All 
cell lines were sub- cultured every 3-4 days at 37◦C under 5% CO2. The TZM-bl cells contained 
reporter luciferase and β -galactocidase reporter genes that were activated by expression of HIV-
1 tat. DTG and RAL were provided by Gilead Sciences (Foster City, CA, USA). 
Construction of HIV-1 INT chimeric viruses 
HIV-1 full length integrase PCR products were cloned into pREC NFL IN/URA3 vector and Sac- 
charomyces cerevisiae MYA-906 cells (ATCC) using the yeast homologous recombination-gap 
repair system (638). Following homologous recombination, plasmids were extracted from the 
yeast cells and transformed into electrocompetent Escherichia coli Stbl4 cells (Invitrogen). 
Plasmids were extracted using Qiagen miniprep kits and plasmid DNA was quantified using a 
NanoDrop spectrophotometer (Thermo Scientific). The presence of the mutation in the generated 
plas- mid was confirmed by sequencing. Chimeric pREC NFL INT plasmids were co-transfected 
into HEK293T cells (3 × 104 cells/well) along with the complementing plasmid pCMV cplt using 
Fu- gene 6 reagent (Promega, Madison, WI) as described previously (638). Virus was then 
propagated on U87.CD4.CXCR4 cells as described (638). 
Drug susceptibility assay in TZM-bl cells 
HIV-1 susceptibility to DTG and RAL was determined using TZM-bl cells. Briefly, 20,000 cells 
per well were exposed to wildtype (WT), and mutant HIV-1 in presence of 10-fold dilutions of 
DTG or RAL (100 µM to 10−7 µM) and polybrene (1mg/ml) in 96-well tissue culture plates 
(Corning). The amount of virus added to each well was normalised to a multiplicity of infection 
(MOI) of 0.05 based on the infectious titer. After 48 hr incubation at 37°C and 5% CO2, the 
infectivity of viruses was quantified using Galacto-Star chemiluminescent reporter gene assay 
and detection was done using Cytation 5 plate reader (BioTek USA). The fold changes in the 
effective concentrations for 50% inhibition (EC50) and standard errors of the mean (SEM) were 
calculated based on two sets of experiments, each performed in quadruplicate. Drug sensitivity 
curves were generated using nonlinear regression curve fitting features of GraphPad Prism 8.0 




in EC50 between WT and mutant viruses. 
Sequence analysis 
We processed the FASTQ files generated by the Illumina MiSeq platform using a customized 
version of the MiCall pipeline (https://github.com/PoonLab/MiCall-Lite) (687). First, the 
pipeline extracts the empirical φ X174 error rates from the ‘ErrorMetricsOut’ binary InterOp file 
associated with the MiSeq run, and then censors bases in the FASTQ files associated with 
problematic cycle-tile combinations with error rates exceeding a cutoff of 7.5%. Next, the 
program cutadapt (version 1.11) (703) was used to filter the FASTQ read data for Illumina adapter 
sequences. The pipeline subsequently used the alignment program Bowtie2 (version 2.2.6) (704) 
to map the paired- end read data to the full-length sequence encoding HIV-1 integrase of the HXB2 
reference genome (Genbank accession K03455). This preliminary mapping stage was followed 
by the iterative re- mapping of reads from the original FASTQ files to new reference sequences, 
which were progressively updated with the plurality consensus of reads that were successfully 
mapped in the previous iteration (687). A mapping quality score cutoff of Q = 20 was applied at 
this stage to filter ambiguously mapped reads.  The primary outputs of the pipeline included the 
sample-specific nucleotide consensus sequence, coverage maps, and the matrix of amino acid 
frequencies in the coordinate system of the HXB2 reference; insertions relative to this reference 
coordinate system were written to a separate output file. 
We used a Python script to filter the amino acid frequency matrices generated by the pipeline 
described above, using a minimum coverage threshold of at least 1,000 mapped reads per amino 
acid. First, any matrix corresponding to a pair of FASTQ files was discarded if the overall number 
of reads mapped to the sample-specific consensus sequence was below this threshold. Next, any 
individual amino acid position below this coverage threshold was coded as missing data in the 
remaining frequency matrices. Additionally, any sites with discordant amino acid frequencies 
within the overlapping region of the two amplicons — i.e., where the frequency of an amino acid 
exceeded the threshold in one amplicon but not the other — was also coded as missing data. Next, 
the script converted the amino acid frequency data for each sample into a long binary vector that 
indicated whether each of the 20 amino acids was observed above a frequency threshold of 1% at 
every position in the integrase gene; these outputs are herein denoted the low-threshold (LT) data 




threshold (HT) data set. Hence, the amino acid frequency data from the aligned short reads were 
encoded into two presence-absence matrices, each comprising 20 × 288 = 5, 760 variables. 
(columns) and one row for every pair of FASTQ files.  Similar dichotomization approaches 
(e.g.,sparse binary encoding (688) have previously been used for feature selection analyses 
involving amino acid polymorphisms (688,705). All subsequent analyses were replicated across 
these two data sets. 
Data imputation 
A substantial number of patient samples (Supplementary Table S1) were sequenced more than 
once on the MiSeq platform to take advantage of the large number of index combinations and 
sequencing yield of this instrument. In other words, the number of rows in the presence-absence 
matrix produced by the previous step was greater than the number of patient samples. To 
incorporate the entire data collection without unnecessarily and arbitrarily discarding or pooling 
repeated measurements, we randomly down-sampled redundant rows to obtain a reduced 
presence-absence matrix with one row per sample and repeated this procedure to yield 10 
replicate matrices. All subsequent analyses were replicated across these matrices. 
The next stage of our analysis employed a support vector machine (SVM) classifier to identify 
putative associations between amino acid polymorphisms and RAL failure. Although extensions 
of SVMs have recently been developed to handle missing data (706), the prevailing approach is 
to use a generic method to impute missing values prior to the SVM analysis. We used multivariate 
imputation by chained equations as implemented in the R package mice (707). Based on the overall 
proportion of missing observations in our data sets (3.2% for the LT data set and 2.9% for the HT 
data set), the recommended minimum number of imputations was 3 (708).  We decided to generate 
5 imputed data sets for each of the 10 normalised data sets from the previous section. Further, we 
duplicated this approach for the LT and HT data sets for a total of 5 × 10 × 2 = 100 imputed data 
sets. To speed up the multivariate imputation, we used the quickpred variable selection procedure 
implemented in the mice package to filter the data for potentially significant predictors based on 
a simple correlation statistic. We excluded sites with an absolute correlation with the group labels 
below 50% and output the remaining variables to a preliminary predictor matrix. Each imputation 
was run for 20 iterations instead of the default 5 iterations, and convergence was visually assessed 




results from the SVM analysis, we filtered amino acid features with non-zero weights (based on 
their incorporation into support vectors) by a minimum frequency of 80% across imputations, i.e., 
at least 40 out of 50. 
SVM analysis 
The preceding imputation step yielded 100 large presence-absence matrices encoding the observed 
HIV-1 integrase amino acid polymorphisms across baseline and treatment failure samples. We 
analyzed each imputed data matrix with a support vector machine (SVM) in which the samples 
which was encoded by +1 and −1, respectively, as stipulated by the soft-margin linear SVM model 
were mapped to a high-dimensional feature space based on the presence or absence of amino acids, 
(709)[52]. Our samples were recategorized into two groups of outcomes (labels): samples from 
patients who experienced treatment failure on a RAL-based regimen (abbreviated to ‘RAL 
failure’); and samples from treatment-naive patients and patients who experienced treatment failure 
on first- and second-line regimens without integrase inhibitors (‘RAL naive’). An SVM attempts 
to locate the hyperplane, defined by a subset of data points (the support vectors), that most 
effectively separates the training data into the two groups. We performed an SVM analysis with the 
svm.fs function from the R package penalizedSVM (710) using an L1-norm penalty. Compared to 
an unpenalized SVM, this penalty function aggressively zeroes-out the coefficients associated 
with features that are less informative for classifying the data, and thereby provides a framework 
for feature selection (711). To calibrate the λ tuning parameter of the SVM model, which controls 
the severity of penalizing data points that cross the margin of the hyperplane, we used a discrete 
grid search to determine the optimal λ with minimal misclassification error by 5-fold cross-
validation (712). After training and cross-validation, we generated the final SVM model for the 
entire data set using the optimized λ parameter. For each of the 100 data sets, we extracted the 
average feature weights and counts from the SVM results. 
To corroborate the assignments of the most positive or negative feature weights to specific amino 
acids per treatment group, we calculated the odds ratios to quantify the statistical associations 
between the amino acid and outcomes (group labels). We calculated odds ratios and 95% 
confidence intervals by unconditional maximum likelihood estimation (Wald method) as 
implemented in the R package epitools, adding a fixed n = 0.5 value to every single cell of its 




Subsequently, we averaged the results for each feature across all 100 data sets. Additional details 
on the sequence processing and SVM analysis are provided as Supplementary Text S1. 
Drug resistance prediction 
To obtain resistance predictions from the sequence data from the IN coding region, we generated 
a consensus sequence at a polymorphism threshold of 20%, such that any position with two or 
more nucleotide frequencies above this threshold was encoded as an ambiguous base using the 
corresponding IUPAC symbol. Further, we censored all positions with fewer than 50 mapped 
reads as missing data – this threshold was less stringent than the minimum number of mapped 
reads (1000) required for positions to be carried over to the SVM analysis, because the objective of 
the latter was to detect associations with polymorphisms at a minimum frequency of 1%. Since a 
minimum of 10 mapped reads (1% × 1000) was required to be interpreted as a real polymorphism, 
the same number of mapped reads was required to influence the consensus sequence at a cutoff of 
20% (50 reads × 20% = 10 reads). Drug resistance prediction scores on the resulting consensus 
sequences were obtained for RAL using the Stanford HIV-1db algorithm version 8.4 (updated 
2017- 06-16) (677). 
Subtype and phylogenetic analysis 
We used the same consensus sequences generated for drug resistance prediction to predict subtypes 
and reconstruct the phylogeny. We used the SCUEAL algorithm in HyPhy (608) to generate subtype 
classifications and detect inter- and intra-subtype recombination. Next, we excluded predicted 
recombinant sequences and sequences that were classified as circulating recombinant forms 
(CRFs), and generated a multiple sequence alignment from the remaining sequences using 
MUSCLE (version 3.8.425) (714). This alignment also incorporated the HIV-1 reference 
sequences curated by the Los Alamos National Laboratory (LANL) HIV-1 Sequence Database 
(http://www.HIV-1.lanl.gov) for subtypes A1, C, D and G, where this selection of references was 
based on subtyping results from this study population. The alignment was manually inspected 
and refined in AliView (version 1.19-beta-3) (610). We used jModelTest (version 2.1.10) (612) 
to select the most effective nucleotide substitution model based on the Akaike Information 
Criterion (AIC). Finally, we used PhyML (version 20160207) (715) to reconstruct a phylogenetic 




analysis (1,000 replicates). The tree was visualized and manually annotated for subtypes in 
FigTree (version 1.4.2, A. Rambaut, http://tree.bio.ed.ac.uk/software/figtree). 
Structural analysis 
The α-helix that connects the catalytic core domain (CCD) to the C-terminal domain (CTD) of 
the HIV-1 integrase protein is not resolved in the available DNA bound three-dimensional (3D) 
structure (PDB ID 5U1C). We therefore modelled the coordinates of the missing α-helix region 
(a total of 22 amino acids derived from PDB ID 1EX4) into one monomer (chain A) of the 
original structure (PDB ID 5U1C) using the program MODELLER (version 9.21) (716) to create 
an extended structure (PDB ID 5U1C extended). Using the extended structure as template, we 
built structural models of the I203M, I208L and combined I203M and I208L mutations 
respectively. The protein refinement program 3Drefine was used for energy minimization and 
optimization of all models (717). Furthermore, we used the molecular structure visualization 
program PyMOL (version 1.7.2.1, http://pymol.org; Schrödinger, LLC) to visualize the sites where 
the I203M and I208L mutations are located on the 3D structure (PDB IDs 5U1C, 5U1C extended 




















We obtained plasma samples for a total of 380 patients receiving treatment for HIV-1 infection at 
the Joint Clinical Research Center in Kampala, Uganda, for genotypic drug resistance testing by 
deep sequencing on the Illumina MiSeq platform. Of the 328 samples from INSTI-naive 
individuals (RAL naive), 85 samples were categorized as treatment-naive, 127 as first-line 
treatment failures, and 116 as second-line treatment failures. The remaining 52 samples (14% of 
total) were obtained from individuals who had experienced treatment failures on raltegravir-based 
salvage regimens (RAL failure). From these samples, we generated a total of n = 524 paired FASTQ 
files with a mean of 83,185 reads per pair. Using the MiCall pipeline (687), which iteratively 
re-maps read data to update sample-specific reference sequences, we mapped an average of 81,189 
reads (97.6% of the raw totals) to the HIV-1 IN coding region from each sample. This pipeline 
enforced a number of coverage and quality filtering criteria (see Methods), including a minimum 
requirement of 1,000 read coverage per amino acid position. Consequently, we discarded n = 7 
FASTQ files due to insufficient numbers of reads that mapped to the HIV-1 reference. 
The φ X174 control error rates associated with the two MiSeq runs used for these sequencing 
experiments displayed the typical exponential decay with increasing cycle number, starting at a 
median of 0.44% (interquartile range, IQR: 0.32%, 0.96%) and ending at 9.2% (6.7%, 15.6%; 
Supplementary Figure S1). The overall median error rate was 1.5% (0.49%, 3.7%), which was 
consistent with previously reported error rates for this platform. Out of a total of 22,800 tile-cycle 
combinations, 2,095 and 3,360 combinations with an error rate exceeding 7.5% from the respective 
runs were excluded from further analysis. These combinations were concentrated in the last 100 
cycles of the second reads (80.3% and 74.6%). The median sequence length after mapping with 
soft clips was 498 (IQR 325, 525) nt, indicating that the majority of the dropped base calls due to 
bad tile-cycles could be compensated by high quality base calls in the first reads at the paired-end 
read merger step of the pipeline. 
A key challenge in detecting genetic associations in deep sequencing data from rapidly-evolving 
pathogens like HIV-1 is that polymorphisms can be observed at many, if not most, sites. 




by sequencing errors from actual variants with potential clinical significance. Because it was not 
feasible to replicate all downstream analyses for an exhaustive sample of frequency thresholds, 
we proceeded with 1% (low threshold, LT) and 20% (high threshold, HT) to dichotomize the 
amino acid frequency data into binary presence/absence values. These values were chosen on the 
basis of prior information on the expected error rate for this sequencing platform (687) and the 
detection limit of Sanger sequencing (680,682), respectively. 
 
After excluding reads with low map quality scores and censoring low quality or discordant base 
calls, we obtained a mean coverage of 18,907 and 19,076 reads per amino acid site for LT and HT 
data sets, respectively. We restricted our subsequent analyses to amino acid polymorphisms, 
excluding variation due to insertions, deletions, and premature stop codons. On average, we 
observed 10−4 insertions and 8 × 10−5 deletions per nucleotide, which was within the expected 
range of indel error rates for this sequencing platform (718). Ambiguous amino acid 
polymorphisms due to low base quality or incomplete coverage affected a small fraction of the 
data sets (3.2% and 2.9% for the LT and HT data, respectively). These ambiguities were encoded 




Subtyping analysis of the majority consensus sequences derived from the NGS samples confirmed 
that the majority of samples were assigned to HIV-1 subtypes A (n = 159, 49.7%) and D (n = 70, 
21.3%) as expected for this study population in Uganda.  An additional n = 28 (8.4%) samples 
were predicted to be A/D recombinants, and n = 16 (4.2%) samples were predicted to be sub-
type C. The remaining samples were assigned to other inter-subtype recombinants or could not 
be confidently assigned to a known subtype or circulating recombinant form.  We found no 
significant association between predicted HIV-1 subtypes and RAL-based treatment failure 
(Fisher’s exact test, P = 0.5). Variation among sequences was best explained by the general time 
reversible model of nucleotide substitution with invariant sites and a gamma distribution to model 
rate variation across sites (GTR+I+G). We reconstructed a maximum likelihood phylogeny under 




reference sequences, where sequences assigned to subtypes A, C and D comprised monophyletic 
clades with high bootstrap support values (>85%). 
 
Drug susceptibility by genotyping 
Applying the Stanford HIV-1db algorithm to the NGS consensus sequences to predict resistance 
to RAL, we confirmed that less than one-third of RAL-based treatment failures (shortened to 
‘RAL failures’) manifested the classical RAL resistance pathways (540). The complete 
breakdowns of resistance prediction scores by HIV-1 subtype in the RAL naive and RAL failure 
groups are summarized in Fig. 34. Out of 52 consensus sequences from RAL failure samples, 
only 14 samples (26.9%) were predicted to have high-level resistance to RAL (score ≥ 60). One 
of these samples (score 120) harbored the major RAL resistance mutation G140A (in 99.12% of 
reads) in combination with the accessory mutation E138K (99.1%).  
 
Figure 34. Distribution of RAL resistance predictions on sample consensus sequences by 
HIV-1 subtype and treatment outcomes. Resistance prediction scores were obtained by the 
Stanford HIV-1db algorithm [7]. The study population was split into RAL naive (left, n=328) 
and RAL failure (right, n = 52) patients; accordingly, these plots are on different scales. Each 
stacked barplot stratifies patients by predicted HIV-1 subtype and categorizes the prediction 
scores into high-level (60+, red), intermediate (30-59, orange), low-level (15-29, yellow) and 





An additional 10 samples carried the major mutation N155H at frequencies between 94.2% and 
99.7%, and two samples carried the major RAL resistance mutation T66K (at 93.8% and 62.7%, 
respectively). Finally, two samples with high RAL resistance scores in this group carried the 
major mutation Q148R in combination with accessory mutation G163R. This relative lack of 
expected mutational pathways in the RAL failure group, quantified by the low number of patient 
samples with resistance prediction scores in the susceptible to low-level resistance range (Fig. 
22), motivated a more comprehensive analysis of HIV-1 integrase polymorphisms in the deep 
sequencing data. 
Support vector machine analyses 
A key challenge in detecting genetic associations in deep sequence data from rapidly-evolving 
infections like HIV-1 is that potentially any amino acid may appear at any position. We followed 
the sparse binary encoding approach in (688) so that every sample was represented by a total of 5,760 
binary variables for 20 amino acids at 288 positions in the HIV-1 integrase reference. This is an 
unwieldy number of predictor variables for conventional association tests like logistic regression. 
Support vector machines (SVMs (719) were developed to handle this sort of scenario, where the 
number of observed cases is vastly exceeded by the number of predictor variables, and have been 
employed in a number of studies of HIV-1 variation (720,721). 
We used penalized SVMs to select features (polymorphisms) that most effectively separated 
patient samples into RAL naive and RAL failure categories. Our results are summarized by the 
mean feature weights (the relative contributions of different polymorphisms to the separation of 
labels) for the low (1%) and high (20%) amino acid frequency threshold (LT and HT) data sets, 
respectively. Figs. 35A (for LT) and 35B (for HT) display these results in comparison to the mean 
univariate odds ratios (ORs) for polymorphisms selected by the SVM analyses to provide more 
intuitive measures of association. To account for variation induced by missing data, we excluded 
features that were selected in fewer than 40 out of 50 imputed matrices for both LT and HT data 







Figure 35. Summary of results from support vector machine analyses. (top) Feature weights 
and odds ratios for selected polymorphisms in the LT (A) and HT (B) databases. Each point 
corresponds to an amino acid polymorphism (feature) selected by support vectors. To reduce 
clutter and identify features robust to missing data, we removed all features selected in fewer than 
40 out of 50 imputations. The x-axis corresponds to feature weights, and the y-axis represents the 
log-transformed mean odds ratio (OR) for each feature against the labels. Vertical lines indicate 
the empirical 95% confidence interval in ORs. Points are coloured grey if this interval spans 1 
(not significant) and otherwise according to mutation categorization, if any, by the Stanford HIV-
1 Drug Resistance Database (see inset legend). (bottom) Positive weight selected from the SVM 
analysis and greater than one Odd ratio polymorphisms for the LT (C) and HT (D) data sets. The 
HIV-1 integrase reference coordinates are marked along the x-axis, and log-transformed OR 





In general, we observed strong positive correlations between the SVM feature weights and 
mean ORs for the LT (Spearman’s ρ = 0.59, P < 2.2 × 10−16) and HT (ρ =0.68, P < 2.2 × 10−16) 
data sets. 
To identify the most promising features from these results, we filtered the features that were 
selected in at least 40 imputations and where the mean lower 95% confidence limit in odds ratios 
was greater than 1. In total, we recorded 663 features selected by support vectors, of which 83 
(12.5%) were reproducibly selected in at least 40 imputed matrices. Although the known major 
RAL resistance mutations T66K (722) and Q148R (723) had positive mean feature weights, they 
appeared in only 13 out of 50 imputed data sets. Only the major mutation N155H (724) was selected 
in a majority of imputations (all 50) with the fourth highest mean weight. An additional 8 features 
were known accessory or minor RAL resistance mutations (T66A (725),  L74M (726),  T97A 
(671),  V151I (616),  N155D (727), E157Q (728), G163R (616) and R263K (729); with the 
exception of R263K, all were assigned positive weights (Supplementary Table S2). Only G163R, 
V151I and T97A were selected in a majority (>80%) of analyses, and in fact were selected for 
all 50 imputed matrices.  Overall, our filtering criteria selected the following polymorphisms in 
descending order of weight: G163R, V165I, N155H, V151I, I203M, T97A, K211N, A129S, 
D288E, K240R, Q148K, I135F, C65R, I208L and T218S. 
The relative locations of these polymorphisms are summarized in Fig. 35C. For instance, we 
observed a cluster of 6 selected polymorphisms within the interval IN 198 to 218, which is distal 
to both the integrase active site and RAL binding site. 
The higher frequency threshold (<20%) for the HT data set substantially reduced the effective 
number of amino acid polymorphisms; as a result, there were few features selected in the support 
vectors (n = 299). Applying the same criteria as above to identify the most significant features 
yielded the following six substitutions (in decreasing order of weight): N155H, G163R, T97A, 
I208L, I203M and G134N (Fig. 35D). Of these features, only the primary mutation N155H and 
secondary mutations T97A and G163R have been previously described. 
 
 
I203M and I208L alone or together do not confer resistance to INSTIs in vitro 




investigation, as they appeared in both lists of the most significant features from the LT and HT 
data sets. Figure 36 contrasts the intra-host frequencies of I203M and I208L in the context of 
known major RAL mutations, as defined by the Stanford HIV-1 Drug Resistance Database. These 
frequency distributions revealed four distinct clusters of mutations among n = 30 (58%) patients 
failing a RAL-based treatment regimen and carrying at least one of these polymorphisms.   
 
Figure 36. Summary of intra-host frequencies for known major RAL mutations and two 
candidate mutations I203M and I208L. Samples from n = 30 RAL failures patients carrying at 
least one of these mutations are each represented by a set of barplots representing mutation 
frequencies on the right. The height of each bar is proportional to 1+log10(p) for p ranging from 
1% to 100% (see legend in bottom-left). The vertical ordering of samples was determined by a 
hierarchical clustering analysis, with the corresponding dendrogram displayed on the left. 
Vertical bars have been added on the left to highlight the subsequent specific pathways. 
 
Two clusters of patients in this RAL failure group carried one of two known major RAL resistance 
mutations Q148K/R or N155H. There were no patient samples containing the polymorphism 




I203M and/or I208L to the exclusion of all known major RAL resistance mutations with the 
exception of Q148K/R. This pattern suggests that I203M and I208L may comprise novel 
mutational pathways for RAL resistance. 
 
To experimentally validate the predicted effects on resistance to RAL and other INSTIs, the 
I203M and I208L mutations were placed in the IN of the subtype B laboratory strain NL4-3 (NL4-
3_I203M and NL4-3_I208L). Wild type NL4-3, NL4-3_I203M and NL4-3_I208L were 
propagated and then used in INSTI susceptibility assays as described in the Materials and 
Methods.  I203M or I208L did not impact susceptibility of NL4-3 to RAL or DTG as shown in 
Figure 37A and B.  It is important to note that these two mutations as associated with RAL failure 
was defined by SVM analyses on Ugandan cohort infected with subtype A and D.  As such, we 
cloned into NL4-3 the HIV-1 subtype A IN from patient DR.110.13 with both I208L and I203M 
(DR.110.13_I203M+I208L) and from patient DR.372.15 with only I208L (DR.372.15_I208L).  
These viruses were compared for INSTI susceptibility in TZMbl cells as described.  Even in a 
subtype A IN coding region, the I203M+I208L or I208L did not alter RAL or DTG susceptibility 




Figure 37. Drug susceptibility assays on the effects of I203M and I208L on INSTI resistance. 
The top row of plots correspond to raltegravir drug susceptibility curves for NL4-3 (wildtype, in 
black) and mutants I203M, I208L, or I203M and I208L in either subtype B or A backbone. 
Similarly, the second row of plots correspond to the dolutegravir drug susceptibility curves for 




or A backbone. Each point for curves in A-D corresponds to the mean and error bars represent 
the standard error of at least four replicate assays 
 
I203M and I208L are natural polymorphisms 
To assess whether I203M and I208L mutations are present as natural polymorphisms in the 
general population, we queried the Stanford HIV-1 Drug Resistance Database (HIV-1db; last 
accessed February 21, 2019) for all available HIV-1 IN sequences (n = 17, 605) from INSTI naive 
and experienced patients and evaluated the frequencies of these variants in subtypes A, B and D 
(Table 12). This database comprised n = 1, 248 records from RAL-experienced individuals, of 
which only n =129 were infected with a non-B subtype — in comparison, our study would 
contribute an additional n = 52 sequences, about 40% of the current number. The frequencies of 
I203M and I208L in the RAL-naive category in the HIV-1db database were 5.9% and 5.0%, 
respectively, suggesting these two mutations are natural polymorphisms that circulate at low 
frequencies (> 0.5%).  
Table 12. Frequencies of I203M, I208L and RAL INSTI major mutations in HIV-1 IN 
stratified by treatment according to Stanford HIV-1 Drug Resistance Database whereas 
reported RAL-experienced individuals breakdown is reported 
 
T66K coverage was 16,027 for naive, I203M and I208L coverage was 15,997 for naive and 1573 for 
experienced patients. Other major combinations include: G140A/C/S + Y143C/H/R (9 INI), 
G140A/C/S + N155H (19 INI), G140A/C/S + Y143C/H/R + Q148H/K/R (9 INI), G140A/C/S + 
Q148H/K/R + N155H (21 INI), G140A/C/S + Y143C/H/R + Q148H/K/R + N155H (2 INI), 
Y143C/H/R + Q148H/K/R (10 INI), Y143C/H/R + N155H (26 INI), Y143C/H/R + Q148H/K/R + 
N155H (2 INI), Q148H/K/R + N155H (27 INI), T66K + G140A/C/S + Q148H/K/R (1 INI), INI = 
INSTI-experienced, RAL = Raltegravir. Fisher’s exact tests (experienced vs. naive, RAL- vs. non-




We noticed only slight but statistically significant increases in these frequencies in association 
with the RAL-experienced category in HIV-1db (Table 12).  
Table 13. Frequencies of I203M and I208L polymorphisms in HIV-1 IN stratified by 
treatment for this study cohort and by minor allele frequency. 
 
Low threshold = 1% (LT) and high threshold = 20% (HT). Fisher’s exact tests (experienced vs. naive): 
* = P < 0:05; ** = P < 0:01; *** = P < 0:001 
Although we observed more substantial increases in association with the RAL failure category in 
our study population (Table 13), this is not directly comparable to the RAL experienced category 
in the HIV-1db database that comprises an unknown proportion of treatment failures. In addition, 
we also collected the frequencies of the known major RAL resistance mutations in HIV-1db. 
These mutations were almost always observed with INSTI-experienced patients, being almost 
absent in INSTI naive patients (Table 12). 
 
Structural analysis 
Based on their location in the primary sequence, I203M and I208L maps near the C-terminal base 
of the α-helix connecting the C-terminal domain (CTD) to the catalytic core domain (CCD) of 
HIV-1 integrase in the unliganded structure (91). Figure 38A displays the structure of HIV-1 
integrase complexed with viral and host DNA (PDB ID 5U1C) and in which only the I203M 
position could be mapped. However, as discussed in the methods section, a model of HIV-1 
integrase was constructed to create an extension of this structure (5U1C extended), such that when 





Figure 38. Structural mapping of the novel amino acid replacements. (A) a cryo-electron 
microscope structure (PDB ID 5U1C) of integrase protein (lightteal) in complex with host and 
viral DNA. The modelled extended structure (palecyan) is superimposed on chain A to show the 
missing a-helix where the I208L mutation is located (B) a crystal structure of integrase protein 
CCD (shown as a green cartoon) bound to the human LEDGEF protein (shown as sticks) (C) the 
modelled I203M mutant structure (limegreen) of HIV-1 integrase superimposed on the modelled 
extended wild type structure (greencyan) (D) the modelled I208L mutant structure (aquamarine) 
of HIV-1 integrase superimposed on the modelled extended wild type structure (greencyan) (E) 
the modelled I203M and I208M mutant structure (lime) of HIV-1 integrase superimposed on the 
modelled extended wild type structure (greencyan). All catalytic active site residues are colored 
purple while the novel mutation sites are colored blue (I203M) and red (I208L) respectively. The 
known major RAL major resistance mutation sites were colored as follows: T66 (cyan), Y143 





From both structures, the I203M and I208L residues are distally located from the catalytic active 
site of HIV-1 DNA processing, the binding site for most INSTI, as well as the location of most drug 
resistance mutations (all the known major RAL mutations are also shown in the structure in Fig. 
38A). Structural mapping shows that the I203M and I208L mutations were on the opposite side 
of the C-terminal domain engaged in LEDGEF binding (reference) (Fig. 38B). 
 
Structural modeling of the I203M mutation in HIV-1 integrase shows a conformational change in 
the α-helix connecting the CCD to the CTD (Figure 38C). Similarly, the structural model having 
both the I203M and I208L mutations also show a conformational change the α-helix connecting 
the CCD to the CTD (Fig. 36E). On the other hand, structural modeling of the I208L mutation in 
HIV-1 integrase shows very little to no conformational changes (Fig. 38D). These residues are 
closer to the C-terminal domain of HIV-1 integrase that may help coordinate binding to both host 























The majority of our knowledge on drug resistance mutations in HIV-1 comes from studies of 
subtype B, even though this subtype represents only a small proportion of infections worldwide. 
In a previous study (540), we observed an absence of known DRMs associated with RAL resistance 
in half of the HIV-1-infected Ugandans failing a third line RAL-based treatment. This absence 
could be attributed to either complete non-adherence, or a failure to detect resistance-associated 
polymorphisms below the threshold of detection of Sanger sequencing (about 20% (682). Based 
on an initial viral load decrease and adherence tracking during this third line regimen, complete 
non-adherence resulting in a return of wild type HIV-1 was unlikely for all n = 51 patients 
(540). 
Though we cannot retrospectively quantify the extent and impact of drug non-adherence, we can 
explore the possibility of unique, uncharacterized mutations associated with INSTI resistance with 
NGS-based genotyping. 
Based on previous assay cutoff analyses, the Illumina MiSeq platform is capable of reproducibly 
detecting mutations at a lower frequency threshold of about 1% (684–686), which confers a 
substantially improved sensitivity over conventional Sanger sequencing. Setting a frequency 
threshold of 1% is only meaningful if a sufficient number of virus genomes from the plasma 
sample are represented in the sequencing library. For instance, if the input number of templates 
is fewer than 100, then any variant detected at a frequency of 1% or less is likely the result of 
sequencing error. Our study population comprised patients either sampled prior to initiating ART 
or following treatment failure. In previous work, we have reported that plasma viral loads averaged 
about 5.4 log10 copies/mL at baseline (732). Although drug resistance testing in Uganda is 
requested for patients failing treatment above 1,000 copies/mL, the majority of requests were 
obtained when viral loads exceed 10,000 copies/mL (averaging 4.8 log10 copies/mL for first-line 
treatment failure, and >5.0 log10 copies/mL for RAL-based/third-line treatment failure) 
(540,696). 
Our most conservative estimates are that about one-sixth of the viral RNA from 200µL of plasma 
was transferred from the sample extraction to the RT-PCR reaction mixture, and that about one-
half was converted to cDNA. Given that half of the reaction mixture was used for PCR amplification 




evaluate the effect of template resampling on our ability to measure variant frequencies, we can 
simulate the sampling process assuming that extraction and aliquoting is sampling uniformly at 
random without replacement, and that sequencing post-amplification is sampling uniformly at 
random with replacement. For instance, we predict that a variant found in 500 copies/mL (0.5% of 
the plasma sample) has a 0.03% probability of being sampled to a frequency of 1% or greater un-
der our experimental conditions (2.5% and 97.5% quantiles = 0.26%, 0.77%; N = 106 replicates). 
Conversely, a variant in 1500 copies/mL (1.5%) would be sampled at 1% or less with probability 
0.93%. We further note that our multiple imputation across repeated NGS of the same samples 
would have averaged out some sampling variation. 
Our NGS analysis of RAL naive and treatment failure samples confirms results from our previous 
study (540), including the absence of previously identified DRMs in about half of RAL failure 
cases. The SVM analysis of these data also identified a number of potentially novel mutations 
associated with reduced sensitivity to RAL. Because this classifier evaluates features by selecting 
data points (the support vectors) to anchor the hyperplane separating labels, some of these features 
may be associated by chance with RAL failures due to their linkage to features with direct effects. 
Consequently, we carried out a post hoc odds ratio analysis to evaluate the significance of 
univariate associations between each feature selected by the SVM and the labels (virologic control 
versus RAL failure). The combined analyses recovered several known major and accessory 
mutations conferring resistance to RAL. For instance, we found a highly significant association 
between the major mutation N155H and patients failing RAL treatment (724), and this mutation 
was significantly linked with accessory mutations such as V151I (616). A limitation of our SVM 
analysis was that we selected two frequency thresholds to dichotomize amino acid polymorphisms 
into binary variables. Although it is possible to directly apply the SVM classifier to continuous 
variables, dichotomizing the observed frequencies into presence/absence states was necessary to 
make the analysis computationally feasible. We selected the two frequency thresholds (1% and 
20%) to span the range bounded by the lower limits of detection for the Illumina MiSeq (687) 
and Sanger sequencing (682), respectively. Additionally, the selection of 1% for dichotomizing 
HIV-1 deep sequence data has also been empirically validated in a recent whole-genome deep 
sequencing study of HIV-1 (733) and employed in a genome-wide association study of HIV-1 




Our SVM analyses identified a cluster of amino acid polymorphisms associated with RAL failure 
in the α helix domain, including the mutations I203M and I208L. With this new information, we 
could map the majority of RAL failure samples to four largely independent mutational pathways 
characterized respectively by I203M, I208L, Q148/R, and N155H (Fig. 29). I203M has 
previously appeared on lists of INSTI resistance mutations in the earlier literature (735,736)[85–
87]. Furthermore, I203M was previously characterized as a minor or accessory mutation with no 
evidence of directly reducing susceptibility, and has also been characterized as a natural 
polymorphism that is observed a substantial frequencies in un- treated individuals (729). In 
contrast, we have found almost no previous mention of I208L in the HIV-1 drug resistance 
literature. 
We subsequently introduced the I203M, I208L mutations through site-directed mutagenesis, and 
used patient-derived viruses carrying I208L or I203M and I208L to evaluate susceptibility of 
these mutants to INSTIs in vitro. Our results indicate that these mutations in IN do not confer 
resistance to RAL or DTG (Fig. 30). However, these mutations could act as secondary mutations 
to mutations outside HIV-1 integrase gene. Resistance mutations in the HIV-1 3’ polypurine tract, 
a conserved motif that primes the synthesis of plus-strand HIV-1 DNA during reverse 
transcription, have been shown to significantly reduce susceptibility of HIV to INSTIs in vitro 
(737). In addition, recent studies suggest that mutations conferring INSTI resistance may co-
evolve with the upstream end of U3 and the downstream end of the U5, i.e. the conserved target 
sequence for dinucleotide cleavage.  We have recently sequenced the LTR of the same Uganda 
patients failing INSTIs to determine possible linkage with the U5 and U3 target sequences with 
I203M and I208L.   Although there is no evidence to date, there is also the possibility that IN 
mutations selected by INSTIs may also impact the efficient of integration into the cellular DNA 
by way of enhanced chromosomal DNA cleavage. We now have preliminary data suggesting that 
treatment failure with INSTI results in dramatic changed in the targeting of proviral DNA 
integration.  How this is associated with the selected IN mutations associated with INSTI (as 
defined by this SVM analyses) is the subject of further study.  Finally, resistance to a drug can 
also be manifested by increased replicative fitness even if susceptibility to drug is unaltered.  For 
example, a 10-fold inhibition can be overcome in terms of viral burden if HIV-1 I203M or I208L 
replicates 10X more efficiently than wild type.  However, our studies indicate that HIV-1 with 




Further experimental work in our laboratory is now directed towards detecting mutations outside 
HIV-1 integrase gene and the integration patterns in the host genome. We suspect that that I203M 
and I208L are associated with INSTI resistance since these mutations define distinct evolutionary 
pathways emerging during INSTI treatment and failure to this treatment.  This I203M and I208L 
evolutionary pathway emerged in lieu of N115H, Y143H/R, and Q148K/R pathways that 
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In this Discussion chapter, I will first outline the slow roll out and need of second generation of 
INSTIs in low-to-middle income countries like Uganda.  Part of this chapter is published in the 
journal, Infectious Diseases of Poverty (2019) but aspect of this topic were also addressed by the 
commentary published in Journal of Infectious Diseases (2017). For the article published in 
Infectious Diseases of Poverty, I wrote and co-authored the article with Dr. Arts. The article 








In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and partners launched 
the 90-90-90 targets. The 90-90-90 global targets by UNAIDS calls for 90% of all people living 
with human immunodeficiency virus (HIV) to know their status, 90% of all people diagnosed 
with HIV infection to be on combined antiretroviral therapy (cART) and 90% of all people 
receiving cART to have suppressed the virus by 2020 (738). The world is progressing towards 
achieving these targets with most European countries close to 90-90-90 targets (739). Some 
countries like Denmark, Iceland, Sweden, Singapore, and the United Kingdom have already 
achieved these target while good progress towards the 90-90-90 targets are observed in Eastern 
and Southern Africa, Eastern Europe and central Asia (740) while countries in West and Central 
Africa are lagging farther behind.  
In a recent report by UNAIDS, antiretroviral therapy (ART) was accessible to only 26% of 
children and 41% adults in Western and Central Africa, compared to 59% of children and 66% 
adults who had access to ART in Eastern and Southern Africa in 2017. There was also almost 
50% reduction in number of AIDS related deaths in West and Central Africa compared to Eastern 
and Southern Africa (24% vs 42% respectively) (741). LICs carry 90% of global HIV burden, 
and though there has been good progress to achieve 90-90-90 targets, pretreatment drug 
resistance (PDR), non-adherence, and side effects associated with the current cART pose a great 
threat. PDR and transmitted drug resistance (TDR) are on the rise in low-income countries (LICs) 
(524,742) and the trend is not likely to change as countries implement World Health Organisation 
(WHO) “Treat All” recommendation (743). It has been shown that increase of TDR results in 
increased treatment switches (744) and positively correlates with cART roll out. 
However, with limited treatment options, LIMCs are facing a dilemma of keeping patients on 
treatment regimens that are deemed less optimal in high income countries. Lack of access to 
drugs having higher genetic barrier to resistance contributes to the transmission of HIV resistant 
virus, and limited virological monitoring affects early detection of drug resistant mutations 
(DRMs). In LIMCs, first line (FL) cART commonly consists of two nucleoside reverse 
transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) commonly efavirenz (EFV) or nevirapine (NVP), with Lopinavir/Ritonavir (LPV/r) 




drugs, Darunavir (DRV), Raltegravir (RAL), and Etravirine (ETR) are sparingly used and 
commonly assessed by patients on salvage therapy and only in a few treatment centres. 
Routine viral load monitoring, more potent drugs with fixed dose combinations with higher 
genetic barrier to DR and adherence support are among areas of emphasis for rapid scale up and 
better care of patients (745). However, these guidelines poor implementation in LMICs due to 
lack of access to such drugs. It has been predicted that with no change of current regimens and 
TDR increasing beyond 10%, there will be 890 000 new deaths, 450 000 new infections and 
increase of cART cost of USD 6.5 billion by 2030 (746). I will discuss cART-based reasons 
underlying these challenges and mitigation strategies. 
The low genetic barrier to drug resistance 
The commonly used NNRTIs in FL, (NVP/EFV), and (LPV/r) based SL therapy in LMICs, have 
low genetic barrier to drug resistance compared to second generation NNRTIs, rilpivirine (RPV) 
and ETR. High-level resistance between these drugs has been reported (513) which reduces 
treatment response more so in patients with TDR. In Uganda for example, where NFV and EFV 
are frequently used in first line, over 96% FL failures, 75% SL failures, and 49% RAL failures, 
have NNRTIs resistance (540). In LMICs, over two-thirds of patients retain NNRTIs resistance 
even many years on second line therapy (540), and Steegen et al. show that ≥ 65% of second line 
failures had NNRTI mutation (747). Lack of HIV genotypic tests in most countries impedes early 
detection of drug resistant variants. Already HIV drug resistance (HIVDR) in patients failing 
LPV/r-based regimen has increased in Africa (748), and the number of patients who need second 
line therapy is likely to increase from 0.5–3.0 million in 2020 to 0.8–4.6 million by 2030. From 
2012, Tenofovir (TDF) is the primary NRTI for first-line cART after replacing zidovudine and 
Stavudine. However, TDF resistance is on rise in LICs with 60% of patients who fail on TDF 
based cART having TDF resistance (749) and this could be due to lack of baseline resistance 
testing and prescription of TDF with EFV or NVP which have low genetic barrier to resistance. 
Side effects of current regimens and poor adherence 
Adherence to treatment is critical to a successful treatment response and may be influenced by 




immunological benefit of using ART. Improved adherence correlates with increased CD4 count 
(750) and is the second-best predictor of disease progression (751). Poor adherence may be 
associated with development of DRMs which may contribute to virological failure (VF). Studies 
have shown that contrary to the belief that people in LICs are naturally non-adherent to treatment, 
adherence can also be achieved in LICs (752). 
The available cART in LICs is complex and associated with huge pill burden, short, and long-
term medication side effects. Adherence was reported to be around 40% in a recent adolescent 
study in 23 sub-Saharan Africa countries (753). The study shows non-adherence as a key problem 
facing health care service in this region, and it is worsened by counselling services focusing on 
outcomes of non-adherence not causes. Short message service and treatment supporters can 
improve adherence in Africa (754), however, such strategies should go in hand with availability 
of more potent drugs with better safety and tolerability profiles. 
Though LPV/r is associated with more adverse gastrointestinal effects than ATV/r or 
darunavir/ritonavir (755), it still forms the backbone of majority of second line treatment. It has 
recently been shown to increase cardiovascular risks of myocardial infarction and stroke in HIV 
infected patients in the US when compared to ATV/r (756). Boosted lopinavir and 2NRTI 
combination has been removed from other regimens category because of huge pill burden and 
greater toxicity (//aidsinfo.nih.gov/guidelines). HIVDR resulting in virologic failure during 
second line treatments in LICs, has been attributed to poor adherence other than LPV/r activity 
(615). In addition, the commonly used NNRTI, EFV, is associated with more adverse 
gastrointestinal effects and rashes compared to RPV (757). 
Pretreatment HIV-1 drug resistance 
Globally, over 10.1% of HIV infected patients have baseline DR (758) and it is associated with 
reduced treatment response in both HICs (759) and in LICs (760). Whereas prevalence of TDR 
remained stable in HICs 2002–2010 at 8%, in LICs, there has been an increase in prevalence with 
roll out of cART. In some countries, frequencies of NNRTI and NRTI DRMs in patients initiating 
cART increased from 0% (2006–2007) (570), to 8.6% (2009– 2010) (571) and 15.4% (2014–
2016) (524). Despite an estimated prevalence of HIVDR of (7.4%) eight years after roll-out of 




largely driven by high NNRTIs resistance (524). This confirms observed positive correlation 
between cART roll out and increase of TDR in LICs (761). In a national survey by 11 LICs 
countries on PDR, six out of 11 countries had prevalence of 10% and above which calls for 
change of first line regimen as per WHO guidelines on HIVDR (524). TDR in LICs is more 
common in NNRTIs (4.5%) and NRTIs (4%) than in protease inhibitors (2.8%) (760) unlike in 
Europe with less baseline NNRTIs resistance (2.5–2.9%) (762,763). Baseline NNRTIs resistance 
has been shown to cause more impact to treatment response (763). In LICs, prevalence of TDR 
in children ≤ 12 years was found at 42.7% in those exposed to prevention of mother to child 
transmission and 12.7% in unexposed (615). These countries now face the dilemma of 
overcoming TDR and this is further complicated by lack of virological monitoring and 
inaccessible genotyping test. Access to baseline genotyping test in the START trial (Strategic 
Timing of Antiretroviral Treatment trial) was found to be 0.1% in Africa, 1.8% in South America 
and 22% in Asia (22%) compared to over 80% in Europe (86.7%), United States (81.3%) and 
Australia (89.9%) (758). Moreover, Sanger sequencing commonly used in these countries cannot 
detect resistant variants below 20% and yet these variants been associated with treatment failure 
(732). Only 22% of patients on cART in middle and LICs get access to virological monitoring 
(764). This implies reliance on clinical and immunological monitoring which detect treatment 
failure late and this leads to emergence of more complicated DRMs. In children below three 
years, the impact of TDR is even stronger than in adults with odds ratio for failure of 15.3 and 
has been associated with VF and acquired DR (574). 
Strategies to address challenges associated with current cART and ways to make more 
potent ART accessible in LICs 
The most ART associated challenges in LICs are mainly rooted on HIV drug resistance among 
other factors like the scarcity of treatment options for HIV infected patients in LICs more so on 
those failing salvage therapy. Several recommendations can be made on how to address these 
challenges and improve the lives of people living with HIV in LICs. 
Firstly, patent licences should be closely monitored, and local drug manufacturers be encouraged. 
Drug price is a major factor contributing to lack of access to these drugs especially due to patent 




treatment (765). However, with expired patent licenses and some expiring soon, it’s high time 
for stake holders to advocate for voluntary and compulsory licensing among other strategies to 
make these drugs more affordable. Basing on data on active pharmaceutical ingredients exported 
in and out of India, the cost of treatment of HIV could be as low as USD 90 annually if substantial 
generic competition is enforced (766). 
HIV integrase inhibitor, DTG has shown superior genetic barrier to resistance 185 and potency 
in patients with DRMs to RAL and elvitegravir. Once daily dosage of DTG can be given to 
patients initiating cART and those failing RAL-based cART as once or twice daily dosage 
depending on presence of integrase strand transfer inhibitors (INSTIs) mutations more so 
Q148K/R/H. National Institutes of Health consultation recommends the use of tenofovir 
alafenamide fumarate (TAF) which has less bone and kidney toxicity, and DTG, which may help 
reduce drug resistance and improve adherence in LICs (767). The compound patent for DTG is 
expected to expire in 2026 and with licenses on adults and pediatric formulations available to all 
LICs through Medicines Patent Pool and ViiV Healthcare, market competition of local 
manufacturers will likely increase access of drug in this setting. The initiative by International 
drug purchase facility (UNITAID) to enrol DTG in some LICs of Kenya, Uganda and Nigeria 
(768) should be encouraged. Neural tube birth defects in children born to mothers who were 
exposed to DTG during pregnancy still raises concern to the safety of using DTG in pregnant 
mothers. In a study that compared the birth outcomes between 1729 pregnant women on DTG 
based ART and 4359 mothers on EFV in Botswana, found no significant differences in the 
individual outcomes of stillbirth, neonatal death, preterm birth, very preterm birth, small for 
gestational age, or very small gestational age, and severe side effects between patients on DTG 
or EFV based ART (769). In a recent study looking at neural tube defects with DTG treatment in 
women who started DTG from the time of conception, 426 (0.94%) infants born from mothers 
who were initiated on DTG at conception, had neural birth defects of encephalocele, 
myelomeningocele and iniencephaly compared to 11 300 (0.12%) infants born to mothers on 
non-DTG regimen at conception (643). In same study, 2812 infants 208 who were born to 
mothers who initiated DTG during pregnancy none had neural tube defects. These observations 
suggest DTG associated neural tube defects may be dictated by the time of DTG initiation to 




women initiating ART but with potential reduction in use of NNRTIs based therapy in LICs, 
more research is necessary in area of DTG use and pregnancy. The current statement of WHO on 
potential risk of birth defects to infants born of mothers exposed to DTG at a time of inception, 
is to initiate pregnant women to EFV based regimen which has confirmed efficacy and safety 
profiles. DTG can only be used in childbearing women only when consistent contraception is 
guaranteed and where other first line regimens can’t be used (770). To concur with this statement, 
a recent study carried across 13 European countries and Thailand investigating association of 
initiating EFV based ART during conception or first trimester of pregnancy and birth defects, 
found no significant difference in prevalence of birth defects between EFV based and non-EFV 
ART based groups (771). There are also reports linking the use of DTG to abnormal weight gain. 
In a study assessing weight change in patients switching from EFV/3TC/ emitricabine (FTC) to 
an INSTI-based regimen, greatest weight gain was observed in patients switched to 
abacavir/3TC/DTG combination (772). Another study reviewing patient data from observational 
SCOLTA project which was looking for drug related adverse effects in patients who started a 
regimen containing, DTG, RAL, EVG, DRV or ETR, found no difference in body mass index 
between patients on INSTIs-based ART and those on non-INSTIs regimens. However, 
precautions should be taken when drawing conclusions as these were retrospective observational 
studies. Therefore randomised, controlled studies are still needed to validate these observations. 
ETR is largely patented in developing countries and with patent restrictions in leading 
manufacturing nations of India, China and Brazil, no generic form is available. The patent on 
novel compound expires in 2026 which is far beyond 2020 target and therefore more advocacies 
required. DRV has high genetic barrier to resistance and is effective in patients with multidrug 
resistant viruses (773) and was approved for use in treatment naïve adults in the US and European 
Union. No high-level resistance to DRV was observed in national survey of 350 patients failing 
second line therapy in South Africa [13]. At least three DRV associated mutations in combination 
with multiple protease inhibitor associated mutations are necessary for DRV resistance to occur 
(774) as shown in POWER 1 and 2 studies. In Madrid study of 1364 genotypes of cART naïve 
and experienced patients for the impact of HIV subtype to DRV and tipranavir, all 29 non-subtype 
B cART naïve patients had 100% susceptibility with DRV, and associated DRMs were more 




majority of patients in LICs fail treatment with multiple DRMs, DRV provides best alternative 
for those switching to second line therapy. Despite compound patent on DRV expiring in 2013 
and patents on pseudopolymorph and/ or on the combination with ritonavir been granted to most 
LICs, it is still not widely available in LICs. Countries should take advantage of availability of 
license not to enforce patents on DRV in sub-Saharan Africa and least developed countries to 
encourage wide manufacturing of generic forms to increase access. 
Secondly, access to single pill formulations, drugs with high genetic barrier to resistance, and 
those with promising results in clinical trials, should be made a priority. Indeed, high TDR 
prevalence and lack of baseline resistance testing call for robust ART for patients starting on 
treatment. RPV approved for treatment of NNRTIs-naïve patients is more tolerable and allows 
simplification due to its single pill formulations of TDF/FTC/RPV, and TDF/TAF/RPV which 
improves adherence and general response to treatment. ETR is approved for use in NNRTIs 
experienced patients and has shown high potency to both wild type and NNRTIs resistant virus 
(776). However, the high HIVDR due to Y181C after NVP exposure (777) necessitates genotypic 
test before use of ETR as salvage therapy. Doravirine being tested in once daily 
doravirine/3TC/TDF combination, is more tolerable, has high efficacy, and activity against 
viruses with resistant mutations K103N and Y181C (778). It was non-inferior to EFV with 84% 
vs 81% of patients in doravirine and EFV arms achieving undetectable VL after 48 weeks 
respectively in phase 3 DRIVE-AHEAD study (779). Cabotegravir in advanced stages of clinical 
trials, look promising for its use as long acting injectable with monthly or bimonthly 
administration for pre-exposure prophylaxis use and treatment of HIV infection. It has shown 
better safety profile and high acceptability in low risk uninfected participants in on-going clinical 
trial HPTN 077 (780). Though there is possibility of cross resistance with already approved 
INSTIs through Q148 pathway, it still provides better alternative. In addition to minimal side 
effects, injectable cabotegravir provides convenience, flexibility, and fitness of patient lifestyles 
which improves adherence. Bictegravir when given in a fixed-dose combination with FTC and 
TAF, was not inferior to DTG given in DTG/FTC/TAF combination in treatment-naïve patients 
after 48 weeks in phase 3 of Study 1490 (781). MK-8591 a long-acting nucleoside reverse 




prophylaxis in phase 1b clinical study showing half-life of 2.3 to 56.8 and 78.5 to 128 hours with 
patent and triphosphate form (MK-8591-TP) respectively (782). 
Thirdly, HIV drug resistance surveillance should be emphasized as HIV drug resistance is one of 
indicators of ART program. The impact of HIVDR has been attributed to be 15.6% of AIDS 
deaths, 9.4% of new infections and 7.9% of ART costs from 2017 to 2021 (783). Therefore, 
monitoring of all three forms of HIVDR, TDR, and PDR, and acquired drug resistance, by putting 
in place checkpoints to track emerging and spreading HIVDR becomes very paramount. This 
becomes even more crucial at a time when countries are starting all persons infected with HIV 
on treatment and wide coverage of prevention of mother to child transmission programs. Much 
as prevention of mother to child transmission program has drastically reduced the number of 
babies acquiring HIV from their HIV positive mothers to < 10%, HIVDR especially to NNRTIs 
has been increasing in children who still become HIV infected through prevention of mother to 
child transmission program (Table 13). This is mostly attributed to initiating these children to 
first line treatment with NNRTIs component due to lack of recommended protease inhibitors in 
these settings. This therefore calls for more support to ART programs to ensure adequate and 
reliable supply of child dosage combinations in these countries. It is not uncommon in some of 
these settings for clinics to provide children formulations to adults by prescribing high dosage 
where there is shortage of adult regimens. This form of practice affects pediatric HIV treatment 


















Abbreviations: CI: Confidence interval, HIV Human immune deficiency syndrome, PDR Pretreatment 
drug resistance, NNRTIs Non-nucleoside reverse transcriptase inhibitors, PMTCT Prevention of 
mothers to child transmission. -: not applicable 
Much as the global burden of HIVDR especially in LICs is known and mitigation strategies well 
stipulated, most of these countries are struggling to implement these strategies due to mostly 
inadequate resources and lack of political will by governments in some countries. As a result, 
there is insufficient monitoring of emerging drug resistance. The early warning indicators by 
WHO for drug resistance provide alternative way of monitoring for emerging drug resistance in 
this setting. They include offering optimal 300 treatment and according to the guidelines, 
checking for percentage of patients with loss of follow up after 12 months, looking at percentage 
of patients retained on ART at 12 months, patients with on time pill pick up/ clinic appointment, 
drug stock outs, and looking at patients under viral load monitoring and suppression [56]. Much 
as there are challenges in implementing this form of monitoring, it remains the feasible tool to 
combat the challenge of rising HIVDR in LICs. 
The HIVDR monitoring programs cannot afford not to prioritise population at most risk; girls 
and women, men who have sex with other men, sex workers, drug users, and people in fishing 
communities; who face a lot of stigma and discrimination. Surveillance on access of HIV services 
to these vulnerable groups needs to be emphasized by ensuring that monitoring and evaluation 
systems for reporting on implementation are functional. The generic form of DTG has allowed a 
rapid roll out of this drug in most LICs. It is expected to change the landscape of HIVDR in LICs 
due to its high genetic barrier to resistance, better tolerability, and safety profiles basing on 
research commonly done in subtype B viruses. However, more research is still required to access 
its efficacy in non-B subtypes since DTG associated drug resistance appears to be HIV subtype 
specific. As such, there should be well articulated treatment guidelines and frequent surveillance 
of resistance to guide its proper use in ART naïve and highly treatment experienced patients in 
LICs. 
Conclusions 
The availability of more potent ART in LICs is of utmost importance if UNAIDS 2020 and 2030 
goals are to be realized and sustained not only in HICs but also in LICs. Countries that have 




individuals expected to be 323 800 000 annually from 30 million in 2017 to 36.4 million in 2025 
[37]. In countries which rolled out cART earlier, the prevalence of TDR increased by 12.3% in 
span of four years and will likely keep increasing. With increased drug switches which is 
associated with TDR, and acquired drug resistance common in LICs, more potent ART offer 
therapeutic and preventive incentives which will reduce treatment costs and increase drug 
options. In addition to making these drugs available, governments must address current loopholes 
through their jurisdictions as well as addressing lack of political commitment and poor policy 
decisions seen in some countries. It’s also imperative to strengthen quality service delivery in 
terms of retention of patients to treatment, support for adherence to cART, patient follow up, and 
adequate drug stocks to help achieve a free AIDS generation. 
Roll out of second generation of INSTIs should be in concert with screening for INSTI 
resistance in LIMCs  
DTG is increasingly being rolled out in many LMICs though INSTIs still account to only about 
1% of active first-line regimens in LMICs (698). Due to cost related factors, INSTIs are sparingly 
used in LMICs with RAL-based regimens been used in highly treatment experienced with 
multiple non-INSTIs mutations (628,699,700). HIVDR presents a huge challenge for future 
treatments to outcome. Over 10-15% of patients will fail on ART each year due to HIVDR in 
LMICs. HIVDR to INSTIs has been extensively analyzed and screened in subtype B HIV-1 
which predominate infections of HICs. Contrary, HIVDR especially to INSTIs in non-B subtypes 
is significantly lacking despite 90% of HIV-1 infections caused by non-B HIV-1 subtypes. To 
understand the burden of HIVDR to INSTIs in non-B HIV-1 subtypes, we have screened for 
DRMs associated with INSTIs in a cohort of Ugandan patients attending HIV-1 testing and 
treatment services at Joint clinical research center (JCRC), Kampala, Uganda. Samples from a 
total of 417 ART naïve and patients receiving different lines of ART were tested for presence of 
INSTIs associated DRMs. In this cohort, INSTIs associated mutations were not observed in 
INSTIs naïve (n=366) but in 47% of patients failing on RAL-based regimen (see chapter one). 
Among the 47% with INSTIs DRMs, 4% (2/51) of patients (subtype A and D) harboring multiple 
primary INSTIs DRMs conferring resistance DTG, a unique observation in both LMICs and 
HICs. Nonetheless, DTG resistance was shown to be rare in LMICs which encourages its use 




most other LMICs. Basing on absence of DTG cross resistance in INSTIs naïve patients, DTG 
provides best option for patients initiating ART and those failing RAL-based regimen in absence 
of multiple INSTIs primary mutations.  
INSTIs susceptibility/phenotypic studies have remained elusive in most LMICs including 
Uganda. In this settings, national treatment guidelines rely almost exclusively on predictions from 
HIV-1 resistance databases including International AIDS Society-USA Drug Resistance 
Mutations Group (784) and Stanford HIV-1 drug resistance database (607) and yet our cohort of 
patients had unique combination of DRMs not observed previously (421). INSTIs associated 
resistance has been shown to be subtype-specific with some mutations preferentially selected in 
HIV-1 types B compared to non-B subtypes; for instance, Q148 mutations are more frequent in 
HIV-1 subtype B compared to non-B subtypes (492). Therefore, phenotypic assays to ascertain 
the level of susceptibility of these patient viruses was critical to understanding INSTI resistance 
in Uganda.  
We phenotypically tested eleven HIV-1-derived integrases from subtype A, D, and recombinant 
A/D infected patients (RAL-failures) for susceptibility to DTG, RAL and EVG. The viruses 
harboring single RAL/EVG primary INSTIs mutations (~50%) remained susceptible to DTG 
with fold-change in EC50 values nearly equivalent to that of wild-type. This may imply that in 
such patients failing RAL-based regimens with single RAL/EVG primary INSTIs mutations, 
twice daily DTG in combination with best possible NRTIs, may suppress the virus and improve 
treatment outcomes. From this analysis, we confirmed that subtype A with 
E138A/G140A/G163R/Q148R and subtype D with E138K/G140A/S147G/Q148K viruses on 
RAL-based regimen are highly resistant to all currently available INSTIs in LMICs. The 
complexity of these mutations and level of resistance, >100-fold DTG, and >1000-fold RAL and 
EVG has not been observed before neither in subtype B or non-B HIV-1 infected individuals. 
These results indicate that prescribing DTG-based combination to patients failing RAL-based 
regimens with multiple primary INSTIs DRMs may not be beneficial. Therapeutic strategy of 
keeping patients on regimens which sustains DRMs associated with reduced RC may help to 
avoid continual immune deterioration especially in settings with limited ART options. 
Interestingly, viruses carrying multiple INSTIs primary DRMs showed divergent viral fitness 




E138A/G140A/G163R/Q148R having nearly wild type replicative capacity. To maintain active 
infection in patients with impaired replicative capacity, the loss could be compensated by 
emergence of secondary mutations which restore viral fitness and/ or even increase fitness in 
presence of INSTIs (671). It has also been shown that maintaining NRTI such as lamivudine 
(3TC) or emitricabine (FTC) in a treatment regimen even with the emergence of associated drug 
resistance helps to avoid increased viremia (785) and may even help to stabilize the FTC/3TC 
resistant mutation, M184V which has been associated with delayed emergence of mutations 
conferring resistance to DTG (455,785).  
To further characterise INSTI resistance to different INSTIs in HIV-1 non-B subtypes, we tested 
8 patient-derived viruses from our cohort for susceptibility to novel BIC and CAB INSTIs. 
Recombinant viruses with HIV-1 IN harboring single or in combination with secondary 
mutations remained susceptible to both BIC and CAB. Presence of multiple primary INSTIs 
DRMs leads to increased resistance to CAB and BIC. Overall, BIC showed more potency against 
viruses carrying various INSTIs-associated resistant mutations compared to CAB (p=0.03). 
Though not currently indicated, BIC and CAB offer alternative to patients with single primary 
and or in combination with secondary mutations especially in settings with limited HIV-1 drug 
options. 
Over the years, next generation sequencing has increasingly been used in clinical monitoring of 
HIVDR especially in LMICs where treatment failure and interrupted therapy often results in 
primary drug resistant viruses fading in the patient’s population below the limit of Sanger 
sequencing detection.  The role of minority variants remains to be elucidated in HICs, but in 
Uganda, low frequency drug resistance variants may account for over 64% of HIV-1 patients 
failing first-line and where dominant drug resistant HIV-1 was not detected (732). In our 
screening study for INSTIs DRMs, we observed that over 50% of patients failing RAL-based 
regimens in Uganda lacked signature INSTIs DRMs, either as dominant in the intrapatient HIV-
1 population or low frequency variants. Using deep-sequencing and SVM analysis, we identified 
I203M and I208L mutations in the HIV-1 IN coding region of subtype A and D infected patients 
failing RAL but we failed to confirm that these mutations conferred resistance to RAL and DTG. 
From structural analysis, I203 and I208 residues are found in C-terminal domain and quite distal 




or polymorphisms but new findings suggest that these mutations may have co-evolved with 
changes in the HIV-1 IN recognition sequence in the proviral DNA (upstream start of U3 and 
downstream end of U5).   The combination of the I203M and/or I208L mutations with mutations 
in the U3 and U5 sequence may confer resistance to INSTIs by increasing the binding of viral or 
host DNA, increased dinucleotide cleavage, and/or increased integration efficiency. It is 
important to note that both I203M and/or I208L cause replication fitness loss in subtype A, B, or 
D IN coding region within an NL4-3 backbone but we had not yet sequenced and compared the 
U3 and U5 LTR sequences nor have we introduced the patient-specific, subtype-specific U3 and 
U5 sequences linked with the I203M and/or I208L IN sequences.  We are currently exploring 
this possibility leading to INSTI resistance and that would confirm the high odds ratio that I203M 
and I208L are linked to INSTI resistance in about 1/2 to 1/3rd of the subtype A and D infected 
patients failing a RAL-based treatment regimen in Uganda.   
In a nutshell, emergence of INSTIs resistance appears in part to be subtype specific with even 
N155H reducing DTG susceptibility more so in subtype A and D than in subtype B HIV-1. 
Surveillance for INSTIs-associated resistance remains critical in LMICs for early detection of 
resistance mutations. Early detection of virological failure, detection of novel INSTIs-DRMs, and 
increased HIVDR surveillance remains critical in LMICs to avoid the irreversible and detrimental 
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